{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 427010, "items": [{"indexed": {"date-parts": [[2019, 12, 20]], "date-time": "2019-12-20T16:43:59Z", "timestamp": 1576860239687}, "reference-count": 115, "publisher": "Springer Science and Business Media LLC", "issue": "12", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2017, 11, 6]], "date-time": "2017-11-06T00:00:00Z", "timestamp": 1509926400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Nat Rev Neurol"], "published-print": {"date-parts": [[2017, 12]]}, "DOI": "10.1038/nrneurol.2017.144", "type": "journal-article", "created": {"date-parts": [[2017, 11, 6]], "date-time": "2017-11-06T04:42:09Z", "timestamp": 1509943329000}, "page": "755-763", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 32, "title": ["Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives"], "prefix": "10.1038", "volume": "13", "author": [{"given": "Lidia M.", "family": "Yshii", "sequence": "first", "affiliation": []}, {"given": "Reinhard", "family": "Hohlfeld", "sequence": "additional", "affiliation": []}, {"given": "Roland S.", "family": "Liblau", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2017, 11, 6]]}, "reference": [{"key": "BFnrneurol2017144_CR1", "doi-asserted-by": "crossref", "first-page": "473", "DOI": "10.1038/nrclinonc.2016.58", "volume": "13", "author": "C Boutros", "year": "2016", "unstructured": "Boutros, C.  et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol. 13, 473\u2013486 (2016).", "journal-title": "Nat. Rev. Clin. Oncol."}, {"key": "BFnrneurol2017144_CR2", "doi-asserted-by": "crossref", "first-page": "646", "DOI": "10.1016/j.cell.2011.02.013", "volume": "144", "author": "D Hanahan", "year": "2011", "unstructured": "Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).", "journal-title": "Cell"}, {"key": "BFnrneurol2017144_CR3", "doi-asserted-by": "crossref", "first-page": "1202", "DOI": "10.1016/j.cell.2015.08.047", "volume": "162", "author": "JP Allison", "year": "2015", "unstructured": "Allison, J. P. Checkpoints. Cell 162, 1202\u20131205 (2015).", "journal-title": "Cell"}, {"key": "BFnrneurol2017144_CR4", "doi-asserted-by": "crossref", "first-page": "255", "DOI": "10.1038/ni.3682", "volume": "18", "author": "E Tran", "year": "2017", "unstructured": "Tran, E., Robbins, P. F. & Rosenberg, S. A. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nat. Immunol. 18, 255\u2013262 (2017).", "journal-title": "Nat. Immunol."}, {"key": "BFnrneurol2017144_CR5", "doi-asserted-by": "crossref", "first-page": "1463", "DOI": "10.1126/science.aaf1490", "volume": "351", "author": "N McGranahan", "year": "2016", "unstructured": "McGranahan, N.  et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463\u20131469 (2016).", "journal-title": "Science"}, {"key": "BFnrneurol2017144_CR6", "doi-asserted-by": "crossref", "first-page": "227", "DOI": "10.1038/nri3405", "volume": "13", "author": "L Chen", "year": "2013", "unstructured": "Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227\u2013242 (2013).", "journal-title": "Nat. Rev. Immunol."}, {"key": "BFnrneurol2017144_CR7", "doi-asserted-by": "crossref", "first-page": "205", "DOI": "10.1016/j.cell.2015.03.030", "volume": "161", "author": "P Sharma", "year": "2015", "unstructured": "Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205\u2013214 (2015).", "journal-title": "Cell"}, {"key": "BFnrneurol2017144_CR8", "doi-asserted-by": "crossref", "first-page": "711", "DOI": "10.1056/NEJMoa1003466", "volume": "363", "author": "FS Hodi", "year": "2010", "unstructured": "Hodi, F. S.  et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrneurol2017144_CR9", "doi-asserted-by": "crossref", "first-page": "2517", "DOI": "10.1056/NEJMoa1104621", "volume": "364", "author": "C Robert", "year": "2011", "unstructured": "Robert, C.  et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517\u20132526 (2011).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrneurol2017144_CR10", "doi-asserted-by": "crossref", "first-page": "1889", "DOI": "10.1200/JCO.2014.56.2736", "volume": "33", "author": "D Schadendorf", "year": "2015", "unstructured": "Schadendorf, D.  et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33, 1889\u20131894 (2015).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrneurol2017144_CR11", "doi-asserted-by": "crossref", "first-page": "320", "DOI": "10.1056/NEJMoa1412082", "volume": "372", "author": "C Robert", "year": "2015", "unstructured": "Robert, C.  et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320\u2013330 (2015).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrneurol2017144_CR12", "doi-asserted-by": "crossref", "first-page": "122", "DOI": "10.1056/NEJMoa1302369", "volume": "369", "author": "JD Wolchok", "year": "2013", "unstructured": "Wolchok, J. D.  et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122\u2013133 (2013).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrneurol2017144_CR13", "doi-asserted-by": "crossref", "first-page": "1627", "DOI": "10.1056/NEJMoa1507643", "volume": "373", "author": "H Borghaei", "year": "2015", "unstructured": "Borghaei, H.  et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627\u20131639 (2015).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrneurol2017144_CR14", "doi-asserted-by": "crossref", "first-page": "1803", "DOI": "10.1056/NEJMoa1510665", "volume": "373", "author": "RJ Motzer", "year": "2015", "unstructured": "Motzer, R. J.  et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803\u20131813 (2015).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrneurol2017144_CR15", "doi-asserted-by": "crossref", "first-page": "311", "DOI": "10.1056/NEJMoa1411087", "volume": "372", "author": "SM Ansell", "year": "2015", "unstructured": "Ansell, S. M.  et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311\u2013319 (2015).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrneurol2017144_CR16", "doi-asserted-by": "crossref", "first-page": "23", "DOI": "10.1056/NEJMoa1504030", "volume": "373", "author": "J Larkin", "year": "2015", "unstructured": "Larkin, J.  et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrneurol2017144_CR17", "doi-asserted-by": "crossref", "first-page": "1837", "DOI": "10.1016/S0140-6736(16)00587-0", "volume": "387", "author": "L Fehrenbacher", "year": "2016", "unstructured": "Fehrenbacher, L.  et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837\u20131846 (2016).", "journal-title": "Lancet"}, {"key": "BFnrneurol2017144_CR18", "doi-asserted-by": "crossref", "first-page": "67", "DOI": "10.1016/S0140-6736(16)32455-2", "volume": "389", "author": "AV Balar", "year": "2017", "unstructured": "Balar, A. V.  et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67\u201376 (2017).", "journal-title": "Lancet"}, {"key": "BFnrneurol2017144_CR19", "doi-asserted-by": "crossref", "first-page": "111", "DOI": "10.1016/j.immuni.2007.05.016", "volume": "27", "author": "MJ Butte", "year": "2007", "unstructured": "Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H. & Freeman, G. J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27, 111\u2013122 (2007).", "journal-title": "Immunity"}, {"key": "BFnrneurol2017144_CR20", "doi-asserted-by": "crossref", "first-page": "707", "DOI": "10.1016/j.cell.2017.01.017", "volume": "168", "author": "P Sharma", "year": "2017", "unstructured": "Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).", "journal-title": "Cell"}, {"key": "BFnrneurol2017144_CR21", "doi-asserted-by": "crossref", "first-page": "989", "DOI": "10.1016/j.immuni.2016.05.001", "volume": "44", "author": "AC Anderson", "year": "2016", "unstructured": "Anderson, A. C., Joller, N. & Kuchroo, V. K. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44, 989\u20131004 (2016).", "journal-title": "Immunity"}, {"key": "BFnrneurol2017144_CR22", "doi-asserted-by": "crossref", "first-page": "66", "DOI": "10.1111/imr.12525", "volume": "276", "author": "EC Nowak", "year": "2017", "unstructured": "Nowak, E. C.  et al. Immunoregulatory functions of VISTA. Immunol. Rev. 276, 66\u201379 (2017).", "journal-title": "Immunol. Rev."}, {"key": "BFnrneurol2017144_CR23", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1016/j.ejca.2016.12.001", "volume": "73", "author": "S Cuzzubbo", "year": "2017", "unstructured": "Cuzzubbo, S.  et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur. J. Cancer 73, 1\u20138 (2017).", "journal-title": "Eur. J. Cancer"}, {"key": "BFnrneurol2017144_CR24", "doi-asserted-by": "crossref", "first-page": "e529", "DOI": "10.1016/S1470-2045(16)30571-X", "volume": "17", "author": "W Wick", "year": "2016", "unstructured": "Wick, W., Hertenstein, A. & Platten, M. Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol. 17, e529\u2013e541 (2016).", "journal-title": "Lancet Oncol."}, {"key": "BFnrneurol2017144_CR25", "doi-asserted-by": "crossref", "first-page": "806", "DOI": "10.1097/WCO.0000000000000391", "volume": "29", "author": "AF Hottinger", "year": "2016", "unstructured": "Hottinger, A. F. Neurologic complications of immune checkpoint inhibitors. Curr. Opin. Neurol. 29, 806\u2013812 (2016).", "journal-title": "Curr. Opin. Neurol."}, {"key": "BFnrneurol2017144_CR26", "first-page": "377", "volume": "28", "author": "L Spain", "year": "2017", "unstructured": "Spain, L.  et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann. Oncol. 28, 377\u2013385 (2017).", "journal-title": "Ann. Oncol."}, {"key": "BFnrneurol2017144_CR27", "doi-asserted-by": "crossref", "first-page": "294", "DOI": "10.1002/ana.24715", "volume": "80", "author": "LA Gerdes", "year": "2016", "unstructured": "Gerdes, L. A.  et al. CTLA4 as immunological checkpoint in the development of multiple sclerosis. Ann. Neurol. 80, 294\u2013300 (2016).", "journal-title": "Ann. Neurol."}, {"key": "BFnrneurol2017144_CR28", "doi-asserted-by": "crossref", "first-page": "709", "DOI": "10.1634/theoncologist.2016-0487", "volume": "22", "author": "J Larkin", "year": "2017", "unstructured": "Larkin, J.  et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist 22, 709\u2013718 (2017).", "journal-title": "Oncologist"}, {"key": "BFnrneurol2017144_CR29", "doi-asserted-by": "crossref", "first-page": "928", "DOI": "10.1001/jamaneurol.2016.1399", "volume": "73", "author": "TJ Williams", "year": "2016", "unstructured": "Williams, T. J.  et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 73, 928\u2013933 (2016).", "journal-title": "JAMA Neurol."}, {"key": "BFnrneurol2017144_CR30", "doi-asserted-by": "crossref", "first-page": "670", "DOI": "10.1177/1352458514549403", "volume": "21", "author": "EJ Gettings", "year": "2015", "unstructured": "Gettings, E. J., Hackett, C. T. & Scott, T. F. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult. Scler. 21, 670 (2015).", "journal-title": "Mult. Scler."}, {"key": "BFnrneurol2017144_CR31", "doi-asserted-by": "crossref", "first-page": "66", "DOI": "10.1186/s40425-016-0170-9", "volume": "4", "author": "MA Wilson", "year": "2016", "unstructured": "Wilson, M. A.  et al. Acute visual loss after ipilimumab treatment for metastatic melanoma. J. Immunother. Cancer 4, 66 (2016).", "journal-title": "J. Immunother. Cancer"}, {"key": "BFnrneurol2017144_CR32", "doi-asserted-by": "crossref", "first-page": "991", "DOI": "10.1093/annonc/mdr028", "volume": "22", "author": "S Wilgenhof", "year": "2011", "unstructured": "Wilgenhof, S. & Neyns, B. Anti-CTLA-4 antibody-induced Guillain\u2013Barr\u00e9 syndrome in a melanoma patient. Ann. Oncol. 22, 991\u2013993 (2011).", "journal-title": "Ann. Oncol."}, {"key": "BFnrneurol2017144_CR33", "doi-asserted-by": "crossref", "first-page": "589", "DOI": "10.1093/neuonc/nou001", "volume": "16", "author": "B Liao", "year": "2014", "unstructured": "Liao, B., Shroff, S., Kamiya-Matsuoka, C. & Tummala, S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 16, 589\u2013593 (2014).", "journal-title": "Neuro Oncol."}, {"key": "BFnrneurol2017144_CR34", "doi-asserted-by": "crossref", "first-page": "2407", "DOI": "10.1007/s10637-011-9787-1", "volume": "30", "author": "F Bompaire", "year": "2012", "unstructured": "Bompaire, F.  et al. Severe meningo-radiculo-neuritis associated with ipilimumab. Invest. New Drugs 30, 2407\u20132410 (2012).", "journal-title": "Invest. New Drugs"}, {"key": "BFnrneurol2017144_CR35", "doi-asserted-by": "crossref", "first-page": "77", "DOI": "10.1097/CJI.0000000000000070", "volume": "38", "author": "I Thaipisuttikul", "year": "2015", "unstructured": "Thaipisuttikul, I., Chapman, P. & Avila, E. K. Peripheral neuropathy associated with ipilimumab: a report of 2 cases. J. Immunother. 38, 77\u201379 (2015).", "journal-title": "J. Immunother."}, {"key": "BFnrneurol2017144_CR36", "doi-asserted-by": "crossref", "first-page": "307", "DOI": "10.1002/mus.24648", "volume": "52", "author": "AI Loochtan", "year": "2015", "unstructured": "Loochtan, A. I., Nickolich, M. S. & Hobson-Webb, L. D. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 52, 307\u2013308 (2015).", "journal-title": "Muscle Nerve"}, {"key": "BFnrneurol2017144_CR37", "doi-asserted-by": "crossref", "first-page": "1553", "DOI": "10.1212/WNL.0000000000002594", "volume": "86", "author": "Y Cao", "year": "2016", "unstructured": "Cao, Y.  et al. CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology 86, 1553\u20131556 (2016).", "journal-title": "Neurology"}, {"key": "BFnrneurol2017144_CR38", "doi-asserted-by": "crossref", "first-page": "1299", "DOI": "10.1158/2326-6066.CIR-15-0141", "volume": "3", "author": "C Maurice", "year": "2015", "unstructured": "Maurice, C.  et al. Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunol. Res. 3, 1299\u20131302 (2015).", "journal-title": "Cancer Immunol. Res."}, {"key": "BFnrneurol2017144_CR39", "doi-asserted-by": "crossref", "first-page": "16", "DOI": "10.1016/j.jneuroim.2016.12.016", "volume": "305", "author": "MP Brown", "year": "2017", "unstructured": "Brown, M. P., Hissaria, P., Hsieh, A. H., Kneebone, C. & Vallat, W. Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy. J. Neuroimmunol. 305, 16\u201318 (2017).", "journal-title": "J. Neuroimmunol."}, {"key": "BFnrneurol2017144_CR40", "doi-asserted-by": "crossref", "first-page": "749", "DOI": "10.1634/theoncologist.2016-0366", "volume": "22", "author": "S Bossart", "year": "2017", "unstructured": "Bossart, S.  et al. Case report: encephalitis, with brainstem involvement, following checkpoint inhibitor therapy in metastatic melanoma. Oncologist 22, 749\u2013753 (2017).", "journal-title": "Oncologist"}, {"key": "BFnrneurol2017144_CR41", "doi-asserted-by": "crossref", "first-page": "2923", "DOI": "10.1093/brain/aww225", "volume": "139", "author": "LM Yshii", "year": "2016", "unstructured": "Yshii, L. M.  et al. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain 139, 2923\u20132934 (2016).", "journal-title": "Brain"}, {"key": "BFnrneurol2017144_CR42", "doi-asserted-by": "crossref", "first-page": "945", "DOI": "10.1016/S1474-4422(15)00141-6", "volume": "14", "author": "A Waisman", "year": "2015", "unstructured": "Waisman, A., Liblau, R. S. & Becher, B. Innate and adaptive immune responses in the CNS. Lancet Neurol. 14, 945\u2013955 (2015).", "journal-title": "Lancet Neurol."}, {"key": "BFnrneurol2017144_CR43", "doi-asserted-by": "crossref", "first-page": "71", "DOI": "10.1084/jem.20022119", "volume": "198", "author": "AD Salama", "year": "2003", "unstructured": "Salama, A. D.  et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198, 71\u201378 (2003).", "journal-title": "J. Exp. Med."}, {"key": "BFnrneurol2017144_CR44", "doi-asserted-by": "crossref", "first-page": "16073", "DOI": "10.1073/pnas.1315828110", "volume": "110", "author": "Y Rui", "year": "2013", "unstructured": "Rui, Y., Honjo, T. & Chikuma, S. Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response. Proc. Natl Acad. Sci. USA 110, 16073\u201316078 (2013).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrneurol2017144_CR45", "doi-asserted-by": "crossref", "first-page": "2290", "DOI": "10.2353/ajpath.2009.081012", "volume": "174", "author": "A Kroner", "year": "2009", "unstructured": "Kroner, A.  et al. Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants. Am. J. Pathol. 174, 2290\u20132299 (2009).", "journal-title": "Am. J. Pathol."}, {"key": "BFnrneurol2017144_CR46", "doi-asserted-by": "crossref", "first-page": "1783", "DOI": "10.1016/j.celrep.2016.10.042", "volume": "17", "author": "TT Jiang", "year": "2016", "unstructured": "Jiang, T. T.  et al. Programmed death-1 culls peripheral accumulation of high-affinity autoreactive CD4 T cells to protect against autoimmunity. Cell Rep. 17, 1783\u20131794 (2016).", "journal-title": "Cell Rep."}, {"key": "BFnrneurol2017144_CR47", "doi-asserted-by": "crossref", "first-page": "496", "DOI": "10.1016/0166-2236(89)90109-4", "volume": "12", "author": "A Vincent", "year": "1989", "unstructured": "Vincent, A., Lang, B. & Newsom-Davis, J. Autoimmunity to the voltage-gated calcium channel underlies the Lambert\u2013Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci. 12, 496\u2013502 (1989).", "journal-title": "Trends Neurosci."}, {"key": "BFnrneurol2017144_CR48", "doi-asserted-by": "crossref", "first-page": "1543", "DOI": "10.1056/NEJMra023009", "volume": "349", "author": "RB Darnell", "year": "2003", "unstructured": "Darnell, R. B. & Posner, J. B. Paraneoplastic syndromes involving the nervous system. N. Engl. J. Med. 349, 1543\u20131554 (2003).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrneurol2017144_CR49", "doi-asserted-by": "crossref", "first-page": "201", "DOI": "10.1038/ni0303-201", "volume": "4", "author": "RB Darnell", "year": "2003", "unstructured": "Darnell, R. B. & Posner, J. B. Observing the invisible: successful tumor immunity in humans. Nat. Immunol. 4, 201 (2003).", "journal-title": "Nat. Immunol."}, {"key": "BFnrneurol2017144_CR50", "doi-asserted-by": "crossref", "first-page": "592", "DOI": "10.1002/ana.410180513", "volume": "18", "author": "KA Jaeckle", "year": "1985", "unstructured": "Jaeckle, K. A.  et al. Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen. Ann. Neurol. 18, 592\u2013600 (1985).", "journal-title": "Ann. Neurol."}, {"key": "BFnrneurol2017144_CR51", "doi-asserted-by": "crossref", "first-page": "544", "DOI": "10.1002/ana.410270515", "volume": "27", "author": "J Dalmau", "year": "1990", "unstructured": "Dalmau, J., Furneaux, H. M., Gralla, R. J., Kris, M. G. & Posner, J. B. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer \u2014 a quantitative western blot analysis. Ann. Neurol. 27, 544\u2013552 (1990).", "journal-title": "Ann. Neurol."}, {"key": "BFnrneurol2017144_CR52", "doi-asserted-by": "crossref", "first-page": "e27384", "DOI": "10.4161/onci.27384", "volume": "2", "author": "BS Pignolet", "year": "2013", "unstructured": "Pignolet, B. S., Gebauer, C. M. & Liblau, R. S. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry. Oncoimmunology 2, e27384 (2013).", "journal-title": "Oncoimmunology"}, {"key": "BFnrneurol2017144_CR53", "doi-asserted-by": "crossref", "first-page": "3201", "DOI": "10.1002/eji.201445191", "volume": "44", "author": "L Steinman", "year": "2014", "unstructured": "Steinman, L. Conflicting consequences of immunity to cancer versus autoimmunity to neurons: insights from paraneoplastic disease. Eur. J. Immunol. 44, 3201\u20133205 (2014).", "journal-title": "Eur. J. Immunol."}, {"key": "BFnrneurol2017144_CR54", "doi-asserted-by": "crossref", "first-page": "473", "DOI": "10.1159/000477162", "volume": "10", "author": "S Schneider", "year": "2017", "unstructured": "Schneider, S., Potthast, S., Komminoth, P., Schwegler, G. & Bohm, S. PD-1 checkpoint inhibitor associated autoimmune encephalitis. Case Rep. Oncol. 10, 473\u2013478 (2017).", "journal-title": "Case Rep. Oncol."}, {"key": "BFnrneurol2017144_CR55", "doi-asserted-by": "crossref", "first-page": "46", "DOI": "10.1186/s40425-017-0249-y", "volume": "5", "author": "H Laubli", "year": "2017", "unstructured": "Laubli, H.  et al. Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. J. Immunother. Cancer 5, 46 (2017).", "journal-title": "J. Immunother. Cancer"}, {"key": "BFnrneurol2017144_CR56", "unstructured": "Salam, S., Lavin, T. & Turan, A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep. \n                    http://dx.doi.org/10.1136/bcr-2016-215012\n                    \n                   (2016).", "DOI": "10.1136/bcr-2016-215012", "doi-asserted-by": "publisher"}, {"key": "BFnrneurol2017144_CR57", "doi-asserted-by": "crossref", "first-page": "1511", "DOI": "10.1016/j.jtho.2016.05.028", "volume": "11", "author": "E Arriola", "year": "2016", "unstructured": "Arriola, E.  et al. Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC. J. Thorac. Oncol. 11, 1511\u20131521 (2016).", "journal-title": "J. Thorac. Oncol."}, {"key": "BFnrneurol2017144_CR58", "doi-asserted-by": "crossref", "first-page": "883", "DOI": "10.1016/S1470-2045(16)30098-5", "volume": "17", "author": "SJ Antonia", "year": "2016", "unstructured": "Antonia, S. J.  et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 17, 883\u2013895 (2016).", "journal-title": "Lancet Oncol."}, {"key": "BFnrneurol2017144_CR59", "doi-asserted-by": "crossref", "first-page": "33", "DOI": "10.1016/j.jaut.2014.06.004", "volume": "54", "author": "A Ben-Nun", "year": "2014", "unstructured": "Ben-Nun, A.  et al. From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development. J. Autoimmun. 54, 33\u201350 (2014).", "journal-title": "J. Autoimmun."}, {"key": "BFnrneurol2017144_CR60", "doi-asserted-by": "crossref", "first-page": "124", "DOI": "10.1016/j.jneuroim.2006.10.006", "volume": "182", "author": "LL Carter", "year": "2007", "unstructured": "Carter, L. L.  et al. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 182, 124\u2013134 (2007).", "journal-title": "J. Neuroimmunol."}, {"key": "BFnrneurol2017144_CR61", "doi-asserted-by": "crossref", "first-page": "78", "DOI": "10.1016/j.jneuroim.2014.06.018", "volume": "274", "author": "S Takizawa", "year": "2014", "unstructured": "Takizawa, S.  et al. Role of the programmed death-1 (PD-1) pathway in regulation of Theiler's murine encephalomyelitis virus-induced demyelinating disease. J. Neuroimmunol. 274, 78\u201385 (2014).", "journal-title": "J. Neuroimmunol."}, {"key": "BFnrneurol2017144_CR62", "doi-asserted-by": "crossref", "first-page": "198", "DOI": "10.1016/S1474-4422(15)00334-8", "volume": "15", "author": "R Hohlfeld", "year": "2016", "unstructured": "Hohlfeld, R., Dornmair, K., Meinl, E. & Wekerle, H. The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets. Lancet Neurol. 15, 198\u2013209 (2016).", "journal-title": "Lancet Neurol."}, {"key": "BFnrneurol2017144_CR63", "doi-asserted-by": "crossref", "first-page": "317", "DOI": "10.1016/S1474-4422(15)00313-0", "volume": "15", "author": "R Hohlfeld", "year": "2016", "unstructured": "Hohlfeld, R., Dornmair, K., Meinl, E. & Wekerle, H. The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. Lancet Neurol. 15, 317\u2013331 (2016).", "journal-title": "Lancet Neurol."}, {"key": "BFnrneurol2017144_CR64", "doi-asserted-by": "crossref", "first-page": "551", "DOI": "10.1007/s00262-017-1954-6", "volume": "66", "author": "AV Balar", "year": "2017", "unstructured": "Balar, A. V. & Weber, J. S. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol. Immunother. 66, 551\u2013564 (2017).", "journal-title": "Cancer Immunol. Immunother."}, {"key": "BFnrneurol2017144_CR65", "doi-asserted-by": "crossref", "first-page": "495", "DOI": "10.1038/nature22396", "volume": "545", "author": "SR Gordon", "year": "2017", "unstructured": "Gordon, S. R.  et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545, 495\u2013499 (2017).", "journal-title": "Nature"}, {"key": "BFnrneurol2017144_CR66", "doi-asserted-by": "crossref", "first-page": "29", "DOI": "10.1007/s11102-009-0193-z", "volume": "13", "author": "T Dillard", "year": "2010", "unstructured": "Dillard, T., Yedinak, C. G., Alumkal, J. & Fleseriu, M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 13, 29\u201338 (2010).", "journal-title": "Pituitary"}, {"key": "BFnrneurol2017144_CR67", "doi-asserted-by": "crossref", "first-page": "195", "DOI": "10.1038/nrendo.2016.205", "volume": "13", "author": "DJ Byun", "year": "2017", "unstructured": "Byun, D. J., Wolchok, J. D., Rosenberg, L. M. & Girotra, M. Cancer immunotherapy \u2014 immune checkpoint blockade and associated endocrinopathies. Nat. Rev. Endocrinol. 13, 195\u2013207 (2017).", "journal-title": "Nat. Rev. Endocrinol."}, {"key": "BFnrneurol2017144_CR68", "doi-asserted-by": "crossref", "first-page": "195", "DOI": "10.1530/EJE-14-0845", "volume": "172", "author": "F Albarel", "year": "2015", "unstructured": "Albarel, F.  et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur. J. Endocrinol. 172, 195\u2013204 (2015).", "journal-title": "Eur. J. Endocrinol."}, {"key": "BFnrneurol2017144_CR69", "doi-asserted-by": "crossref", "first-page": "905", "DOI": "10.1507/endocrj.EJ16-0161", "volume": "63", "author": "Y Okano", "year": "2016", "unstructured": "Okano, Y.  et al. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr. J. 63, 905\u2013912 (2016).", "journal-title": "Endocr. J."}, {"key": "BFnrneurol2017144_CR70", "doi-asserted-by": "crossref", "first-page": "3225", "DOI": "10.1016/j.ajpath.2016.08.020", "volume": "186", "author": "P Caturegli", "year": "2016", "unstructured": "Caturegli, P.  et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am. J. Pathol. 186, 3225\u20133235 (2016).", "journal-title": "Am. J. Pathol."}, {"key": "BFnrneurol2017144_CR71", "doi-asserted-by": "crossref", "first-page": "230ra45", "DOI": "10.1126/scitranslmed.3008002", "volume": "6", "author": "S Iwama", "year": "2014", "unstructured": "Iwama, S.  et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med. 6, 230ra45 (2014).", "journal-title": "Sci. Transl. Med."}, {"key": "BFnrneurol2017144_CR72", "doi-asserted-by": "crossref", "first-page": "2018", "DOI": "10.1056/NEJMoa1501824", "volume": "372", "author": "EB Garon", "year": "2015", "unstructured": "Garon, E. B.  et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018\u20132028 (2015).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrneurol2017144_CR73", "doi-asserted-by": "crossref", "first-page": "278", "DOI": "10.1136/practneurol-2012-000447", "volume": "13", "author": "I Bot", "year": "2013", "unstructured": "Bot, I., Blank, C. U., Boogerd, W. & Brandsma, D. Neurological immune-related adverse events of ipilimumab. Pract. Neurol. 13, 278\u2013280 (2013).", "journal-title": "Pract. Neurol."}, {"key": "BFnrneurol2017144_CR74", "doi-asserted-by": "crossref", "first-page": "e76", "DOI": "10.1200/JCO.2011.38.7886", "volume": "30", "author": "M Maur", "year": "2012", "unstructured": "Maur, M.  et al. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J. Clin. Oncol. 30, e76\u2013e78 (2012).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrneurol2017144_CR75", "doi-asserted-by": "crossref", "first-page": "1622", "DOI": "10.1093/brain/aws082", "volume": "135", "author": "CG Bien", "year": "2012", "unstructured": "Bien, C. G.  et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 135, 1622\u20131638 (2012).", "journal-title": "Brain"}, {"key": "BFnrneurol2017144_CR76", "doi-asserted-by": "crossref", "first-page": "234", "DOI": "10.1001/jamaoncol.2015.4368", "volume": "2", "author": "DB Johnson", "year": "2016", "unstructured": "Johnson, D. B.  et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2, 234\u2013240 (2016).", "journal-title": "JAMA Oncol."}, {"key": "BFnrneurol2017144_CR77", "doi-asserted-by": "crossref", "first-page": "368", "DOI": "10.1093/annonc/mdx377.007", "volume": "28", "author": "AM Menzies", "year": "2017", "unstructured": "Menzies, A. M.  et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann. Oncol. 28, 368\u2013376 (2017).", "journal-title": "Ann. Oncol."}, {"key": "BFnrneurol2017144_CR78", "doi-asserted-by": "crossref", "first-page": "1845", "DOI": "10.1056/NEJMoa1611299", "volume": "375", "author": "AM Eggermont", "year": "2016", "unstructured": "Eggermont, A. M.  et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845\u20131855 (2016).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrneurol2017144_CR79", "doi-asserted-by": "crossref", "first-page": "1237", "DOI": "10.1093/brain/awv408", "volume": "139", "author": "C Dansokho", "year": "2016", "unstructured": "Dansokho, C.  et al. Regulatory T cells delay disease progression in Alzheimer-like pathology. Brain 139, 1237\u20131251 (2016).", "journal-title": "Brain"}, {"key": "BFnrneurol2017144_CR80", "doi-asserted-by": "crossref", "first-page": "135", "DOI": "10.1038/nm.4022", "volume": "22", "author": "K Baruch", "year": "2016", "unstructured": "Baruch, K.  et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease. Nat. Med. 22, 135\u2013137 (2016).", "journal-title": "Nat. Med."}, {"key": "BFnrneurol2017144_CR81", "doi-asserted-by": "crossref", "first-page": "976", "DOI": "10.1016/S1470-2045(16)30053-5", "volume": "17", "author": "SB Goldberg", "year": "2016", "unstructured": "Goldberg, S. B.  et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 17, 976\u2013983 (2016).", "journal-title": "Lancet Oncol."}, {"key": "BFnrneurol2017144_CR82", "doi-asserted-by": "crossref", "first-page": "785", "DOI": "10.1200/JCO.2015.66.1389", "volume": "35", "author": "JS Weber", "year": "2017", "unstructured": "Weber, J. S.  et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J. Clin. Oncol. 35, 785\u2013792 (2017).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrneurol2017144_CR83", "doi-asserted-by": "crossref", "first-page": "955", "DOI": "10.1016/j.immuni.2016.05.002", "volume": "44", "author": "FA Schildberg", "year": "2016", "unstructured": "Schildberg, F. A., Klein, S. R., Freeman, G. J. & Sharpe, A. H. Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity 44, 955\u2013972 (2016).", "journal-title": "Immunity"}, {"key": "BFnrneurol2017144_CR84", "doi-asserted-by": "crossref", "first-page": "1767", "DOI": "10.1056/NEJMra1514296", "volume": "375", "author": "VA Boussiotis", "year": "2016", "unstructured": "Boussiotis, V. A. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N. Engl. J. Med. 375, 1767\u20131778 (2016).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrneurol2017144_CR85", "doi-asserted-by": "crossref", "first-page": "57", "DOI": "10.1146/annurev-immunol-030409-101243", "volume": "28", "author": "M Croft", "year": "2010", "unstructured": "Croft, M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu. Rev. Immunol. 28, 57\u201378 (2010).", "journal-title": "Annu. Rev. Immunol."}, {"key": "BFnrneurol2017144_CR86", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1016/j.ejca.2016.06.028", "volume": "67", "author": "DA Knee", "year": "2016", "unstructured": "Knee, D. A., Hewes, B. & Brogdon, J. L. Rationale for anti-GITR cancer immunotherapy. Eur. J. Cancer 67, 1\u201310 (2016).", "journal-title": "Eur. J. Cancer"}, {"key": "BFnrneurol2017144_CR87", "doi-asserted-by": "crossref", "first-page": "195", "DOI": "10.1189/jlb.0610351", "volume": "89", "author": "J Denoeud", "year": "2011", "unstructured": "Denoeud, J. & Moser, M. Role of CD27/CD70 pathway of activation in immunity and tolerance. J. Leukoc. Biol. 89, 195\u2013203 (2011).", "journal-title": "J. Leukoc. Biol."}, {"key": "BFnrneurol2017144_CR88", "doi-asserted-by": "crossref", "first-page": "117", "DOI": "10.3389/fonc.2015.00117", "volume": "5", "author": "T Bartkowiak", "year": "2015", "unstructured": "Bartkowiak, T. & Curran, M. A. 4-1BB agonists: multi-potent potentiators of tumor immunity. Front. Oncol. 5, 117 (2015).", "journal-title": "Front. Oncol."}, {"key": "BFnrneurol2017144_CR89", "doi-asserted-by": "crossref", "first-page": "513", "DOI": "10.1002/eji.201445388", "volume": "46", "author": "AR Sanchez-Paulete", "year": "2016", "unstructured": "Sanchez-Paulete, A. R.  et al. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy. Eur. J. Immunol. 46, 513\u2013522 (2016).", "journal-title": "Eur. J. Immunol."}, {"key": "BFnrneurol2017144_CR90", "doi-asserted-by": "crossref", "first-page": "307", "DOI": "10.1146/annurev.immunol.22.012703.104533", "volume": "22", "author": "SA Quezada", "year": "2004", "unstructured": "Quezada, S. A., Jarvinen, L. Z., Lind, E. F. & Noelle, R. J. CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol. 22, 307\u2013328 (2004).", "journal-title": "Annu. Rev. Immunol."}, {"key": "BFnrneurol2017144_CR91", "doi-asserted-by": "crossref", "first-page": "3", "DOI": "10.1186/s40425-016-0107-3", "volume": "4", "author": "J Yuan", "year": "2016", "unstructured": "Yuan, J.  et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J. Immunother. Cancer 4, 3 (2016).", "journal-title": "J. Immunother. Cancer"}, {"key": "BFnrneurol2017144_CR92", "doi-asserted-by": "crossref", "first-page": "10391", "DOI": "10.1038/ncomms10391", "volume": "7", "author": "K Dubin", "year": "2016", "unstructured": "Dubin, K.  et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016).", "journal-title": "Nat. Commun."}, {"key": "BFnrneurol2017144_CR93", "doi-asserted-by": "crossref", "first-page": "1255", "DOI": "10.1016/j.immuni.2016.06.001", "volume": "44", "author": "JM Pitt", "year": "2016", "unstructured": "Pitt, J. M.  et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity 44, 1255\u20131269 (2016).", "journal-title": "Immunity"}, {"key": "BFnrneurol2017144_CR94", "doi-asserted-by": "crossref", "first-page": "1084", "DOI": "10.1126/science.aac4255", "volume": "350", "author": "A Sivan", "year": "2015", "unstructured": "Sivan, A.  et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084\u20131089 (2015).", "journal-title": "Science"}, {"key": "BFnrneurol2017144_CR95", "doi-asserted-by": "crossref", "first-page": "1428", "DOI": "10.1126/science.aaf1292", "volume": "355", "author": "E Hui", "year": "2017", "unstructured": "Hui, E.  et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 355, 1428\u20131433 (2017).", "journal-title": "Science"}, {"key": "BFnrneurol2017144_CR96", "doi-asserted-by": "crossref", "first-page": "1423", "DOI": "10.1126/science.aaf0683", "volume": "355", "author": "AO Kamphorst", "year": "2017", "unstructured": "Kamphorst, A. O.  et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355, 1423\u20131427 (2017).", "journal-title": "Science"}, {"key": "BFnrneurol2017144_CR97", "doi-asserted-by": "crossref", "first-page": "11929", "DOI": "10.1523/JNEUROSCI.1860-14.2014", "volume": "34", "author": "Y Zhang", "year": "2014", "unstructured": "Zhang, Y.  et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34, 11929\u201311947 (2014).", "journal-title": "J. Neurosci."}, {"key": "BFnrneurol2017144_CR98", "first-page": "87", "volume": "7", "author": "V Mishra", "year": "2015", "unstructured": "Mishra, V., Schuetz, H. & Haorah, J. Differential induction of PD-1/PD-L1 in neuroimmune cells by drug of abuse. Int. J. Physiol. Pathophysiol. Pharmacol. 7, 87\u201397 (2015).", "journal-title": "Int. J. Physiol. Pathophysiol. Pharmacol."}, {"key": "BFnrneurol2017144_CR99", "doi-asserted-by": "crossref", "first-page": "47", "DOI": "10.1080/09273940802491884", "volume": "17", "author": "L Chen", "year": "2009", "unstructured": "Chen, L.  et al. Constitutive neuronal expression of the immune regulator, programmed death 1 (PD-1), identified during experimental autoimmune uveitis. Ocul. Immunol. Inflamm. 17, 47\u201355 (2009).", "journal-title": "Ocul. Immunol. Inflamm."}, {"key": "BFnrneurol2017144_CR100", "doi-asserted-by": "crossref", "first-page": "2578", "DOI": "10.1161/STROKEAHA.111.613182", "volume": "42", "author": "X Ren", "year": "2011", "unstructured": "Ren, X., Akiyoshi, K., Vandenbark, A. A., Hurn, P. D. & Offner, H. Programmed death-1 pathway limits central nervous system inflammation and neurologic deficits in murine experimental stroke. Stroke 42, 2578\u20132583 (2011).", "journal-title": "Stroke"}, {"key": "BFnrneurol2017144_CR101", "doi-asserted-by": "crossref", "first-page": "5430", "DOI": "10.4049/jimmunol.0803557", "volume": "182", "author": "TW Phares", "year": "2009", "unstructured": "Phares, T. W.  et al. Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity. J. Immunol. 182, 5430\u20135438 (2009).", "journal-title": "J. Immunol."}, {"key": "BFnrneurol2017144_CR102", "doi-asserted-by": "crossref", "first-page": "3117", "DOI": "10.1002/eji.200324270", "volume": "33", "author": "N Rodig", "year": "2003", "unstructured": "Rodig, N.  et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur. J. Immunol. 33, 3117\u20133126 (2003).", "journal-title": "Eur. J. Immunol."}, {"key": "BFnrneurol2017144_CR103", "doi-asserted-by": "crossref", "first-page": "2706", "DOI": "10.1002/eji.200838137", "volume": "38", "author": "B Schreiner", "year": "2008", "unstructured": "Schreiner, B., Bailey, S. L., Shin, T., Chen, L. & Miller, S. D. PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE. Eur. J. Immunol. 38, 2706\u20132717 (2008).", "journal-title": "Eur. J. Immunol."}, {"key": "BFnrneurol2017144_CR104", "doi-asserted-by": "crossref", "first-page": "155", "DOI": "10.1186/1742-2094-8-155", "volume": "8", "author": "CL Pittet", "year": "2011", "unstructured": "Pittet, C. L., Newcombe, J., Prat, A. & Arbour, N. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. J. Neuroinflammation 8, 155 (2011).", "journal-title": "J. Neuroinflammation"}, {"key": "BFnrneurol2017144_CR105", "doi-asserted-by": "crossref", "first-page": "135", "DOI": "10.1038/nn2034", "volume": "11", "author": "GW O'Keeffe", "year": "2008", "unstructured": "O'Keeffe, G. W., Gutierrez, H., Pandolfi, P. P., Riccardi, C. & Davies, A. M. NGF-promoted axon growth and target innervation requires GITRL\u2013GITR signaling. Nat. Neurosci. 11, 135\u2013142 (2008).", "journal-title": "Nat. Neurosci."}, {"key": "BFnrneurol2017144_CR106", "doi-asserted-by": "crossref", "first-page": "2188", "DOI": "10.1002/jnr.22378", "volume": "88", "author": "H Hwang", "year": "2010", "unstructured": "Hwang, H., Lee, S., Lee, W. H., Lee, H. J. & Suk, K. Stimulation of glucocorticoid-induced tumor necrosis factor receptor family-related protein ligand (GITRL) induces inflammatory activation of microglia in culture. J. Neurosci. Res. 88, 2188\u20132196 (2010).", "journal-title": "J. Neurosci. Res."}, {"key": "BFnrneurol2017144_CR107", "doi-asserted-by": "crossref", "first-page": "1141", "DOI": "10.1126/science.1148536", "volume": "318", "author": "AC Anderson", "year": "2007", "unstructured": "Anderson, A. C.  et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 318, 1141\u20131143 (2007).", "journal-title": "Science"}, {"key": "BFnrneurol2017144_CR108", "doi-asserted-by": "crossref", "first-page": "e30892", "DOI": "10.1371/journal.pone.0030892", "volume": "7", "author": "D Wei", "year": "2012", "unstructured": "Wei, D., Ren, C., Chen, X. & Zhao, H. The chronic protective effects of limb remote preconditioning and the underlying mechanisms involved in inflammatory factors in rat stroke. PLoS ONE 7, e30892 (2012).", "journal-title": "PLoS ONE"}, {"key": "BFnrneurol2017144_CR109", "doi-asserted-by": "crossref", "first-page": "aah3374", "DOI": "10.1126/science.aah3374", "volume": "353", "author": "X Mao", "year": "2016", "unstructured": "Mao, X.  et al. Pathological \u03b1-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353, aah3374 (2016).", "journal-title": "Science"}, {"key": "BFnrneurol2017144_CR110", "doi-asserted-by": "crossref", "first-page": "7", "DOI": "10.1016/S0165-5728(99)00124-1", "volume": "101", "author": "N Abdel-Haq", "year": "1999", "unstructured": "Abdel-Haq, N., Hao, H. N. & Lyman, W. D. Cytokine regulation of CD40 expression in fetal human astrocyte cultures. J. Neuroimmunol. 101, 7\u201314 (1999).", "journal-title": "J. Neuroimmunol."}, {"key": "BFnrneurol2017144_CR111", "doi-asserted-by": "crossref", "first-page": "643", "DOI": "10.1093/emboj/21.4.643", "volume": "21", "author": "J Tan", "year": "2002", "unstructured": "Tan, J.  et al. CD40 is expressed and functional on neuronal cells. EMBO J. 21, 643\u2013652 (2002).", "journal-title": "EMBO J."}, {"key": "BFnrneurol2017144_CR112", "doi-asserted-by": "crossref", "first-page": "1402", "DOI": "10.4049/jimmunol.176.3.1402", "volume": "176", "author": "ED Ponomarev", "year": "2006", "unstructured": "Ponomarev, E. D., Shriver, L. P. & Dittel, B. N. CD40 expression by microglial cells is required for their completion of a two-step activation process during central nervous system autoimmune inflammation. J. Immunol. 176, 1402\u20131410 (2006).", "journal-title": "J. Immunol."}, {"key": "BFnrneurol2017144_CR113", "doi-asserted-by": "crossref", "first-page": "166", "DOI": "10.1016/S0165-5728(02)00423-X", "volume": "134", "author": "KM Omari", "year": "2003", "unstructured": "Omari, K. M. & Dorovini-Zis, K. CD40 expressed by human brain endothelial cells regulates CD4+ T cell adhesion to endothelium. J. Neuroimmunol. 134, 166\u2013178 (2003).", "journal-title": "J. Neuroimmunol."}, {"key": "BFnrneurol2017144_CR114", "doi-asserted-by": "crossref", "first-page": "67", "DOI": "10.1002/jnr.10727", "volume": "74", "author": "C Reali", "year": "2003", "unstructured": "Reali, C.  et al. Expression of CD137 and its ligand in human neurons, astrocytes, and microglia: modulation by FGF-2. J. Neurosci. Res. 74, 67\u201373 (2003).", "journal-title": "J. Neurosci. Res."}, {"key": "BFnrneurol2017144_CR115", "doi-asserted-by": "crossref", "first-page": "e56", "DOI": "10.1111/nan.12135", "volume": "41", "author": "AE Blank", "year": "2015", "unstructured": "Blank, A. E.  et al. Tumour necrosis factor receptor superfamily member 9 (TNFRSF9) is up-regulated in reactive astrocytes in human gliomas. Neuropathol. Appl. Neurobiol. 41, e56\u2013e67 (2015).", "journal-title": "Neuropathol. Appl. Neurobiol."}], "container-title": ["Nature Reviews Neurology"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/nrneurol.2017.144.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrneurol.2017.144", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/doifinder/10.1038/nrneurol.2017.144", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}, {"URL": "http://www.nature.com/articles/nrneurol.2017.144.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 10, 2]], "date-time": "2019-10-02T20:30:25Z", "timestamp": 1570048225000}, "score": 74.85938, "issued": {"date-parts": [[2017, 11, 6]]}, "references-count": 115, "journal-issue": {"published-print": {"date-parts": [[2017, 12]]}, "issue": "12"}, "alternative-id": ["BFnrneurol2017144"], "URL": "http://dx.doi.org/10.1038/nrneurol.2017.144", "relation": {"cites": []}, "ISSN": ["1759-4758", "1759-4766"], "issn-type": [{"value": "1759-4758", "type": "print"}, {"value": "1759-4766", "type": "electronic"}], "assertion": [{"value": "6 November 2017", "order": 1, "name": "first_online", "label": "First Online", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"value": "The authors declare no competing financial interests.", "order": 1, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Competing interests"}}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T16:47:44Z", "timestamp": 1575305264780}, "reference-count": 159, "publisher": "Springer Science and Business Media LLC", "issue": "6", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2018, 5, 24]], "date-time": "2018-05-24T00:00:00Z", "timestamp": 1527120000000}, "delay-in-days": 0, "content-version": "tdm"}], "funder": [{"name": "Princess Margaret Cancer Foundation OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development.", "award": []}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["CNS Drugs"], "published-print": {"date-parts": [[2018, 6]]}, "DOI": "10.1007/s40263-018-0526-4", "type": "journal-article", "created": {"date-parts": [[2018, 5, 24]], "date-time": "2018-05-24T05:16:50Z", "timestamp": 1527139010000}, "page": "527-542", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors"], "prefix": "10.1007", "volume": "32", "author": [{"given": "Grainne M.", "family": "O\u2019Kane", "sequence": "first", "affiliation": []}, {"ORCID": "http://orcid.org/0000-0002-8690-403X", "authenticated-orcid": false, "given": "Natasha B.", "family": "Leighl", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2018, 5, 24]]}, "reference": [{"issue": "1", "key": "526_CR1", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1016/j.nec.2010.08.007", "volume": "22", "author": "BD Fox", "year": "2011", "unstructured": "Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G. Epidemiology of metastatic brain tumors. Neurosurg Clin N Am. 2011;22(1):1\u20136, v.", "journal-title": "Neurosurg Clin N Am."}, {"issue": "3", "key": "526_CR2", "doi-asserted-by": "publisher", "first-page": "275", "DOI": "10.1007/s11060-009-9839-y", "volume": "92", "author": "G Al-Shamy", "year": "2009", "unstructured": "Al-Shamy G, Sawaya R. Management of brain metastases: the indispensable role of surgery. J Neurooncol. 2009;92(3):275\u201382.", "journal-title": "J Neurooncol"}, {"issue": "3", "key": "526_CR3", "doi-asserted-by": "publisher", "first-page": "293", "DOI": "10.1081/CNV-120001173", "volume": "20", "author": "G Bernardo", "year": "2002", "unstructured": "Bernardo G, Cuzzoni Q, Strada MR, Bernardo A, Brunetti G, Jedrychowska I, et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest. 2002;20(3):293\u2013302.", "journal-title": "Cancer Invest"}, {"issue": "19", "key": "526_CR4", "doi-asserted-by": "publisher", "first-page": "1823", "DOI": "10.1056/NEJMoa1606774", "volume": "375", "author": "M Reck", "year": "2016", "unstructured": "Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.", "journal-title": "N Engl J Med"}, {"key": "526_CR5", "doi-asserted-by": "publisher", "first-page": "166", "DOI": "10.1186/1748-717X-6-166", "volume": "6", "author": "O Arrieta", "year": "2011", "unstructured": "Arrieta O, Villarreal-Garza C, Zamora J, Blake-Cerda M, de la Mata MD, Zavala DG, et al. Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation. Radiat Oncol. 2011;6:166.", "journal-title": "Radiat Oncol."}, {"issue": "4", "key": "526_CR6", "doi-asserted-by": "publisher", "first-page": "682", "DOI": "10.1002/1097-0142(195407)7:4<682::AID-CNCR2820070409>3.0.CO;2-S", "volume": "7", "author": "JH Chao", "year": "1954", "unstructured": "Chao JH, Phillips R, Nickson JJ. Roentgen-ray therapy of cerebral metastases. Cancer. 1954;7(4):682\u20139.", "journal-title": "Cancer"}, {"issue": "21", "key": "526_CR7", "doi-asserted-by": "publisher", "first-page": "5038", "DOI": "10.1002/cncr.25254", "volume": "116", "author": "JL Hubbs", "year": "2010", "unstructured": "Hubbs JL, Boyd JA, Hollis D, Chino JP, Saynak M, Kelsey CR. Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer. 2010;116(21):5038\u201346.", "journal-title": "Cancer"}, {"issue": "9", "key": "526_CR8", "doi-asserted-by": "publisher", "first-page": "953", "DOI": "10.1200/JCO.2015.64.8824", "volume": "34", "author": "S Senan", "year": "2016", "unstructured": "Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34(9):953\u201362.", "journal-title": "J Clin Oncol"}, {"issue": "4", "key": "526_CR9", "doi-asserted-by": "publisher", "first-page": "312", "DOI": "10.3111/13696998.2014.1003644", "volume": "18", "author": "A Guerin", "year": "2015", "unstructured": "Guerin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R, et al. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. J Med Econ. 2015;18(4):312\u201322.", "journal-title": "J Med Econ"}, {"issue": "18", "key": "526_CR10", "doi-asserted-by": "publisher", "first-page": "4502", "DOI": "10.1002/cncr.27409", "volume": "118", "author": "RC Doebele", "year": "2012", "unstructured": "Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer. 2012;118(18):4502\u201311.", "journal-title": "Cancer"}, {"issue": "2", "key": "526_CR11", "doi-asserted-by": "publisher", "first-page": "173", "DOI": "10.2478/raon-2014-0016", "volume": "48", "author": "K Stanic", "year": "2014", "unstructured": "Stanic K, Zwitter M, Hitij NT, Kern I, Sadikov A, Cufer T. Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiol Oncol. 2014;48(2):173\u201383.", "journal-title": "Radiol Oncol."}, {"key": "526_CR12", "doi-asserted-by": "publisher", "first-page": "101", "DOI": "10.1016/j.lungcan.2016.04.004", "volume": "96", "author": "F Hsu", "year": "2016", "unstructured": "Hsu F, De Caluwe A, Anderson D, Nichol A, Toriumi T, Ho C. EGFR mutation status on brain metastases from non-small cell lung cancer. Lung Cancer. 2016;96:101\u20137.", "journal-title": "Lung Cancer"}, {"issue": "4", "key": "526_CR13", "doi-asserted-by": "publisher", "first-page": "419", "DOI": "10.1200/JCO.2011.38.0527", "volume": "30", "author": "PW Sperduto", "year": "2012", "unstructured": "Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419\u201325.", "journal-title": "J Clin Oncol"}, {"issue": "6", "key": "526_CR14", "doi-asserted-by": "publisher", "first-page": "827", "DOI": "10.1001/jamaoncol.2016.3834", "volume": "3", "author": "PW Sperduto", "year": "2017", "unstructured": "Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol. 2017;3(6):827\u201331.", "journal-title": "JAMA Oncol"}, {"issue": "2", "key": "526_CR15", "first-page": "98", "volume": "8", "author": "S Paget", "year": "1989", "unstructured": "Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8(2):98\u2013101.", "journal-title": "Cancer Metastasis Rev"}, {"issue": "7249", "key": "526_CR16", "doi-asserted-by": "publisher", "first-page": "1005", "DOI": "10.1038/nature08021", "volume": "459", "author": "PD Bos", "year": "2009", "unstructured": "Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459(7249):1005\u20139.", "journal-title": "Nature"}, {"issue": "5", "key": "526_CR17", "doi-asserted-by": "publisher", "first-page": "1755", "DOI": "10.1158/1078-0432.CCR-08-2124", "volume": "15", "author": "H Grinberg-Rashi", "year": "2009", "unstructured": "Grinberg-Rashi H, Ofek E, Perelman M, Skarda J, Yaron P, Hajduch M, et al. The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. Clin Cancer Res. 2009;15(5):1755\u201361.", "journal-title": "Clin Cancer Res"}, {"issue": "6", "key": "526_CR18", "doi-asserted-by": "publisher", "first-page": "1193", "DOI": "10.1083/jcb.151.6.1193", "volume": "151", "author": "JB Kim", "year": "2000", "unstructured": "Kim JB, Islam S, Kim YJ, Prudoff RS, Sass KM, Wheelock MJ, et al. N-Cadherin extracellular repeat 4 mediates epithelial to mesenchymal transition and increased motility. J Cell Biol. 2000;151(6):1193\u2013206.", "journal-title": "J Cell Biol"}, {"issue": "2", "key": "526_CR19", "doi-asserted-by": "publisher", "first-page": "219", "DOI": "10.1007/s11060-012-0890-8", "volume": "109", "author": "JY Yoo", "year": "2012", "unstructured": "Yoo JY, Yang SH, Lee JE, Cho DG, Kim HK, Kim SH, et al. E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer, and its regulation by pioglitazone in a preclinical model. J Neurooncol. 2012;109(2):219\u201327.", "journal-title": "J Neurooncol"}, {"issue": "12", "key": "526_CR20", "doi-asserted-by": "publisher", "first-page": "4190", "DOI": "10.1158/0008-5472.CAN-03-3235", "volume": "64", "author": "Y Shintani", "year": "2004", "unstructured": "Shintani Y, Higashiyama S, Ohta M, Hirabayashi H, Yamamoto S, Yoshimasu T, et al. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res. 2004;64(12):4190\u20136.", "journal-title": "Cancer Res"}, {"issue": "18", "key": "526_CR21", "doi-asserted-by": "publisher", "first-page": "5229", "DOI": "10.1158/0008-5472.CAN-13-2995", "volume": "74", "author": "CY Lin", "year": "2014", "unstructured": "Lin CY, Chen HJ, Huang CC, Lai LC, Lu TP, Tseng GC, et al. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Res. 2014;74(18):5229\u201343.", "journal-title": "Cancer Res"}, {"issue": "11", "key": "526_CR22", "doi-asserted-by": "publisher", "first-page": "1164", "DOI": "10.1158/2159-8290.CD-15-0369", "volume": "5", "author": "PK Brastianos", "year": "2015", "unstructured": "Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015;5(11):1164\u201377.", "journal-title": "Cancer Discov"}, {"issue": "6", "key": "526_CR23", "doi-asserted-by": "publisher", "first-page": "1663", "DOI": "10.1158/1078-0432.CCR-06-2854", "volume": "13", "author": "JF Deeken", "year": "2007", "unstructured": "Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007;13(6):1663\u201374.", "journal-title": "Clin Cancer Res"}, {"issue": "7", "key": "526_CR24", "doi-asserted-by": "publisher", "first-page": "741", "DOI": "10.1001/archneur.1988.00520310047016", "volume": "45", "author": "JY Delattre", "year": "1988", "unstructured": "Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases. Arch Neurol. 1988;45(7):741\u20134.", "journal-title": "Arch Neurol"}, {"issue": "5", "key": "526_CR25", "doi-asserted-by": "publisher", "first-page": "443", "DOI": "10.1016/S1474-4422(06)70443-4", "volume": "5", "author": "B Gleissner", "year": "2006", "unstructured": "Gleissner B, Chamberlain MC. Neoplastic meningitis. Lancet Neurol. 2006;5(5):443\u201352.", "journal-title": "Lancet Neurol"}, {"issue": "1", "key": "526_CR26", "doi-asserted-by": "publisher", "first-page": "207", "DOI": "10.1083/jcb.34.1.207", "volume": "34", "author": "TS Reese", "year": "1967", "unstructured": "Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol. 1967;34(1):207\u201317.", "journal-title": "J Cell Biol"}, {"key": "526_CR27", "doi-asserted-by": "publisher", "first-page": "2859", "DOI": "10.1038/srep02859", "volume": "3", "author": "X Liu", "year": "2013", "unstructured": "Liu X, Ide JL, Norton I, Marchionni MA, Ebling MC, Wang LY, et al. Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging. Sci Rep. 2013;3:2859.", "journal-title": "Sci Rep."}, {"issue": "2", "key": "526_CR28", "doi-asserted-by": "publisher", "first-page": "173", "DOI": "10.1124/pr.57.2.4", "volume": "57", "author": "BT Hawkins", "year": "2005", "unstructured": "Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57(2):173\u201385.", "journal-title": "Pharmacol Rev"}, {"issue": "5", "key": "526_CR29", "doi-asserted-by": "publisher", "first-page": "1781", "DOI": "10.1046/j.1471-4159.1998.70051781.x", "volume": "70", "author": "WM Pardridge", "year": "1998", "unstructured": "Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J Neurochem. 1998;70(5):1781\u201392.", "journal-title": "J Neurochem"}, {"issue": "10", "key": "526_CR30", "doi-asserted-by": "publisher", "first-page": "8366", "DOI": "10.18632/oncotarget.3187", "volume": "6", "author": "YD Zeng", "year": "2015", "unstructured": "Zeng YD, Liao H, Qin T, Zhang L, Wei WD, Liang JZ, et al. Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. Oncotarget. 2015;6(10):8366\u201376.", "journal-title": "Oncotarget"}, {"issue": "17", "key": "526_CR31", "doi-asserted-by": "publisher", "first-page": "1485", "DOI": "10.1001/jama.280.17.1485", "volume": "280", "author": "RA Patchell", "year": "1998", "unstructured": "Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280(17):1485\u20139.", "journal-title": "JAMA"}, {"issue": "8", "key": "526_CR32", "doi-asserted-by": "publisher", "first-page": "494", "DOI": "10.1056/NEJM199002223220802", "volume": "322", "author": "RA Patchell", "year": "1990", "unstructured": "Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494\u2013500.", "journal-title": "N Engl J Med"}, {"key": "526_CR33", "author": "MA Kamp", "year": "2018", "unstructured": "Kamp MA, Dibue-Adjei M, Cornelius JF, Slotty PJ, Steiger HJ, Ahmadi SA, et al. Is it all a matter of size? Impact of maximization of surgical resection in cerebral tumors. Neurosurg Rev. 2018. \n                    https://doi.org/10.1007/s10143-018-0963-z\n                    \n                   (Epub 20 Mar 2018).", "journal-title": "Neurosurg Rev", "DOI": "10.1007/s10143-018-0963-z", "doi-asserted-by": "publisher"}, {"key": "526_CR34", "doi-asserted-by": "publisher", "first-page": "6", "DOI": "10.1016/j.wneu.2016.06.098", "volume": "94", "author": "F Pessina", "year": "2016", "unstructured": "Pessina F, Navarria P, Cozzi L, Ascolese AM, Maggi G, Rossi M, et al. role of surgical resection in patients with single large brain metastases: feasibility, morbidity, and local control evaluation. World Neurosurg. 2016;94:6\u201312.", "journal-title": "World Neurosurg"}, {"issue": "3", "key": "526_CR35", "doi-asserted-by": "publisher", "first-page": "299", "DOI": "10.1007/s11060-007-9510-4", "volume": "87", "author": "A Muacevic", "year": "2008", "unstructured": "Muacevic A, Wowra B, Siefert A, Tonn JC, Steiger HJ, Kreth FW. Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial. J Neurooncol. 2008;87(3):299\u2013307.", "journal-title": "J Neurooncol"}, {"key": "526_CR36", "doi-asserted-by": "publisher", "first-page": "144", "DOI": "10.12659/MSM.892405", "volume": "21", "author": "H Qin", "year": "2015", "unstructured": "Qin H, Wang C, Jiang Y, Zhang X, Zhang Y, Ruan Z. Patients with single brain metastasis from non-small cell lung cancer equally benefit from stereotactic radiosurgery and surgery: a systematic review. Med Sci Monit. 2015;21:144\u201352.", "journal-title": "Med Sci Monit"}, {"issue": "5", "key": "526_CR37", "first-page": "1021", "volume": "56", "author": "SH Paek", "year": "2005", "unstructured": "Paek SH, Audu PB, Sperling MR, Cho J, Andrews DW. Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery. 2005;56(5):1021\u201334 (discussion 34).", "journal-title": "Neurosurgery"}, {"key": "526_CR38", "first-page": "CD003869", "volume": "4", "author": "MN Tsao", "year": "2012", "unstructured": "Tsao MN, Lloyd N, Wong RK, Chow E, Rakovitch E, Laperriere N, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev. 2012;4:CD003869.", "journal-title": "Cochrane Database Syst Rev"}, {"issue": "1", "key": "526_CR39", "doi-asserted-by": "publisher", "first-page": "65", "DOI": "10.1200/JCO.2011.41.0639", "volume": "31", "author": "R Soffietti", "year": "2013", "unstructured": "Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, et al. A European organisation for research and treatment of cancer phase iii trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013;31(1):65\u201372.", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "526_CR40", "doi-asserted-by": "publisher", "first-page": "134", "DOI": "10.1200/JCO.2010.30.1655", "volume": "29", "author": "M Kocher", "year": "2011", "unstructured": "Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134\u201341.", "journal-title": "J Clin Oncol"}, {"issue": "11", "key": "526_CR41", "doi-asserted-by": "publisher", "first-page": "1037", "DOI": "10.1016/S1470-2045(09)70263-3", "volume": "10", "author": "EL Chang", "year": "2009", "unstructured": "Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037\u201344.", "journal-title": "Lancet Oncol"}, {"issue": "10055", "key": "526_CR42", "doi-asserted-by": "publisher", "first-page": "2004", "DOI": "10.1016/S0140-6736(16)30825-X", "volume": "388", "author": "P Mulvenna", "year": "2016", "unstructured": "Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388(10055):2004\u201314.", "journal-title": "Lancet"}, {"issue": "4", "key": "526_CR43", "doi-asserted-by": "publisher", "first-page": "387", "DOI": "10.1016/S1470-2045(14)70061-0", "volume": "15", "author": "M Yamamoto", "year": "2014", "unstructured": "Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15(4):387\u201395.", "journal-title": "Lancet Oncol"}, {"issue": "5", "key": "526_CR44", "doi-asserted-by": "publisher", "first-page": "674", "DOI": "10.3109/02688697.2012.690913", "volume": "26", "author": "KE Banfill", "year": "2012", "unstructured": "Banfill KE, Bownes PJ, St Clair SE, Loughrey C, Hatfield P. Stereotactic radiosurgery for the treatment of brain metastases: impact of cerebral disease burden on survival. Br J Neurosurg. 2012;26(5):674\u20138.", "journal-title": "Br J Neurosurg"}, {"issue": "9", "key": "526_CR45", "doi-asserted-by": "publisher", "first-page": "2486", "DOI": "10.1002/cncr.26515", "volume": "118", "author": "M Tsao", "year": "2012", "unstructured": "Tsao M, Xu W, Sahgal A. A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer. 2012;118(9):2486\u201393.", "journal-title": "Cancer"}, {"issue": "2", "key": "526_CR46", "doi-asserted-by": "publisher", "first-page": "382", "DOI": "10.1097/JTO.0b013e3182398e4f", "volume": "7", "author": "PG Morris", "year": "2012", "unstructured": "Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012;7(2):382\u20135.", "journal-title": "J Thorac Oncol"}, {"issue": "1", "key": "526_CR47", "doi-asserted-by": "publisher", "first-page": "59", "DOI": "10.1023/A:1008338312647", "volume": "12", "author": "G Robinet", "year": "2001", "unstructured": "Robinet G, Thomas P, Breton JL, Lena H, Gouva S, Dabouis G, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol. 2001;12(1):59\u201367.", "journal-title": "Ann Oncol"}, {"issue": "11", "key": "526_CR48", "doi-asserted-by": "publisher", "first-page": "2466", "DOI": "10.1093/annonc/mdr003", "volume": "22", "author": "F Barlesi", "year": "2011", "unstructured": "Barlesi F, Gervais R, Lena H, Hureaux J, Berard H, Paillotin D, et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol. 2011;22(11):2466\u201370.", "journal-title": "Ann Oncol"}, {"issue": "4", "key": "526_CR49", "doi-asserted-by": "publisher", "first-page": "873", "DOI": "10.1007/s00280-015-2847-z", "volume": "76", "author": "L Fang", "year": "2015", "unstructured": "Fang L, Sun X, Song Y, Zhang Y, Li F, Xu Y, et al. Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study. Cancer Chemother Pharmacol. 2015;76(4):873\u20137.", "journal-title": "Cancer Chemother Pharmacol"}, {"issue": "36", "key": "526_CR50", "doi-asserted-by": "publisher", "first-page": "13306", "DOI": "10.1073/pnas.0405220101", "volume": "101", "author": "W Pao", "year": "2004", "unstructured": "Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101(36):13306\u201311.", "journal-title": "Proc Natl Acad Sci USA"}, {"issue": "5676", "key": "526_CR51", "doi-asserted-by": "publisher", "first-page": "1497", "DOI": "10.1126/science.1099314", "volume": "304", "author": "JG Paez", "year": "2004", "unstructured": "Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497\u2013500.", "journal-title": "Science"}, {"issue": "21", "key": "526_CR52", "doi-asserted-by": "publisher", "first-page": "2129", "DOI": "10.1056/NEJMoa040938", "volume": "350", "author": "TJ Lynch", "year": "2004", "unstructured": "Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129\u201339.", "journal-title": "N Engl J Med"}, {"issue": "2", "key": "526_CR53", "doi-asserted-by": "publisher", "first-page": "154", "DOI": "10.1097/JTO.0000000000000033", "volume": "9", "author": "Y Shi", "year": "2014", "unstructured": "Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154\u201362.", "journal-title": "J Thorac Oncol"}, {"issue": "3", "key": "526_CR54", "doi-asserted-by": "publisher", "first-page": "239", "DOI": "10.1016/S1470-2045(11)70393-X", "volume": "13", "author": "R Rosell", "year": "2012", "unstructured": "Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239\u201346.", "journal-title": "Lancet Oncol"}, {"issue": "10", "key": "526_CR55", "doi-asserted-by": "publisher", "first-page": "947", "DOI": "10.1056/NEJMoa0810699", "volume": "361", "author": "TS Mok", "year": "2009", "unstructured": "Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947\u201357.", "journal-title": "N Engl J Med"}, {"issue": "25", "key": "526_CR56", "doi-asserted-by": "publisher", "first-page": "2380", "DOI": "10.1056/NEJMoa0909530", "volume": "362", "author": "M Maemondo", "year": "2010", "unstructured": "Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380\u20138.", "journal-title": "N Engl J Med"}, {"issue": "2", "key": "526_CR57", "doi-asserted-by": "publisher", "first-page": "121", "DOI": "10.1016/S1470-2045(09)70364-X", "volume": "11", "author": "T Mitsudomi", "year": "2010", "unstructured": "Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121\u20138.", "journal-title": "Lancet Oncol"}, {"issue": "9", "key": "526_CR58", "doi-asserted-by": "publisher", "first-page": "1877", "DOI": "10.1093/annonc/mdv276", "volume": "26", "author": "C Zhou", "year": "2015", "unstructured": "Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015;26(9):1877\u201383.", "journal-title": "Ann Oncol"}, {"issue": "27", "key": "526_CR59", "doi-asserted-by": "publisher", "first-page": "3327", "DOI": "10.1200/JCO.2012.44.2806", "volume": "31", "author": "LV Sequist", "year": "2013", "unstructured": "Sequist LV, Yang JC, Yamamoto N, O\u2019Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327\u201334.", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "526_CR60", "doi-asserted-by": "publisher", "first-page": "213", "DOI": "10.1016/S1470-2045(13)70604-1", "volume": "15", "author": "YL Wu", "year": "2014", "unstructured": "Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213\u201322.", "journal-title": "Lancet Oncol"}, {"issue": "9", "key": "526_CR61", "doi-asserted-by": "publisher", "first-page": "1883", "DOI": "10.1093/annonc/mdv270", "volume": "26", "author": "YL Wu", "year": "2015", "unstructured": "Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26(9):1883\u20139.", "journal-title": "Ann Oncol"}, {"issue": "2", "key": "526_CR62", "doi-asserted-by": "publisher", "first-page": "141", "DOI": "10.1016/S1470-2045(14)71173-8", "volume": "16", "author": "JC Yang", "year": "2015", "unstructured": "Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141\u201351.", "journal-title": "Lancet Oncol"}, {"key": "526_CR63", "doi-asserted-by": "publisher", "first-page": "40374", "DOI": "10.1038/srep40374", "volume": "7", "author": "D Zhao", "year": "2017", "unstructured": "Zhao D, Chen X, Qin N, Su D, Zhou L, Zhang Q, et al. The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer. Sci Rep. 2017;7:40374.", "journal-title": "Sci Rep"}, {"issue": "2", "key": "526_CR64", "doi-asserted-by": "publisher", "first-page": "113", "DOI": "10.1056/NEJMoa1713137", "volume": "378", "author": "JC Soria", "year": "2018", "unstructured": "Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325.", "journal-title": "N Engl J Med"}, {"issue": "23", "key": "526_CR65", "doi-asserted-by": "publisher", "first-page": "5873", "DOI": "10.1158/1078-0432.CCR-10-1588", "volume": "16", "author": "S Heon", "year": "2010", "unstructured": "Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010;16(23):5873\u201382.", "journal-title": "Clin Cancer Res"}, {"issue": "11", "key": "526_CR66", "doi-asserted-by": "publisher", "first-page": "1193", "DOI": "10.1093/neuonc/noq076", "volume": "12", "author": "AF Eichler", "year": "2010", "unstructured": "Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010;12(11):1193\u20139.", "journal-title": "Neuro Oncol"}, {"issue": "27", "key": "526_CR67", "doi-asserted-by": "publisher", "first-page": "4517", "DOI": "10.1200/JCO.2006.06.6126", "volume": "24", "author": "DM Jackman", "year": "2006", "unstructured": "Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006;24(27):4517\u201320.", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "526_CR68", "doi-asserted-by": "publisher", "first-page": "283", "DOI": "10.1007/s11060-010-0128-6", "volume": "99", "author": "JL Clarke", "year": "2010", "unstructured": "Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010;99(2):283\u20136.", "journal-title": "J Neurooncol"}, {"issue": "6", "key": "526_CR69", "doi-asserted-by": "publisher", "first-page": "1384", "DOI": "10.1016/j.chest.2015.12.017", "volume": "149", "author": "Q Huang", "year": "2016", "unstructured": "Huang Q, Li J, Sun Y, Wang R, Cheng X, Chen H. Efficacy of EGFR tyrosine kinase inhibitors in the adjuvant treatment for operable non-small cell lung cancer by a meta-analysis. Chest. 2016;149(6):1384\u201392.", "journal-title": "Chest"}, {"issue": "24", "key": "526_CR70", "doi-asserted-by": "publisher", "first-page": "7232", "DOI": "10.1158/1078-0432.CCR-06-0658", "volume": "12", "author": "GJ Riely", "year": "2006", "unstructured": "Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res. 2006;12(24):7232\u201341.", "journal-title": "Clin Cancer Res"}, {"issue": "2", "key": "526_CR71", "doi-asserted-by": "publisher", "first-page": "300", "DOI": "10.1016/j.critrevonc.2013.08.003", "volume": "89", "author": "G Bronte", "year": "2014", "unstructured": "Bronte G, Rolfo C, Giovannetti E, Cicero G, Pauwels P, Passiglia F, et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Oncol Hematol. 2014;89(2):300\u201313.", "journal-title": "Crit Rev Oncol Hematol"}, {"issue": "20", "key": "526_CR72", "doi-asserted-by": "publisher", "first-page": "5130", "DOI": "10.1158/1078-0432.CCR-16-0399", "volume": "22", "author": "P Ballard", "year": "2016", "unstructured": "Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130\u201340.", "journal-title": "Clin Cancer Res"}, {"issue": "2", "key": "526_CR73", "doi-asserted-by": "publisher", "first-page": "313", "DOI": "10.1016/j.lungcan.2013.08.013", "volume": "82", "author": "Y Chen", "year": "2013", "unstructured": "Chen Y, Wang M, Zhong W, Zhao J. Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. Lung Cancer. 2013;82(2):313\u20138.", "journal-title": "Lung Cancer"}, {"issue": "1", "key": "526_CR74", "doi-asserted-by": "publisher", "first-page": "89", "DOI": "10.1158/1078-0432.CCR-10-1934", "volume": "17", "author": "MA Elmeliegy", "year": "2011", "unstructured": "Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res. 2011;17(1):89\u201399.", "journal-title": "Clin Cancer Res"}, {"issue": "3", "key": "526_CR75", "doi-asserted-by": "publisher", "first-page": "399", "DOI": "10.1007/s00280-012-1929-4", "volume": "70", "author": "Y Togashi", "year": "2012", "unstructured": "Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2012;70(3):399\u2013405.", "journal-title": "Cancer Chemother Pharmacol"}, {"issue": "16", "key": "526_CR76", "doi-asserted-by": "publisher", "first-page": "4406", "DOI": "10.1158/1078-0432.CCR-12-0357", "volume": "18", "author": "S Heon", "year": "2012", "unstructured": "Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012;18(16):4406\u201314.", "journal-title": "Clin Cancer Res"}, {"issue": "1", "key": "526_CR77", "doi-asserted-by": "publisher", "first-page": "245", "DOI": "10.1186/s12885-017-3165-0", "volume": "17", "author": "MX Li", "year": "2017", "unstructured": "Li MX, He H, Ruan ZH, Zhu YX, Li RQ, He X, et al. Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study. BMC Cancer. 2017;17(1):245.", "journal-title": "BMC Cancer"}, {"issue": "6", "key": "526_CR78", "doi-asserted-by": "publisher", "first-page": "1465", "DOI": "10.1007/s00280-011-1555-6", "volume": "67", "author": "T Masuda", "year": "2011", "unstructured": "Masuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M, et al. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol. 2011;67(6):1465\u20139.", "journal-title": "Cancer Chemother Pharmacol"}, {"issue": "8", "key": "526_CR79", "doi-asserted-by": "publisher", "first-page": "1069", "DOI": "10.1097/JTO.0b013e318294c8e8", "volume": "8", "author": "E Lee", "year": "2013", "unstructured": "Lee E, Keam B, Kim DW, Kim TM, Lee SH, Chung DH, et al. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol. 2013;8(8):1069\u201374.", "journal-title": "J Thorac Oncol"}, {"issue": "1", "key": "526_CR80", "doi-asserted-by": "publisher", "first-page": "S271", "DOI": "10.1016/j.jtho.2016.11.268", "volume": "12", "author": "K Ota", "year": "2017", "unstructured": "Ota K, Shiraishi Y, Harada T, Himeji D, Kitazaki T, Ebi N, et al. OA08. 02 Phase II study of erlotinib in advanced non-small cell lung cancer patients with leptomeningeal metastasis (LOGIK1101). J Thorac Oncol. 2017;12(1):S271\u20132.", "journal-title": "J Thorac Oncol"}, {"issue": "12", "key": "526_CR81", "doi-asserted-by": "publisher", "first-page": "1364", "DOI": "10.1093/neuonc/nor121", "volume": "13", "author": "C Grommes", "year": "2011", "unstructured": "Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, et al. \u201cPulsatile\u201d high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011;13(12):1364\u20139.", "journal-title": "Neuro Oncol"}, {"issue": "1", "key": "526_CR82", "doi-asserted-by": "publisher", "first-page": "102", "DOI": "10.1016/j.lungcan.2012.12.024", "volume": "80", "author": "JL Kuiper", "year": "2013", "unstructured": "Kuiper JL, Smit EF. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases\u2014one with a remarkable thoracic response as well. Lung Cancer. 2013;80(1):102\u20135.", "journal-title": "Lung Cancer"}, {"issue": "6", "key": "526_CR83", "doi-asserted-by": "publisher", "first-page": "4527", "DOI": "10.18632/oncotarget.2886", "volume": "6", "author": "DM Jackman", "year": "2015", "unstructured": "Jackman DM, Cioffredi LA, Jacobs L, Sharmeen F, Morse LK, Lucca J, et al. A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget. 2015;6(6):4527\u201336.", "journal-title": "Oncotarget"}, {"issue": "34", "key": "526_CR84", "doi-asserted-by": "publisher", "first-page": "4702", "DOI": "10.1038/onc.2008.109", "volume": "27", "author": "D Li", "year": "2008", "unstructured": "Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27(34):4702\u201311.", "journal-title": "Oncogene"}, {"issue": "2", "key": "526_CR85", "doi-asserted-by": "publisher", "first-page": "233", "DOI": "10.1038/aps.2016.107", "volume": "38", "author": "SR Zhang", "year": "2017", "unstructured": "Zhang SR, Zhu LC, Jiang YP, Zhang J, Xu RJ, Xu YS, et al. Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice. Acta Pharmacol Sin. 2017;38(2):233\u201340.", "journal-title": "Acta Pharmacol Sin"}, {"issue": "1", "key": "526_CR86", "doi-asserted-by": "publisher", "first-page": "156", "DOI": "10.1097/JTO.0000000000000380", "volume": "10", "author": "P Hoffknecht", "year": "2015", "unstructured": "Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schutz M, et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2015;10(1):156\u201363.", "journal-title": "J Thorac Oncol"}, {"issue": "3", "key": "526_CR87", "doi-asserted-by": "publisher", "first-page": "380", "DOI": "10.1016/j.jtho.2015.11.014", "volume": "11", "author": "M Schuler", "year": "2016", "unstructured": "Schuler M, Wu YL, Hirsh V, O\u2019Byrne K, Yamamoto N, Mok T, et al. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016;11(3):380\u201390.", "journal-title": "J Thorac Oncol"}, {"key": "526_CR88", "doi-asserted-by": "publisher", "first-page": "S273", "DOI": "10.1016/j.jtho.2016.11.270", "volume": "12", "author": "ATM Tamiya", "year": "2017", "unstructured": "Tamiya ATM, Nishihara T, et al. Efficacy and cerebrospinal fluid concentration of afatinib in NSCLC patients with EGFR mutation developing leptomeningeal carcinomatosis. J Thorac Oncol. 2017;12:S273.", "journal-title": "J Thorac Oncol"}, {"key": "526_CR89", "doi-asserted-by": "publisher", "first-page": "93", "DOI": "10.1016/j.lungcan.2016.04.003", "volume": "96", "author": "L Zhou", "year": "2016", "unstructured": "Zhou L, He J, Xiong W, Liu Y, Xiang J, Yu Q, et al. Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study. Lung Cancer. 2016;96:93\u2013100.", "journal-title": "Lung Cancer"}, {"issue": "9", "key": "526_CR90", "doi-asserted-by": "publisher", "first-page": "707", "DOI": "10.1016/S2213-2600(17)30262-X", "volume": "5", "author": "JJ Yang", "year": "2017", "unstructured": "Yang JJ, Zhou C, Huang Y, Feng J, Lu S, Song Y, et al. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. Lancet Respir Med. 2017;5(9):707\u201316.", "journal-title": "Lancet Respir Med"}, {"issue": "3", "key": "526_CR91", "doi-asserted-by": "publisher", "first-page": "268", "DOI": "10.1016/j.lungcan.2015.06.001", "volume": "89", "author": "L Gong", "year": "2015", "unstructured": "Gong L, Xiong M, Huang Z, Miao L, Fan Y. Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations. Lung Cancer. 2015;89(3):268\u201373.", "journal-title": "Lung Cancer"}, {"issue": "9", "key": "526_CR92", "doi-asserted-by": "publisher", "first-page": "1046", "DOI": "10.1158/2159-8290.CD-14-0337", "volume": "4", "author": "DA Cross", "year": "2014", "unstructured": "Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046\u201361.", "journal-title": "Cancer Discov"}, {"key": "526_CR93", "unstructured": "Vansteenkiste J ea. CNS response to osimertinib vs. standard-of-care EGFR-TKI as first-line treatment in patients with egfrm advanced NSCLC: FLAURA [abstract no. LBA5]. Presented at the ESMO Asia 2017 Congress; 17\u201319 Nov 2017: Singapore."}, {"issue": "7", "key": "526_CR94", "doi-asserted-by": "publisher", "first-page": "629", "DOI": "10.1056/NEJMoa1612674", "volume": "376", "author": "TS Mok", "year": "2017", "unstructured": "Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629\u201340.", "journal-title": "N Engl J Med"}, {"issue": "3", "key": "526_CR95", "doi-asserted-by": "publisher", "first-page": "687", "DOI": "10.1093/annonc/mdx820", "volume": "29", "author": "G Goss", "year": "2018", "unstructured": "Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crino L, et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two Phase II trials. Ann Oncol. 2018;29(3):687\u201393.", "journal-title": "Ann Oncol"}, {"issue": "15 Suppl", "key": "526_CR96", "doi-asserted-by": "publisher", "first-page": "2006", "DOI": "10.1200/JCO.2017.35.15_suppl.2006", "volume": "35", "author": "MJ Ahn", "year": "2017", "unstructured": "Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, et al. Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-na\u00efve, EGFRm NSCLC with CNS metastases. J Clin Oncol. 2017;35(15 Suppl):2006.", "journal-title": "J Clin Oncol"}, {"issue": "1", "key": "526_CR97", "doi-asserted-by": "publisher", "first-page": "32", "DOI": "10.1038/bjc.2017.394", "volume": "118", "author": "S Nanjo", "year": "2018", "unstructured": "Nanjo S, Hata A, Okuda C, Kaji R, Okada H, Tamura D, et al. Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer. Br J Cancer. 2018;118(1):32\u20137.", "journal-title": "Br J Cancer"}, {"issue": "15 Suppl", "key": "526_CR98", "doi-asserted-by": "publisher", "first-page": "2020", "DOI": "10.1200/JCO.2017.35.15_suppl.2020", "volume": "35", "author": "JCH Yang", "year": "2017", "unstructured": "Yang JCH, Cho BC, Kim DW, Kim SW, Lee JS, Su WC, et al. Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): updated results from the BLOOM study. J Clin Oncol. 2017;35(15 Suppl):2020.", "journal-title": "J Clin Oncol"}, {"issue": "10", "key": "526_CR99", "doi-asserted-by": "publisher", "first-page": "1070", "DOI": "10.1200/JCO.2016.69.7144", "volume": "35", "author": "WJ Magnuson", "year": "2017", "unstructured": "Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, et al. Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol. 2017;35(10):1070\u20137.", "journal-title": "J Clin Oncol"}, {"issue": "10", "key": "526_CR100", "doi-asserted-by": "publisher", "first-page": "1718", "DOI": "10.1016/j.jtho.2016.05.013", "volume": "11", "author": "T Jiang", "year": "2016", "unstructured": "Jiang T, Su C, Li X, Zhao C, Zhou F, Ren S, et al. EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases. J Thorac Oncol. 2016;11(10):1718\u201328.", "journal-title": "J Thorac Oncol"}, {"issue": "19", "key": "526_CR101", "doi-asserted-by": "publisher", "first-page": "5523", "DOI": "10.1158/1078-0432.CCR-13-0836", "volume": "19", "author": "KL Johung", "year": "2013", "unstructured": "Johung KL, Yao X, Li F, Yu JB, Gettinger SN, Goldberg S, et al. A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer. Clin Cancer Res. 2013;19(19):5523\u201332.", "journal-title": "Clin Cancer Res"}, {"issue": "2", "key": "526_CR102", "doi-asserted-by": "publisher", "first-page": "167", "DOI": "10.1016/j.radonc.2014.12.011", "volume": "114", "author": "YY Soon", "year": "2015", "unstructured": "Soon YY, Leong CN, Koh WY, Tham IW. EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis. Radiother Oncol. 2015;114(2):167\u201372.", "journal-title": "Radiother Oncol"}, {"issue": "18", "key": "526_CR103", "doi-asserted-by": "publisher", "first-page": "16725", "DOI": "10.18632/oncotarget.4264", "volume": "6", "author": "S Luo", "year": "2015", "unstructured": "Luo S, Chen L, Chen X, Xie X. Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases. Oncotarget. 2015;6(18):16725\u201334.", "journal-title": "Oncotarget"}, {"issue": "6", "key": "526_CR104", "doi-asserted-by": "publisher", "first-page": "1055", "DOI": "10.1002/cam4.673", "volume": "5", "author": "T Jiang", "year": "2016", "unstructured": "Jiang T, Min W, Li Y, Yue Z, Wu C, Zhou C. Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis. Cancer Med. 2016;5(6):1055\u201365.", "journal-title": "Cancer Med"}, {"issue": "25", "key": "526_CR105", "doi-asserted-by": "publisher", "first-page": "2385", "DOI": "10.1056/NEJMoa1214886", "volume": "368", "author": "AT Shaw", "year": "2013", "unstructured": "Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385\u201394.", "journal-title": "N Engl J Med"}, {"issue": "23", "key": "526_CR106", "doi-asserted-by": "publisher", "first-page": "2167", "DOI": "10.1056/NEJMoa1408440", "volume": "371", "author": "BJ Solomon", "year": "2014", "unstructured": "Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167\u201377.", "journal-title": "N Engl J Med"}, {"issue": "12", "key": "526_CR107", "doi-asserted-by": "publisher", "first-page": "1570", "DOI": "10.1097/JTO.0000000000000029", "volume": "8", "author": "JF Gainor", "year": "2013", "unstructured": "Gainor JF, Ou SH, Logan J, Borges LF, Shaw AT. The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. J Thorac Oncol. 2013;8(12):1570\u20133.", "journal-title": "J Thorac Oncol"}, {"key": "526_CR108", "doi-asserted-by": "publisher", "first-page": "128", "DOI": "10.1016/j.ctrv.2016.12.006", "volume": "53", "author": "J Remon", "year": "2017", "unstructured": "Remon J, Le Rhun E, Besse B. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: a continuing challenge in the personalized treatment era. Cancer Treat Rev. 2017;53:128\u201337.", "journal-title": "Cancer Treat Rev"}, {"issue": "1", "key": "526_CR109", "doi-asserted-by": "publisher", "first-page": "108", "DOI": "10.1016/j.lungcan.2015.01.020", "volume": "88", "author": "D Rangachari", "year": "2015", "unstructured": "Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015;88(1):108\u201311.", "journal-title": "Lung Cancer"}, {"issue": "4", "key": "526_CR110", "doi-asserted-by": "publisher", "first-page": "439", "DOI": "10.1038/sj.onc.1200849", "volume": "14", "author": "T Iwahara", "year": "1997", "unstructured": "Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 1997;14(4):439\u201349.", "journal-title": "Oncogene"}, {"issue": "2", "key": "526_CR111", "doi-asserted-by": "publisher", "first-page": "123", "DOI": "10.1200/JCO.2015.62.0138", "volume": "34", "author": "KL Johung", "year": "2016", "unstructured": "Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol. 2016;34(2):123\u20139.", "journal-title": "J Clin Oncol"}, {"issue": "6", "key": "526_CR112", "doi-asserted-by": "publisher", "first-page": "1484", "DOI": "10.1002/ijc.28475", "volume": "134", "author": "SC Tang", "year": "2014", "unstructured": "Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014;134(6):1484\u201394.", "journal-title": "Int J Cancer"}, {"issue": "15", "key": "526_CR113", "doi-asserted-by": "publisher", "first-page": "e443", "DOI": "10.1200/JCO.2010.34.1313", "volume": "29", "author": "DB Costa", "year": "2011", "unstructured": "Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29(15):e443\u20135.", "journal-title": "J Clin Oncol"}, {"issue": "24", "key": "526_CR114", "doi-asserted-by": "publisher", "first-page": "2858", "DOI": "10.1200/JCO.2015.63.5888", "volume": "34", "author": "BJ Solomon", "year": "2016", "unstructured": "Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, et al. Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from proFILE 1014. J Clin Oncol. 2016;34(24):2858\u201365.", "journal-title": "J Clin Oncol"}, {"issue": "17", "key": "526_CR115", "doi-asserted-by": "publisher", "first-page": "1881", "DOI": "10.1200/JCO.2014.59.0539", "volume": "33", "author": "DB Costa", "year": "2015", "unstructured": "Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol. 2015;33(17):1881\u20138.", "journal-title": "J Clin Oncol"}, {"issue": "12", "key": "526_CR116", "doi-asserted-by": "publisher", "first-page": "1807", "DOI": "10.1097/JTO.0b013e3182745948", "volume": "7", "author": "AJ Weickhardt", "year": "2012", "unstructured": "Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1807\u201314.", "journal-title": "J Thorac Oncol"}, {"issue": "10072", "key": "526_CR117", "doi-asserted-by": "publisher", "first-page": "917", "DOI": "10.1016/S0140-6736(17)30123-X", "volume": "389", "author": "JC Soria", "year": "2017", "unstructured": "Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917\u201329.", "journal-title": "Lancet"}, {"issue": "24", "key": "526_CR118", "doi-asserted-by": "publisher", "first-page": "2866", "DOI": "10.1200/JCO.2015.65.5936", "volume": "34", "author": "L Crino", "year": "2016", "unstructured": "Crino L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol. 2016;34(24):2866\u201373.", "journal-title": "J Clin Oncol"}, {"issue": "15 Suppl", "key": "526_CR119", "doi-asserted-by": "crossref", "first-page": "8060", "DOI": "10.1200/jco.2015.33.15_suppl.8060", "volume": "33", "author": "E Felip", "year": "2015", "unstructured": "Felip E, Orlov Sergey, Park Keunchil, Chong-Jen Yu, Tsai Chun-Ming, Nishio Makoto, Dols Manuel Cobo, et al. ASCEND-3: a single-arm, open-label, multicenter phase II study of ceritinib in ALKi-na\u00efve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(15 Suppl):8060.", "journal-title": "J Clin Oncol"}, {"key": "526_CR120", "doi-asserted-by": "publisher", "first-page": "54", "DOI": "10.1016/j.ebiom.2015.12.009", "volume": "3", "author": "R Katayama", "year": "2016", "unstructured": "Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, et al. P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. EBioMedicine. 2016;3:54\u201366.", "journal-title": "EBioMedicine."}, {"issue": "5", "key": "526_CR121", "doi-asserted-by": "publisher", "first-page": "679", "DOI": "10.1016/j.ccr.2011.04.004", "volume": "19", "author": "H Sakamoto", "year": "2011", "unstructured": "Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011;19(5):679\u201390.", "journal-title": "Cancer Cell"}, {"issue": "9", "key": "526_CR122", "doi-asserted-by": "publisher", "first-page": "829", "DOI": "10.1056/NEJMoa1704795", "volume": "377", "author": "S Peters", "year": "2017", "unstructured": "Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829\u201338.", "journal-title": "N Engl J Med"}, {"issue": "7", "key": "526_CR123", "doi-asserted-by": "publisher", "first-page": "661", "DOI": "10.1200/JCO.2015.63.9443", "volume": "34", "author": "SH Ou", "year": "2016", "unstructured": "Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase ii global study. J Clin Oncol. 2016;34(7):661\u20138.", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "526_CR124", "doi-asserted-by": "publisher", "first-page": "234", "DOI": "10.1016/S1470-2045(15)00488-X", "volume": "17", "author": "AT Shaw", "year": "2016", "unstructured": "Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17(2):234\u201342.", "journal-title": "Lancet Oncol."}, {"issue": "14", "key": "526_CR125", "doi-asserted-by": "publisher", "first-page": "1515", "DOI": "10.1200/JCO.2016.70.5749", "volume": "35", "author": "T Tamura", "year": "2017", "unstructured": "Tamura T, Kiura K, Seto T, Nakagawa K, Maemondo M, Inoue A, et al. Three-year follow-up of an alectinib phase I/II study in ALK-positive non-small-cell lung cancer: AF-001JP. J Clin Oncol. 2017;35(14):1515\u201321.", "journal-title": "J Clin Oncol"}, {"issue": "10089", "key": "526_CR126", "doi-asserted-by": "publisher", "first-page": "29", "DOI": "10.1016/S0140-6736(17)30565-2", "volume": "390", "author": "T Hida", "year": "2017", "unstructured": "Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390(10089):29\u201339.", "journal-title": "Lancet"}, {"issue": "3", "key": "526_CR127", "doi-asserted-by": "publisher", "first-page": "355", "DOI": "10.1016/j.lungcan.2015.03.022", "volume": "88", "author": "SH Ou", "year": "2015", "unstructured": "Ou SH, Klempner SJ, Azada MC, Rausei-Mills V, Duma C. Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management. Lung Cancer. 2015;88(3):355\u20139.", "journal-title": "Lung Cancer"}, {"issue": "2", "key": "526_CR128", "doi-asserted-by": "publisher", "first-page": "232", "DOI": "10.1097/JTO.0000000000000455", "volume": "10", "author": "JF Gainor", "year": "2015", "unstructured": "Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015;10(2):232\u20136.", "journal-title": "J Thorac Oncol"}, {"issue": "10", "key": "526_CR129", "doi-asserted-by": "publisher", "first-page": "4948", "DOI": "10.1021/acs.jmedchem.6b00306", "volume": "59", "author": "WS Huang", "year": "2016", "unstructured": "Huang WS, Liu S, Zou D, Thomas M, Wang Y, Zhou T, et al. Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase. J Med Chem. 2016;59(10):4948\u201364.", "journal-title": "J Med Chem"}, {"issue": "22", "key": "526_CR130", "doi-asserted-by": "publisher", "first-page": "5527", "DOI": "10.1158/1078-0432.CCR-16-0569", "volume": "22", "author": "S Zhang", "year": "2016", "unstructured": "Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, et al. The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models. Clin Cancer Res. 2016;22(22):5527\u201338.", "journal-title": "Clin Cancer Res"}, {"issue": "22", "key": "526_CR131", "doi-asserted-by": "publisher", "first-page": "2490", "DOI": "10.1200/JCO.2016.71.5904", "volume": "35", "author": "DW Kim", "year": "2017", "unstructured": "Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35(22):2490\u20138.", "journal-title": "J Clin Oncol"}, {"issue": "11", "key": "526_CR132", "doi-asserted-by": "publisher", "first-page": "4720", "DOI": "10.1021/jm500261q", "volume": "57", "author": "TW Johnson", "year": "2014", "unstructured": "Johnson TW, Richardson PF, Bailey S, Brooun A, Burke BJ, Collins MR, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57(11):4720\u201344.", "journal-title": "J Med Chem"}, {"key": "526_CR133", "doi-asserted-by": "publisher", "first-page": "15761", "DOI": "10.1038/ncomms15761", "volume": "8", "author": "TL Collier", "year": "2017", "unstructured": "Collier TL, Normandin MD, Stephenson NA, Livni E, Liang SH, Wooten DW, et al. Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib. Nat Commun. 2017;8:15761.", "journal-title": "Nat Commun."}, {"issue": "12", "key": "526_CR134", "doi-asserted-by": "publisher", "first-page": "1590", "DOI": "10.1016/S1470-2045(17)30680-0", "volume": "18", "author": "AT Shaw", "year": "2017", "unstructured": "Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590\u20139.", "journal-title": "Lancet Oncol"}, {"issue": "10027", "key": "526_CR135", "doi-asserted-by": "publisher", "first-page": "1540", "DOI": "10.1016/S0140-6736(15)01281-7", "volume": "387", "author": "RS Herbst", "year": "2016", "unstructured": "Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540\u201350.", "journal-title": "Lancet"}, {"issue": "2", "key": "526_CR136", "doi-asserted-by": "publisher", "first-page": "123", "DOI": "10.1056/NEJMoa1504627", "volume": "373", "author": "J Brahmer", "year": "2015", "unstructured": "Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123\u201335.", "journal-title": "N Engl J Med"}, {"issue": "17", "key": "526_CR137", "doi-asserted-by": "publisher", "first-page": "1627", "DOI": "10.1056/NEJMoa1507643", "volume": "373", "author": "H Borghaei", "year": "2015", "unstructured": "Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627\u201339.", "journal-title": "N Engl J Med"}, {"issue": "10066", "key": "526_CR138", "doi-asserted-by": "publisher", "first-page": "255", "DOI": "10.1016/S0140-6736(16)32517-X", "volume": "389", "author": "A Rittmeyer", "year": "2017", "unstructured": "Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255\u201365.", "journal-title": "Lancet"}, {"issue": "7560", "key": "526_CR139", "doi-asserted-by": "publisher", "first-page": "337", "DOI": "10.1038/nature14432", "volume": "523", "author": "A Louveau", "year": "2015", "unstructured": "Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523(7560):337\u201341.", "journal-title": "Nature"}, {"issue": "7", "key": "526_CR140", "doi-asserted-by": "publisher", "first-page": "991", "DOI": "10.1084/jem.20142290", "volume": "212", "author": "A Aspelund", "year": "2015", "unstructured": "Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 2015;212(7):991\u20139.", "journal-title": "J Exp Med"}, {"issue": "2", "key": "526_CR141", "first-page": "21", "volume": "4", "author": "AS Berghoff", "year": "2015", "unstructured": "Berghoff AS, Preusser M. The inflammatory microenvironment in brain metastases: potential treatment target? Chin Clin Oncol. 2015;4(2):21.", "journal-title": "Chin Clin Oncol"}, {"issue": "12", "key": "526_CR142", "doi-asserted-by": "crossref", "first-page": "1477", "DOI": "10.1002/glia.21022", "volume": "58", "author": "T Pukrop", "year": "2010", "unstructured": "Pukrop T, Dehghani F, Chuang HN, Lohaus R, Bayanga K, Heermann S, et al. Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way. Glia. 2010;58(12):1477\u201389.", "journal-title": "Glia"}, {"issue": "9", "key": "526_CR143", "doi-asserted-by": "publisher", "first-page": "623", "DOI": "10.1038/nri3265", "volume": "12", "author": "RM Ransohoff", "year": "2012", "unstructured": "Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12(9):623\u201335.", "journal-title": "Nat Rev Immunol"}, {"key": "526_CR144", "doi-asserted-by": "publisher", "first-page": "14", "DOI": "10.1186/1471-2172-7-14", "volume": "7", "author": "P Kivisakk", "year": "2006", "unstructured": "Kivisakk P, Tucky B, Wei T, Campbell JJ, Ransohoff RM. Human cerebrospinal fluid contains CD4+ memory T cells expressing gut- or skin-specific trafficking determinants: relevance for immunotherapy. BMC Immunol. 2006;7:14.", "journal-title": "BMC Immunol"}, {"issue": "26", "key": "526_CR145", "doi-asserted-by": "publisher", "first-page": "2509", "DOI": "10.1056/NEJMoa1500596", "volume": "372", "author": "DT Le", "year": "2015", "unstructured": "Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320.", "journal-title": "N Engl J Med"}, {"issue": "1", "key": "526_CR146", "doi-asserted-by": "publisher", "first-page": "e1057388", "DOI": "10.1080/2162402X.2015.1057388", "volume": "5", "author": "AS Berghoff", "year": "2016", "unstructured": "Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology. 2016;5(1):e1057388.", "journal-title": "Oncoimmunology"}, {"issue": "8", "key": "526_CR147", "doi-asserted-by": "publisher", "first-page": "1064", "DOI": "10.1093/neuonc/nou307", "volume": "17", "author": "AS Berghoff", "year": "2015", "unstructured": "Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2015;17(8):1064\u201375.", "journal-title": "Neuro Oncol"}, {"issue": "Suppl 4", "key": "526_CR148", "doi-asserted-by": "publisher", "first-page": "iv465", "DOI": "10.1093/annonc/mdu349.103", "volume": "25", "author": "AS Berghoff", "year": "2014", "unstructured": "Berghoff AS, et al. Tumor-infiltrating lymphocytes (TILS) and PD-l1 expression in non-small cell lung cancer brain metastases (BM) and matched primary tumors (PT). Ann Oncol. 2014;25(Suppl 4):iv465\u20136.", "journal-title": "Ann Oncol"}, {"issue": "6230", "key": "526_CR149", "doi-asserted-by": "publisher", "first-page": "124", "DOI": "10.1126/science.aaa1348", "volume": "348", "author": "NA Rizvi", "year": "2015", "unstructured": "Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124\u20138.", "journal-title": "Science"}, {"issue": "7", "key": "526_CR150", "doi-asserted-by": "publisher", "first-page": "976", "DOI": "10.1016/S1470-2045(16)30053-5", "volume": "17", "author": "SB Goldberg", "year": "2016", "unstructured": "Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976\u201383.", "journal-title": "Lancet Oncol"}, {"issue": "3", "key": "526_CR151", "doi-asserted-by": "publisher", "first-page": "257", "DOI": "10.1016/S1470-2045(15)70054-9", "volume": "16", "author": "NA Rizvi", "year": "2015", "unstructured": "Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257\u201365.", "journal-title": "Lancet Oncol"}, {"issue": "Suppl 2", "key": "526_CR152", "first-page": "ii28", "volume": "28", "author": "RV Lukas", "year": "2017", "unstructured": "Lukas RV, Gandhi M, O\u2019Hear C, Hu S, Lai C, Patel JD. Safety and efficacy analyses of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients with or without baseline brain metastases. Ann Oncol. 2017;28(Suppl 2):ii28\u201351.", "journal-title": "Ann Oncol"}, {"issue": "20", "key": "526_CR153", "doi-asserted-by": "publisher", "first-page": "1919", "DOI": "10.1056/NEJMoa1709937", "volume": "377", "author": "SJ Antonia", "year": "2017", "unstructured": "Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329.", "journal-title": "N Engl J Med"}, {"issue": "2", "key": "526_CR154", "doi-asserted-by": "publisher", "first-page": "282", "DOI": "10.1016/j.lungcan.2013.08.016", "volume": "82", "author": "T Iuchi", "year": "2013", "unstructured": "Iuchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, Itakura M, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013;82(2):282\u20137.", "journal-title": "Lung Cancer."}, {"issue": "3", "key": "526_CR155", "doi-asserted-by": "publisher", "first-page": "909", "DOI": "10.7314/APJCP.2012.13.3.909", "volume": "13", "author": "YD Zeng", "year": "2012", "unstructured": "Zeng YD, Zhang L, Liao H, Liang Y, Xu F, Liu JL, et al. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study. Asian Pac J Cancer Prev. 2012;13(3):909\u201314.", "journal-title": "Asian Pac J Cancer Prev."}, {"issue": "3", "key": "526_CR156", "doi-asserted-by": "publisher", "first-page": "556", "DOI": "10.1016/j.lungcan.2012.05.092", "volume": "77", "author": "SJ Park", "year": "2012", "unstructured": "Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in nonsmall cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 2012;77(3):556\u201360.", "journal-title": "Lung Cancer."}, {"issue": "3", "key": "526_CR157", "doi-asserted-by": "publisher", "first-page": "624", "DOI": "10.1183/09031936.00195609", "volume": "37", "author": "R Porta", "year": "2011", "unstructured": "Porta R, Sanchez-Torres JM, Paz-Ares L, Massuti B, Reguart N, Mayo C, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2011;37(3):624\u201331.", "journal-title": "Eur Respir J."}, {"issue": "3", "key": "526_CR158", "doi-asserted-by": "publisher", "first-page": "351", "DOI": "10.1016/j.lungcan.2008.12.011", "volume": "65", "author": "JE Kim", "year": "2009", "unstructured": "Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh C, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for neversmokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer. 2009;65(3):351\u20134.", "journal-title": "Lung Cancer."}, {"issue": "4", "key": "526_CR159", "doi-asserted-by": "publisher", "first-page": "452", "DOI": "10.1016/S1470-2045(15)00614-2", "volume": "17", "author": "DW Kim", "year": "2016", "unstructured": "Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016;17(4):452\u201363.", "journal-title": "Lancet Oncol."}], "container-title": ["CNS Drugs"], "language": "en", "link": [{"URL": "http://link.springer.com/article/10.1007/s40263-018-0526-4/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s40263-018-0526-4.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s40263-018-0526-4.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 23]], "date-time": "2019-05-23T23:15:39Z", "timestamp": 1558653339000}, "score": 33.6424, "issued": {"date-parts": [[2018, 5, 24]]}, "references-count": 159, "journal-issue": {"published-print": {"date-parts": [[2018, 6]]}, "issue": "6"}, "alternative-id": ["526"], "URL": "http://dx.doi.org/10.1007/s40263-018-0526-4", "relation": {"cites": []}, "ISSN": ["1172-7047", "1179-1934"], "issn-type": [{"value": "1172-7047", "type": "print"}, {"value": "1179-1934", "type": "electronic"}], "subject": ["Pharmacology (medical)", "Psychiatry and Mental health", "Clinical Neurology"], "assertion": [{"value": "24 May 2018", "order": 1, "name": "first_online", "label": "First Online", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"order": 1, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Compliance with ethical standards"}}, {"value": "Grainne M. O\u2019Kane is supported by the Division of Medical Oncology/Hematology, Princess Margaret Cancer Centre, and Natasha B. Leighl is supported by the Princess Margaret Cancer Foundation OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development. No external funding support was provided for this review.", "order": 2, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Funding"}}, {"value": "Grainne M. O\u2019Kane and Natasha B. Leighl declare that they have no conflicts of interest that might be relevant to the contents of this review.", "order": 3, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Conflict of Interest"}}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T16:30:36Z", "timestamp": 1574872236449}, "reference-count": 259, "publisher": "Elsevier", "isbn-type": [{"value": "9780323549486", "type": "print"}], "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2019, 1, 1]], "date-time": "2019-01-01T00:00:00Z", "timestamp": 1546300800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2019]]}, "DOI": "10.1016/b978-0-323-54948-6.00004-4", "type": "book-chapter", "created": {"date-parts": [[2018, 8, 31]], "date-time": "2018-08-31T23:42:40Z", "timestamp": 1535758960000}, "page": "77-101", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Immune Checkpoint Inhibitors in Gastrointestinal Malignancies"], "prefix": "10.1016", "author": [{"given": "Christos", "family": "Fountzilas", "sequence": "first", "affiliation": []}, {"given": "Sunyoung S.", "family": "Lee", "sequence": "additional", "affiliation": []}, {"given": "Renuka V.", "family": "Iyer", "sequence": "additional", "affiliation": []}, {"given": "Patrick M.", "family": "Boland", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Immune Checkpoint Inhibitors in Cancer"], "link": [{"URL": "https://api.elsevier.com/content/article/PII:B9780323549486000044?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:B9780323549486000044?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 10, 23]], "date-time": "2019-10-23T10:19:17Z", "timestamp": 1571825957000}, "score": 32.42219, "issued": {"date-parts": [[2019]]}, "ISBN": ["9780323549486"], "references-count": 259, "URL": "http://dx.doi.org/10.1016/b978-0-323-54948-6.00004-4"}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T12:45:08Z", "timestamp": 1574858708700}, "reference-count": 160, "publisher": "Wiley", "issue": "2", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2017, 12, 27]], "date-time": "2017-12-27T00:00:00Z", "timestamp": 1514332800000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://onlinelibrary.wiley.com/termsAndConditions#vor", "start": {"date-parts": [[2017, 12, 27]], "date-time": "2017-12-27T00:00:00Z", "timestamp": 1514332800000}, "delay-in-days": 0, "content-version": "vor"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clin Exp Immunol"], "published-print": {"date-parts": [[2018, 2]]}, "DOI": "10.1111/cei.13081", "type": "journal-article", "created": {"date-parts": [[2017, 11, 15]], "date-time": "2017-11-15T11:32:46Z", "timestamp": 1510745566000}, "page": "133-148", "source": "Crossref", "is-referenced-by-count": 25, "title": ["Immune checkpoint inhibitors: new strategies to checkmate cancer"], "prefix": "10.1111", "volume": "191", "author": [{"given": "R. A. M.", "family": "Wilson", "sequence": "first", "affiliation": [{"name": "Institute of Infection, Immunity and Inflammation, University of Glasgow; Glasgow UK"}]}, {"given": "T. R. J.", "family": "Evans", "sequence": "additional", "affiliation": [{"name": "Cancer Research UK Beatson Institute; Glasgow UK"}, {"name": "Institute of Cancer Sciences, University of Glasgow; Glasgow UK"}]}, {"ORCID": "http://orcid.org/0000-0001-7822-650X", "authenticated-orcid": false, "given": "A. R.", "family": "Fraser", "sequence": "additional", "affiliation": [{"name": "Institute of Infection, Immunity and Inflammation, University of Glasgow; Glasgow UK"}, {"name": "Advanced Therapeutics; Scottish National Blood Transfusion Service; Edinburgh UK"}]}, {"given": "R. J. B.", "family": "Nibbs", "sequence": "additional", "affiliation": [{"name": "Institute of Infection, Immunity and Inflammation, University of Glasgow; Glasgow UK"}]}], "member": "311", "published-online": {"date-parts": [[2017, 12, 27]]}, "reference": [{"key": "10.1111/cei.13081-BIB0001|cei13081-cit-0001", "doi-asserted-by": "crossref", "first-page": "1014", "DOI": "10.1038/ni.2703", "article-title": "Innate and adaptive immune cells in the tumor microenvironment", "volume": "14", "author": "Gajewski", "year": "2013", "journal-title": "Nat Immunol"}, {"key": "10.1111/cei.13081-BIB0002|cei13081-cit-0002", "doi-asserted-by": "crossref", "first-page": "599", "DOI": "10.1038/nri.2016.80", "article-title": "Regulatory circuits of T cell function in cancer", "volume": "16", "author": "Speiser", "year": "2016", "journal-title": "Nat Rev Immunol"}, {"key": "10.1111/cei.13081-BIB0003|cei13081-cit-0003", "doi-asserted-by": "crossref", "first-page": "137", "DOI": "10.1016/j.immuni.2004.07.017", "article-title": "The immunobiology of cancer immunosurveillance and immunoediting", "volume": "21", "author": "Dunn", "year": "2004", "journal-title": "Immunity"}, {"key": "10.1111/cei.13081-BIB0004|cei13081-cit-0004", "doi-asserted-by": "crossref", "first-page": "3889", "DOI": "10.1038/onc.2008.35", "article-title": "Immune escape as a fundamental trait of cancer: focus on IDO", "volume": "27", "author": "Prendergast", "year": "2008", "journal-title": "Oncogene"}, {"key": "10.1111/cei.13081-BIB0005|cei13081-cit-0005", "first-page": "907", "article-title": "Immune escape of tumors: apoptosis resistance and tumor counterattack", "volume": "71", "author": "Igney", "year": "2002", "journal-title": "J Leukoc Biol"}, {"key": "10.1111/cei.13081-BIB0006|cei13081-cit-0006", "doi-asserted-by": "crossref", "first-page": "1137", "DOI": "10.1172/JCI31405", "article-title": "Immune surveillance of tumors", "volume": "117", "author": "Swann", "year": "2007", "journal-title": "J Clin Invest"}, {"key": "10.1111/cei.13081-BIB0007|cei13081-cit-0007", "doi-asserted-by": "crossref", "first-page": "1505", "DOI": "10.4049/jimmunol.178.3.1505", "article-title": "Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy", "volume": "178", "author": "Bouzin", "year": "2007", "journal-title": "J Immunol"}, {"key": "10.1111/cei.13081-BIB0008|cei13081-cit-0008", "doi-asserted-by": "crossref", "first-page": "28", "DOI": "10.1038/nm1699", "article-title": "Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy", "volume": "14", "author": "Buckanovich", "year": "2008", "journal-title": "Nat Med"}, {"key": "10.1111/cei.13081-BIB0009|cei13081-cit-0009", "doi-asserted-by": "crossref", "first-page": "36", "DOI": "10.1111/j.1365-2249.2012.04657.x", "article-title": "Suppression, subversion and escape: the role of regulatory T cells in cancer progression", "volume": "171", "author": "Oleinika", "year": "2013", "journal-title": "Clin Exp Immunol"}, {"key": "10.1111/cei.13081-BIB0010|cei13081-cit-0010", "doi-asserted-by": "crossref", "first-page": "2162", "DOI": "10.1158/0008-5472.CAN-11-3687", "article-title": "Regulatory cells: key players in tumor immune escape and angiogenesis", "volume": "72", "author": "Facciabene", "year": "2012", "journal-title": "Cancer Res"}, {"key": "10.1111/cei.13081-BIB0011|cei13081-cit-0011", "doi-asserted-by": "crossref", "first-page": "883", "DOI": "10.1016/j.cell.2010.01.025", "article-title": "Immunity, inflammation, and cancer", "volume": "140", "author": "Grivennikov", "year": "2010", "journal-title": "Cell"}, {"key": "10.1111/cei.13081-BIB0012|cei13081-cit-0012", "doi-asserted-by": "crossref", "first-page": "793", "DOI": "10.1038/nm730", "article-title": "Tumor-associated B7-H1 promotes T cell apoptosis: a potential mechanism of immune evasion", "volume": "8", "author": "Dong", "year": "2002", "journal-title": "Nat Med"}, {"key": "10.1111/cei.13081-BIB0013|cei13081-cit-0013", "doi-asserted-by": "crossref", "first-page": "467", "DOI": "10.1038/nri2326", "article-title": "Inhibitory B7-family molecules in the tumour microenvironment", "volume": "8", "author": "Zou", "year": "2008", "journal-title": "Nat Rev Immunol"}, {"key": "10.1111/cei.13081-BIB0014|cei13081-cit-0014", "doi-asserted-by": "crossref", "first-page": "252", "DOI": "10.1038/nrc3239", "article-title": "The blockade of immune checkpoints in cancer immunotherapy", "volume": "12", "author": "Pardoll", "year": "2012", "journal-title": "Nat Rev Cancer"}, {"key": "10.1111/cei.13081-BIB0015|cei13081-cit-0015", "doi-asserted-by": "crossref", "first-page": "607", "DOI": "10.1038/356607a0", "article-title": "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T cell clones", "volume": "356", "author": "Harding", "year": "1992", "journal-title": "Nature"}, {"key": "10.1111/cei.13081-BIB0016|cei13081-cit-0016", "doi-asserted-by": "crossref", "first-page": "231", "DOI": "10.1111/j.1600-065X.1998.tb01242.x", "article-title": "The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells", "volume": "165", "author": "McAdam", "year": "1998", "journal-title": "Immunol Rev"}, {"key": "10.1111/cei.13081-BIB0017|cei13081-cit-0017", "doi-asserted-by": "crossref", "first-page": "939", "DOI": "10.1038/nri1248", "article-title": "CD28-mediated co-stimulation: a quantitative support for TCR signalling", "volume": "3", "author": "Acuto", "year": "2003", "journal-title": "Nat Rev Immunol"}, {"key": "10.1111/cei.13081-BIB0018|cei13081-cit-0018", "doi-asserted-by": "crossref", "first-page": "227", "DOI": "10.1038/nri3405", "article-title": "Molecular mechanisms of T cell co-stimulation and co-inhibition", "volume": "13", "author": "Chen", "year": "2013", "journal-title": "Nat Rev Immunol"}, {"key": "10.1111/cei.13081-BIB0019|cei13081-cit-0019", "doi-asserted-by": "crossref", "first-page": "459", "DOI": "10.1084/jem.182.2.459", "article-title": "CD28 and CTLA-4 have opposing effects on the response of T cells to Stimulation", "volume": "182", "author": "Krummel", "year": "1995", "journal-title": "J Exp Med"}, {"key": "10.1111/cei.13081-BIB0020|cei13081-cit-0020", "doi-asserted-by": "crossref", "first-page": "405", "DOI": "10.1016/1074-7613(94)90071-X", "article-title": "CTLA-4 can function as a negative regulator of T cell activation", "volume": "1", "author": "Walunas", "year": "1994", "journal-title": "Immunity"}, {"key": "10.1111/cei.13081-BIB0021|cei13081-cit-0021", "doi-asserted-by": "crossref", "first-page": "220", "DOI": "10.1038/35105024", "article-title": "T cell regulation by CD28 and CTLA-4", "volume": "1", "author": "Alegre", "year": "2001", "journal-title": "Nat Rev Immunol"}, {"key": "10.1111/cei.13081-BIB0022|cei13081-cit-0022", "doi-asserted-by": "crossref", "first-page": "2263", "DOI": "10.1126/science.282.5397.2263", "article-title": "Molecular basis of T cell inactivation by CTLA-4", "volume": "282", "author": "Lee", "year": "1998", "journal-title": "Science"}, {"key": "10.1111/cei.13081-BIB0023|cei13081-cit-0023", "doi-asserted-by": "crossref", "first-page": "1972", "DOI": "10.1126/science.1131078", "article-title": "Reversal of the TCR stop signal by CTLA-4", "volume": "313", "author": "Schneider", "year": "2006", "journal-title": "Science"}, {"key": "10.1111/cei.13081-BIB0024|cei13081-cit-0024", "doi-asserted-by": "crossref", "first-page": "852", "DOI": "10.1038/nri3108", "article-title": "The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses", "volume": "11", "author": "Walker", "year": "2011", "journal-title": "Nat Rev Immunol"}, {"key": "10.1111/cei.13081-BIB0025|cei13081-cit-0025", "doi-asserted-by": "crossref", "first-page": "26762", "DOI": "10.1074/jbc.271.43.26762", "article-title": "Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions", "volume": "271", "author": "Greene", "year": "1996", "journal-title": "J Biol Chem"}, {"key": "10.1111/cei.13081-BIB0026|cei13081-cit-0026", "doi-asserted-by": "crossref", "first-page": "23", "DOI": "10.1016/S1074-7613(01)00259-X", "article-title": "Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength", "volume": "16", "author": "Egen", "year": "2002", "journal-title": "Immunity"}, {"key": "10.1111/cei.13081-BIB0027|cei13081-cit-0027", "doi-asserted-by": "crossref", "first-page": "326", "DOI": "10.1016/j.immuni.2010.09.006", "article-title": "Spatiotemporal basis of CTLA-4 costimulatory molecule-mediated negative regulation of T cell activation", "volume": "33", "author": "Yokosuka", "year": "2010", "journal-title": "Immunity"}, {"key": "10.1111/cei.13081-BIB0028|cei13081-cit-0028", "doi-asserted-by": "crossref", "first-page": "600", "DOI": "10.1126/science.1202947", "article-title": "Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4", "volume": "332", "author": "Qureshi", "year": "2011", "journal-title": "Science"}, {"key": "10.1111/cei.13081-BIB0029|cei13081-cit-0029", "doi-asserted-by": "crossref", "first-page": "63", "DOI": "10.1016/j.it.2014.12.001", "article-title": "Confusing signals: recent progress in CTLA-4 biology", "volume": "36", "author": "Walker", "year": "2015", "journal-title": "Trends Immunol"}, {"key": "10.1111/cei.13081-BIB0030|cei13081-cit-0030", "doi-asserted-by": "crossref", "first-page": "541", "DOI": "10.1016/1074-7613(95)90125-6", "article-title": "Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4", "volume": "3", "author": "Tivol", "year": "1995", "journal-title": "Immunity"}, {"key": "10.1111/cei.13081-BIB0031|cei13081-cit-0031", "doi-asserted-by": "crossref", "first-page": "985", "DOI": "10.1126/science.270.5238.985", "article-title": "Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4", "volume": "270", "author": "Waterhouse", "year": "1995", "journal-title": "Science"}, {"key": "10.1111/cei.13081-BIB0032|cei13081-cit-0032", "doi-asserted-by": "crossref", "first-page": "1623", "DOI": "10.1126/science.1255904", "article-title": "Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4", "volume": "345", "author": "Kuehn", "year": "2014", "journal-title": "Science"}, {"key": "10.1111/cei.13081-BIB0033|cei13081-cit-0033", "doi-asserted-by": "crossref", "first-page": "1410", "DOI": "10.1038/nm.3746", "article-title": "Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations", "volume": "20", "author": "Schubert", "year": "2014", "journal-title": "Nat Med"}, {"key": "10.1111/cei.13081-BIB0034|cei13081-cit-0034", "doi-asserted-by": "crossref", "first-page": "1889", "DOI": "10.1136/gutjnl-2014-308541", "article-title": "Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4", "volume": "64", "author": "Zeissig", "year": "2015", "journal-title": "Gut"}, {"key": "10.1111/cei.13081-BIB0035|cei13081-cit-0035", "doi-asserted-by": "crossref", "first-page": "1734", "DOI": "10.1126/science.271.5256.1734", "article-title": "Enhancement of antitumor immunity by CTLA-4 blockade", "volume": "271", "author": "Leach", "year": "1996", "journal-title": "Science"}, {"key": "10.1111/cei.13081-BIB0036|cei13081-cit-0036", "first-page": "2444", "article-title": "Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade", "volume": "60", "author": "Hurwitz", "year": "2000", "journal-title": "Cancer Res"}, {"key": "10.1111/cei.13081-BIB0037|cei13081-cit-0037", "doi-asserted-by": "crossref", "first-page": "32", "DOI": "10.1158/2326-6066.CIR-13-0013", "article-title": "Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells", "volume": "1", "author": "Selby", "year": "2013", "journal-title": "Cancer Immunol Res"}, {"key": "10.1111/cei.13081-BIB0038|cei13081-cit-0038", "doi-asserted-by": "crossref", "first-page": "1935", "DOI": "10.1172/JCI27745", "article-title": "CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells", "volume": "116", "author": "Quezada", "year": "2006", "journal-title": "J Clin Invest"}, {"key": "10.1111/cei.13081-BIB0039|cei13081-cit-0039", "doi-asserted-by": "crossref", "first-page": "1717", "DOI": "10.1084/jem.20082492", "article-title": "Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies", "volume": "206", "author": "Peggs", "year": "2009", "journal-title": "J Exp Med"}, {"key": "10.1111/cei.13081-BIB0040|cei13081-cit-0040", "doi-asserted-by": "crossref", "first-page": "1695", "DOI": "10.1084/jem.20130579", "article-title": "Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma", "volume": "210", "author": "Simpson", "year": "2013", "journal-title": "J Exp Med"}, {"key": "10.1111/cei.13081-BIB0041|cei13081-cit-0041", "doi-asserted-by": "crossref", "first-page": "1685", "DOI": "10.1084/jem.20130573", "article-title": "Activating Fc \u03b3 receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies", "volume": "210", "author": "Bulliard", "year": "2013", "journal-title": "J Exp Med"}, {"key": "10.1111/cei.13081-BIB0042|cei13081-cit-0042", "doi-asserted-by": "crossref", "first-page": "475", "DOI": "10.1038/icb.2014.26", "article-title": "OX40 engagement depletes intratumoral Tregs via activating Fc\u03b3Rs, leading to antitumor efficacy", "volume": "92", "author": "Bulliard", "year": "2014", "journal-title": "Immunol Cell Biol"}, {"key": "10.1111/cei.13081-BIB0043|cei13081-cit-0043", "doi-asserted-by": "crossref", "first-page": "1936", "DOI": "10.1016/j.molonc.2015.10.008", "article-title": "Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy", "volume": "9", "author": "\u015aledzi\u0144ska", "year": "2015", "journal-title": "Mol Oncol"}, {"key": "10.1111/cei.13081-BIB0044|cei13081-cit-0044", "doi-asserted-by": "crossref", "first-page": "6140", "DOI": "10.1073/pnas.1417320112", "article-title": "Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients", "volume": "112", "author": "Romano", "year": "2015", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1111/cei.13081-BIB0045|cei13081-cit-0045", "doi-asserted-by": "crossref", "first-page": "3887", "DOI": "10.1002/j.1460-2075.1992.tb05481.x", "article-title": "Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death", "volume": "11", "author": "Ishida", "year": "1992", "journal-title": "EMBO J"}, {"key": "10.1111/cei.13081-BIB0046|cei13081-cit-0046", "doi-asserted-by": "crossref", "first-page": "765", "DOI": "10.1093/intimm/8.5.765", "article-title": "Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes", "volume": "8", "author": "Agata", "year": "1996", "journal-title": "Int Immunol"}, {"key": "10.1111/cei.13081-BIB0047|cei13081-cit-0047", "doi-asserted-by": "crossref", "first-page": "677", "DOI": "10.1146/annurev.immunol.26.021607.090331", "article-title": "PD-1 and its ligands in tolerance and immunity", "volume": "26", "author": "Keir", "year": "2008", "journal-title": "Annu Rev Immunol"}, {"key": "10.1111/cei.13081-BIB0048|cei13081-cit-0048", "doi-asserted-by": "crossref", "first-page": "5538", "DOI": "10.4049/jimmunol.169.10.5538", "article-title": "Expression of programmed death 1 ligands by murine T cells and APC", "volume": "169", "author": "Yamazaki", "year": "2002", "journal-title": "J Immunol"}, {"key": "10.1111/cei.13081-BIB0049|cei13081-cit-0049", "doi-asserted-by": "crossref", "first-page": "133", "DOI": "10.1080/713774061", "article-title": "Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells", "volume": "9", "author": "Eppihimer", "year": "2002", "journal-title": "Microcirculation"}, {"key": "10.1111/cei.13081-BIB0050|cei13081-cit-0050", "first-page": "662", "article-title": "PD-1 as a potential target in cancer therapy", "volume": "2", "author": "McDermott", "year": "2013", "journal-title": "Cancer Med"}, {"key": "10.1111/cei.13081-BIB0051|cei13081-cit-0051", "doi-asserted-by": "crossref", "first-page": "261", "DOI": "10.1038/85330", "article-title": "PD-L2 is a second ligand for PD-1 and inhibits T cell activation", "volume": "2", "author": "Latchman", "year": "2001", "journal-title": "Nat Immunol"}, {"key": "10.1111/cei.13081-BIB0052|cei13081-cit-0052", "doi-asserted-by": "crossref", "first-page": "1027", "DOI": "10.1084/jem.192.7.1027", "article-title": "Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation", "volume": "192", "author": "Freeman", "year": "2000", "journal-title": "J Exp Med"}, {"key": "10.1111/cei.13081-BIB0053|cei13081-cit-0053", "doi-asserted-by": "crossref", "first-page": "1428", "DOI": "10.1126/science.aaf1292", "article-title": "T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition", "volume": "355", "author": "Hui", "year": "2017", "journal-title": "Science"}, {"key": "10.1111/cei.13081-BIB0054|cei13081-cit-0054", "doi-asserted-by": "crossref", "first-page": "1185", "DOI": "10.1038/ni.1790", "article-title": "Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal", "volume": "10", "author": "Fife", "year": "2009", "journal-title": "Nat Immunol"}, {"key": "10.1111/cei.13081-BIB0055|cei13081-cit-0055", "doi-asserted-by": "crossref", "first-page": "111", "DOI": "10.1016/j.immuni.2007.05.016", "article-title": "Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses", "volume": "27", "author": "Butte", "year": "2007", "journal-title": "Immunity"}, {"key": "10.1111/cei.13081-BIB0056|cei13081-cit-0056", "doi-asserted-by": "crossref", "first-page": "141", "DOI": "10.1016/S1074-7613(00)80089-8", "article-title": "Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor", "volume": "11", "author": "Nishimura", "year": "1999", "journal-title": "Immunity"}, {"key": "10.1111/cei.13081-BIB0057|cei13081-cit-0057", "doi-asserted-by": "crossref", "first-page": "319", "DOI": "10.1126/science.291.5502.319", "article-title": "Autoimmune dilated cardiomyopathy in PD-1 receptor deficient mice", "volume": "291", "author": "Nishimura", "year": "2001", "journal-title": "Science"}, {"key": "10.1111/cei.13081-BIB0058|cei13081-cit-0058", "doi-asserted-by": "crossref", "first-page": "2205", "DOI": "10.1084/jem.188.12.2205", "article-title": "Viral immune evasion due to persistence of activated T cells without effector function", "volume": "188", "author": "Zajac", "year": "1998", "journal-title": "J Exp Med"}, {"key": "10.1111/cei.13081-BIB0059|cei13081-cit-0059", "doi-asserted-by": "crossref", "first-page": "1383", "DOI": "10.1084/jem.187.9.1383", "article-title": "Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes", "volume": "187", "author": "Gallimore", "year": "1998", "journal-title": "J Exp Med"}, {"key": "10.1111/cei.13081-BIB0060|cei13081-cit-0060", "doi-asserted-by": "crossref", "first-page": "682", "DOI": "10.1038/nature04444", "article-title": "Restoring function in exhausted CD8 T cells during chronic viral infection", "volume": "439", "author": "Barber", "year": "2006", "journal-title": "Nature"}, {"key": "10.1111/cei.13081-BIB0061|cei13081-cit-0061", "doi-asserted-by": "crossref", "first-page": "1423", "DOI": "10.1126/science.aaf0683", "article-title": "Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent", "volume": "355", "author": "Kamphorst", "year": "2017", "journal-title": "Science"}, {"key": "10.1111/cei.13081-BIB0062|cei13081-cit-0062", "doi-asserted-by": "crossref", "first-page": "17174", "DOI": "10.1073/pnas.0406351101", "article-title": "Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target", "volume": "101", "author": "Thompson", "year": "2004", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1111/cei.13081-BIB0063|cei13081-cit-0063", "doi-asserted-by": "crossref", "first-page": "1757", "DOI": "10.1158/1078-0432.CCR-06-2599", "article-title": "PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma", "volume": "13", "author": "Thompson", "year": "2007", "journal-title": "Clin Cancer Res"}, {"key": "10.1111/cei.13081-BIB0064|cei13081-cit-0064", "doi-asserted-by": "crossref", "first-page": "1537", "DOI": "10.1182/blood-2008-12-195792", "article-title": "Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired", "volume": "114", "author": "Ahmadzadeh", "year": "2009", "journal-title": "Blood"}, {"key": "10.1111/cei.13081-BIB0065|cei13081-cit-0065", "doi-asserted-by": "crossref", "first-page": "289", "DOI": "10.1038/cmi.2010.28", "article-title": "Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer", "volume": "7", "author": "Zhang", "year": "2010", "journal-title": "Cell Mol Immunol"}, {"key": "10.1111/cei.13081-BIB0066|cei13081-cit-0066", "doi-asserted-by": "crossref", "first-page": "1757", "DOI": "10.1002/cncr.24899", "article-title": "Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma", "volume": "116", "author": "Hino", "year": "2010", "journal-title": "Cancer"}, {"key": "10.1111/cei.13081-BIB0067|cei13081-cit-0067", "doi-asserted-by": "crossref", "first-page": "887", "DOI": "10.1002/ijc.25397", "article-title": "PD-1 and PD-L1 upregulation promotes CD8(+) T cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients", "volume": "128", "author": "Shi", "year": "2011", "journal-title": "Int J Cancer"}, {"key": "10.1111/cei.13081-BIB0068|cei13081-cit-0068", "doi-asserted-by": "crossref", "first-page": "12293", "DOI": "10.1073/pnas.192461099", "article-title": "Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade", "volume": "99", "author": "Iwai", "year": "2002", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1111/cei.13081-BIB0069|cei13081-cit-0069", "doi-asserted-by": "crossref", "first-page": "1140", "DOI": "10.1158/0008-5472.CAN-03-3259", "article-title": "PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells", "volume": "64", "author": "Blank", "year": "2004", "journal-title": "Cancer Res"}, {"key": "10.1111/cei.13081-BIB0070|cei13081-cit-0070", "doi-asserted-by": "crossref", "first-page": "1327", "DOI": "10.1084/jem.20082173", "article-title": "Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1", "volume": "206", "author": "Kuang", "year": "2009", "journal-title": "J Exp Med"}, {"key": "10.1111/cei.13081-BIB0071|cei13081-cit-0071", "doi-asserted-by": "crossref", "first-page": "562", "DOI": "10.1038/nm863", "article-title": "Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity", "volume": "9", "author": "Curiel", "year": "2003", "journal-title": "Nat Med"}, {"key": "10.1111/cei.13081-BIB0072|cei13081-cit-0072", "doi-asserted-by": "crossref", "first-page": "3015", "DOI": "10.1084/jem.20090847", "article-title": "PD-L1 regulates the development, maintenance, and function of induced regulatory T cells", "volume": "206", "author": "Francisco", "year": "2009", "journal-title": "J Exp Med"}, {"key": "10.1111/cei.13081-BIB0073|cei13081-cit-0073", "doi-asserted-by": "crossref", "first-page": "711", "DOI": "10.1056/NEJMoa1003466", "article-title": "Improved survival with ipilimumab in patients with metastatic melanoma", "volume": "363", "author": "Hodi", "year": "2010", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0074|cei13081-cit-0074", "doi-asserted-by": "crossref", "first-page": "321", "DOI": "10.1038/nm0398-321", "article-title": "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma", "volume": "4", "author": "Rosenberg", "year": "1998", "journal-title": "Nat Med"}, {"key": "10.1111/cei.13081-BIB0075|cei13081-cit-0075", "doi-asserted-by": "crossref", "first-page": "5610", "DOI": "10.1158/1078-0432.CCR-08-0116", "article-title": "Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines", "volume": "14", "author": "Smith", "year": "2008", "journal-title": "Clin Cancer Res"}, {"key": "10.1111/cei.13081-BIB0076|cei13081-cit-0076", "doi-asserted-by": "crossref", "first-page": "5591", "DOI": "10.1158/1078-0432.CCR-09-1024", "article-title": "A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma", "volume": "15", "author": "Weber", "year": "2009", "journal-title": "Clin Cancer Res"}, {"key": "10.1111/cei.13081-BIB0077|cei13081-cit-0077", "doi-asserted-by": "crossref", "first-page": "155", "DOI": "10.1016/S1470-2045(09)70334-1", "article-title": "Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study", "volume": "11", "author": "Wolchok", "year": "2010", "journal-title": "Lancet Oncol"}, {"key": "10.1111/cei.13081-BIB0078|cei13081-cit-0078", "doi-asserted-by": "crossref", "first-page": "1712", "DOI": "10.1093/annonc/mdq013", "article-title": "Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study", "volume": "21", "author": "O'Day", "year": "2010", "journal-title": "Ann Oncol"}, {"key": "10.1111/cei.13081-BIB0079|cei13081-cit-0079", "doi-asserted-by": "crossref", "first-page": "1889", "DOI": "10.1200/JCO.2014.56.2736", "article-title": "Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma", "volume": "33", "author": "Schadendorf", "year": "2015", "journal-title": "J Clin Oncol"}, {"key": "10.1111/cei.13081-BIB0080|cei13081-cit-0080", "doi-asserted-by": "crossref", "first-page": "2521", "DOI": "10.1056/NEJMoa1503093", "article-title": "Pembrolizumab versus ipilimumab in advanced melanoma", "volume": "372", "author": "Robert", "year": "2015", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0081|cei13081-cit-0081", "author": "Schachter", "volume": "34", "year": "2016", "article-title": "Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006", "journal-title": "J Clin Oncol", "DOI": "10.1200/JCO.2016.34.15_suppl.9504", "doi-asserted-by": "crossref"}, {"key": "10.1111/cei.13081-BIB0082|cei13081-cit-0082", "doi-asserted-by": "crossref", "first-page": "2443", "DOI": "10.1056/NEJMoa1200690", "article-title": "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", "volume": "366", "author": "Topalian", "year": "2012", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0083|cei13081-cit-0083", "doi-asserted-by": "crossref", "first-page": "1020", "DOI": "10.1200/JCO.2013.53.0105", "article-title": "Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab", "volume": "32", "author": "Topalian", "year": "2014", "journal-title": "J Clin Oncol"}, {"key": "10.1111/cei.13081-BIB0084|cei13081-cit-0084", "doi-asserted-by": "crossref", "first-page": "320", "DOI": "10.1056/NEJMoa1412082", "article-title": "Nivolumab in previously untreated melanoma without BRAF mutation", "volume": "372", "author": "Robert", "year": "2015", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0085|cei13081-cit-0085", "doi-asserted-by": "crossref", "first-page": "122", "DOI": "10.1056/NEJMoa1302369", "article-title": "Nivolumab plus ipilimumab in advanced melanoma", "volume": "369", "author": "Wolchok", "year": "2013", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0086|cei13081-cit-0086", "doi-asserted-by": "crossref", "first-page": "9003", "DOI": "10.1200/jco.2014.32.18_suppl.lba9003", "article-title": "Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)", "volume": "32", "author": "Sznol", "year": "2014", "journal-title": "J Clin Oncol"}, {"key": "10.1111/cei.13081-BIB0087|cei13081-cit-0087", "doi-asserted-by": "crossref", "first-page": "2006", "DOI": "10.1056/NEJMoa1414428", "article-title": "Nivolumab and ipilimumab versus ipilimumab in untreated melanoma", "volume": "372", "author": "Postow", "year": "2015", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0088|cei13081-cit-0088", "doi-asserted-by": "crossref", "first-page": "1558", "DOI": "10.1016/S1470-2045(16)30366-7", "article-title": "Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial", "volume": "17", "author": "Hodi", "year": "2016", "journal-title": "Lancet Oncol"}, {"key": "10.1111/cei.13081-BIB0089|cei13081-cit-0089", "doi-asserted-by": "crossref", "first-page": "23", "DOI": "10.1056/NEJMoa1504030", "article-title": "Combined nivolumab and ipilimumab or monotherapy in untreated melanoma", "volume": "373", "author": "Larkin", "year": "2015", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0090|cei13081-cit-0090", "doi-asserted-by": "crossref", "first-page": "1345", "DOI": "10.1056/NEJMoa1709684", "article-title": "Overall survival with combined nivolumab and ipilimumab in advanced melanoma", "volume": "377", "author": "Wolchok", "year": "2017", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0091|cei13081-cit-0091", "doi-asserted-by": "crossref", "first-page": "943", "DOI": "10.1016/S1470-2045(16)30126-7", "article-title": "Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial", "volume": "17", "author": "Weber", "year": "2016", "journal-title": "Lancet Oncol"}, {"key": "10.1111/cei.13081-BIB0092|cei13081-cit-0092", "doi-asserted-by": "crossref", "first-page": "1109", "DOI": "10.1016/S0140-6736(14)60958-2", "article-title": "Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial", "volume": "384", "author": "Robert", "year": "2014", "journal-title": "Lancet"}, {"key": "10.1111/cei.13081-BIB0093|cei13081-cit-0093", "doi-asserted-by": "crossref", "first-page": "228", "DOI": "10.1016/j.ejca.2008.10.026", "article-title": "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", "volume": "45", "author": "Eisenhauer", "year": "2009", "journal-title": "Eur J Cancer"}, {"key": "10.1111/cei.13081-BIB0094|cei13081-cit-0094", "unstructured": "http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm"}, {"key": "10.1111/cei.13081-BIB0095|cei13081-cit-0095", "doi-asserted-by": "crossref", "first-page": "375", "DOI": "10.1016/S1470-2045(15)70076-8", "article-title": "Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial", "volume": "16", "author": "Weber", "year": "2015", "journal-title": "Lancet Oncol"}, {"key": "10.1111/cei.13081-BIB0096|cei13081-cit-0096", "first-page": "abstr8071", "article-title": "Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)", "volume": "27", "author": "Zatloukal", "year": "2009", "journal-title": "J Clin Oncol"}, {"key": "10.1111/cei.13081-BIB0097|cei13081-cit-0097", "doi-asserted-by": "crossref", "first-page": "2046", "DOI": "10.1200/JCO.2011.38.4032", "article-title": "Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study", "volume": "30", "author": "Lynch", "year": "2012", "journal-title": "J Clin Oncol"}, {"key": "10.1111/cei.13081-BIB0098|cei13081-cit-0098", "doi-asserted-by": "crossref", "first-page": "3449", "DOI": "10.1200/JCO.2016.71.7629", "article-title": "Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer", "volume": "35", "author": "Govindan", "year": "2017", "journal-title": "J Clin Oncol"}, {"key": "10.1111/cei.13081-BIB0099|cei13081-cit-0099", "doi-asserted-by": "crossref", "first-page": "123", "DOI": "10.1056/NEJMoa1504627", "article-title": "Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer", "volume": "373", "author": "Brahmer", "year": "2015", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0100|cei13081-cit-0100", "doi-asserted-by": "crossref", "first-page": "1627", "DOI": "10.1056/NEJMoa1507643", "article-title": "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", "volume": "373", "author": "Borghaei", "year": "2015", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0101|cei13081-cit-0101", "doi-asserted-by": "crossref", "first-page": "257", "DOI": "10.1016/S1470-2045(15)70054-9", "article-title": "Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial", "volume": "16", "author": "Rizvi", "year": "2015", "journal-title": "Lancet Oncol"}, {"key": "10.1111/cei.13081-BIB0102|cei13081-cit-0102", "doi-asserted-by": "crossref", "first-page": "1540", "DOI": "10.1016/S0140-6736(15)01281-7", "article-title": "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial", "volume": "387", "author": "Herbst", "year": "2016", "journal-title": "Lancet"}, {"key": "10.1111/cei.13081-BIB0103|cei13081-cit-0103", "first-page": "1540", "article-title": "Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1-expressing NSCLC: updated outcomes of KEYNOTE-010", "volume": "387", "author": "Herbst", "year": "2016", "journal-title": "Ann Oncol"}, {"key": "10.1111/cei.13081-BIB0104|cei13081-cit-0104", "doi-asserted-by": "crossref", "first-page": "2018", "DOI": "10.1056/NEJMoa1501824", "article-title": "Pembrolizumab for the treatment of non-small-cell lung cancer", "volume": "372", "author": "Garon", "year": "2015", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0105|cei13081-cit-0105", "doi-asserted-by": "crossref", "first-page": "1823", "DOI": "10.1056/NEJMoa1606774", "article-title": "Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer", "volume": "375", "author": "Reck", "year": "2016", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0106|cei13081-cit-0106", "doi-asserted-by": "crossref", "first-page": "2415", "DOI": "10.1056/NEJMoa1613493", "article-title": "First-line nivolumab in stage IV or recurrent non-small-cell lung cancer", "volume": "376", "author": "Carbone", "year": "2017", "journal-title": "New Engl J Med"}, {"key": "10.1111/cei.13081-BIB0107|cei13081-cit-0107", "doi-asserted-by": "crossref", "first-page": "1837", "DOI": "10.1016/S0140-6736(16)00587-0", "article-title": "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial", "volume": "387", "author": "Fehrenbacher", "year": "2016", "journal-title": "Lancet"}, {"key": "10.1111/cei.13081-BIB0108|cei13081-cit-0108", "doi-asserted-by": "crossref", "first-page": "255", "DOI": "10.1016/S0140-6736(16)32517-X", "article-title": "Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial", "volume": "389", "author": "Rittmeyer", "year": "2017", "journal-title": "Lancet"}, {"key": "10.1111/cei.13081-BIB0109|cei13081-cit-0109", "first-page": "vi552", "article-title": "Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC", "volume": "27", "author": "Barles", "year": "2016", "journal-title": "Ann Oncol"}, {"key": "10.1111/cei.13081-BIB0110|cei13081-cit-0110", "doi-asserted-by": "crossref", "first-page": "31", "DOI": "10.1016/S1470-2045(16)30624-6", "article-title": "Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study", "volume": "18", "author": "Hellmann", "year": "2017", "journal-title": "Lancet Oncol"}, {"key": "10.1111/cei.13081-BIB0111|cei13081-cit-0111", "doi-asserted-by": "crossref", "first-page": "70", "DOI": "10.1016/j.lungcan.2017.02.002", "article-title": "Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: current status and future approaches", "volume": "106", "author": "Remon", "year": "2017", "journal-title": "Lung Cancer"}, {"key": "10.1111/cei.13081-BIB0112|cei13081-cit-0112", "doi-asserted-by": "crossref", "first-page": "299", "DOI": "10.1016/S1470-2045(15)00544-6", "article-title": "Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study", "volume": "17", "author": "Antonia", "year": "2016", "journal-title": "Lancet Oncol"}, {"key": "10.1111/cei.13081-BIB0113|cei13081-cit-0113", "unstructured": "https://clinicaltrials.gov/show/NCT02352948"}, {"key": "10.1111/cei.13081-BIB0114|cei13081-cit-0114", "unstructured": "https://clinicaltrials.gov/show/NCT02453282"}, {"key": "10.1111/cei.13081-BIB0115|cei13081-cit-0115", "unstructured": "https://clinicaltrials.gov/show/NCT02542293"}, {"key": "10.1111/cei.13081-BIB0116|cei13081-cit-0116", "doi-asserted-by": "crossref", "first-page": "1919", "DOI": "10.1056/NEJMoa1709937", "article-title": "Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer", "volume": "77", "author": "Antonia", "year": "2017", "journal-title": "New Engl J Med"}, {"key": "10.1111/cei.13081-BIB0117|cei13081-cit-0117", "doi-asserted-by": "crossref", "first-page": "3381", "DOI": "10.1158/0008-5472.CAN-05-4303", "article-title": "Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up", "volume": "66", "author": "Thompson", "year": "2006", "journal-title": "Cancer Res"}, {"key": "10.1111/cei.13081-BIB0118|cei13081-cit-0118", "doi-asserted-by": "crossref", "first-page": "1430", "DOI": "10.1200/JCO.2014.59.0703", "article-title": "Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial", "volume": "33", "author": "Motzer", "year": "2015", "journal-title": "J Clin Oncol"}, {"key": "10.1111/cei.13081-BIB0119|cei13081-cit-0119", "doi-asserted-by": "crossref", "first-page": "1803", "DOI": "10.1056/NEJMoa1510665", "article-title": "Nivolumab versus everolimus in advanced renal-cell carcinoma", "volume": "373", "author": "Motzer", "year": "2015", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0120|cei13081-cit-0120", "doi-asserted-by": "crossref", "first-page": "1909", "DOI": "10.1016/S0140-6736(16)00561-4", "article-title": "Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial", "volume": "387", "author": "Rosenberg", "year": "2016", "journal-title": "Lancet"}, {"key": "10.1111/cei.13081-BIB0121|cei13081-cit-0121", "doi-asserted-by": "crossref", "first-page": "1590", "DOI": "10.1016/S1470-2045(16)30496-X", "article-title": "Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial", "volume": "17", "author": "Sharma", "year": "2016", "journal-title": "Lancet Oncol"}, {"key": "10.1111/cei.13081-BIB0122|cei13081-cit-0122", "doi-asserted-by": "crossref", "first-page": "2189", "DOI": "10.1056/NEJMoa1406498", "article-title": "Genetic basis for clinical response to CTLA-4 blockade in melanoma", "volume": "371", "author": "Snyder", "year": "2014", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0123|cei13081-cit-0123", "doi-asserted-by": "crossref", "first-page": "35", "DOI": "10.1016/j.cell.2016.02.065", "article-title": "Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma", "volume": "165", "author": "Hugo", "year": "2016", "journal-title": "Cell"}, {"key": "10.1111/cei.13081-BIB0124|cei13081-cit-0124", "doi-asserted-by": "crossref", "first-page": "2509", "DOI": "10.1056/NEJMoa1500596", "article-title": "PD-1 blockade in tumors with mismatch-repair deficiency", "volume": "372", "author": "Le", "year": "2015", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0125|cei13081-cit-0125", "doi-asserted-by": "crossref", "first-page": "1103TiP", "DOI": "10.1093/annonc/mdw378.56", "article-title": "MEDIOLA: a phase I/II, open-label trial of olaparib in combination with durvalumab (MEDI4736) in patients with advanced solid tumours", "volume": "27", "author": "Domchek", "year": "2016", "journal-title": "Ann Oncol"}, {"key": "10.1111/cei.13081-BIB0126|cei13081-cit-0126", "doi-asserted-by": "crossref", "first-page": "311", "DOI": "10.1056/NEJMoa1411087", "article-title": "PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma", "volume": "374", "author": "Ansell", "year": "2015", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0127|cei13081-cit-0127", "doi-asserted-by": "crossref", "first-page": "373", "DOI": "10.1200/JCO.2016.67.3467", "article-title": "Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure", "volume": "34", "author": "Armand", "year": "2016", "journal-title": "J Clin Oncol"}, {"key": "10.1111/cei.13081-BIB0128|cei13081-cit-0128", "doi-asserted-by": "crossref", "first-page": "3838", "DOI": "10.1200/JCO.2016.68.1478", "article-title": "Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort", "volume": "34", "author": "Chow", "year": "2016", "journal-title": "J Clin Oncol"}, {"key": "10.1111/cei.13081-BIB0129|cei13081-cit-0129", "doi-asserted-by": "crossref", "first-page": "1856", "DOI": "10.1056/NEJMoa1602252", "article-title": "Nivolumab for recurrent squamous-cell carcinoma of the head and neck", "volume": "375", "author": "Ferris", "year": "2016", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0130|cei13081-cit-0130", "doi-asserted-by": "crossref", "first-page": "628LBA45", "DOI": "10.1093/annonc/mdx440.040", "article-title": "Pembrolizumab versus standard of care for recurrent or metastatic head and neck squamous cell carcinoma: phase 3 KEYNOTE-040 trial", "volume": "28", "author": "Cohen", "year": "2017", "journal-title": "Ann Oncol"}, {"key": "10.1111/cei.13081-BIB0131|cei13081-cit-0131", "doi-asserted-by": "crossref", "first-page": "1374", "DOI": "10.1016/S1470-2045(16)30364-3", "article-title": "Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial", "volume": "17", "author": "Kaufman", "year": "2016", "journal-title": "Lancet Oncol"}, {"key": "10.1111/cei.13081-BIB0132|cei13081-cit-0132", "doi-asserted-by": "crossref", "first-page": "20", "DOI": "10.1016/j.coviro.2016.07.011", "article-title": "Merkel cell polyomavirus infection and Merkel cell carcinoma", "volume": "20", "author": "Liu", "year": "2016", "journal-title": "Curr Opin Virol"}, {"key": "10.1111/cei.13081-BIB0133|cei13081-cit-0133", "doi-asserted-by": "crossref", "first-page": "2542", "DOI": "10.1056/NEJMoa1603702", "article-title": "PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma", "volume": "374", "author": "Nghiem", "year": "2016", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0134|cei13081-cit-0134", "doi-asserted-by": "crossref", "first-page": "3740", "DOI": "10.1200/JCO.2016.67.6601", "article-title": "Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer", "volume": "34", "author": "Reck", "year": "2016", "journal-title": "J Clin Oncol"}, {"key": "10.1111/cei.13081-BIB0135|cei13081-cit-0135", "doi-asserted-by": "crossref", "first-page": "75", "DOI": "10.1093/annonc/mds213", "article-title": "Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial", "volume": "24", "author": "Reck", "year": "2013", "journal-title": "Ann Oncol"}, {"key": "10.1111/cei.13081-BIB0136|cei13081-cit-0136", "doi-asserted-by": "crossref", "first-page": "88395", "DOI": "10.1016/S1470-2045(16)30098-5", "article-title": "Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial", "volume": "17", "author": "Antonia", "year": "2016", "journal-title": "Lancet Oncol"}, {"key": "10.1111/cei.13081-BIB0137|cei13081-cit-0137", "doi-asserted-by": "crossref", "first-page": "abstr7502", "DOI": "10.1200/jco.2015.33.15_suppl.7502", "article-title": "Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): preliminary safety and efficacy results from KEYNOTE-028", "volume": "33", "author": "Ott", "year": "2015", "journal-title": "J Clin Oncol"}, {"key": "10.1111/cei.13081-BIB0138|cei13081-cit-0138", "doi-asserted-by": "crossref", "first-page": "700", "DOI": "10.1016/S1470-2045(14)70189-5", "article-title": "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial", "volume": "15", "author": "Kwon", "year": "2014", "journal-title": "Lancet Oncol"}, {"key": "10.1111/cei.13081-BIB0139|cei13081-cit-0139", "doi-asserted-by": "crossref", "first-page": "7412", "DOI": "10.1158/1078-0432.CCR-09-1624", "article-title": "Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria", "volume": "15", "author": "Wolchok", "year": "2009", "journal-title": "Clin Cancer Res"}, {"key": "10.1111/cei.13081-BIB0140|cei13081-cit-0140", "unstructured": "Phase 3 study of immunotherapy to treat advanced prostate cancer https://clinicaltrials.gov/ct2/show/NCT01057810"}, {"key": "10.1111/cei.13081-BIB0141|cei13081-cit-0141", "doi-asserted-by": "crossref", "first-page": "717", "DOI": "10.1016/S1470-2045(16)00175-3", "article-title": "Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial", "volume": "17", "author": "Muro", "year": "2016", "journal-title": "Lancet Oncol"}, {"key": "10.1111/cei.13081-BIB0142|cei13081-cit-0142", "doi-asserted-by": "crossref", "first-page": "6", "DOI": "10.1200/jco.2016.34.4_suppl.6", "article-title": "Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): results from the CheckMate-032 study", "volume": "34", "author": "Le", "year": "2016", "journal-title": "J Clin Oncol"}, {"key": "10.1111/cei.13081-BIB0143|cei13081-cit-0143", "doi-asserted-by": "crossref", "first-page": "LBA101", "DOI": "10.1200/jco.2015.33.18_suppl.lba101", "article-title": "Phase I/II safety and antitumour activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040", "volume": "33", "author": "El-Khoueiry", "year": "2015", "journal-title": "J Clin Oncol"}, {"key": "10.1111/cei.13081-BIB0144|cei13081-cit-0144", "unstructured": "https://clinicaltrials.gov/ct2/results?term=checkpoint+inhibitors&Search=Search"}, {"key": "10.1111/cei.13081-BIB0145|cei13081-cit-0145", "doi-asserted-by": "crossref", "first-page": "373", "DOI": "10.1038/nature14292", "article-title": "Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer", "volume": "520", "author": "Twyman-Saint Victor", "year": "2015", "journal-title": "Nature"}, {"key": "10.1111/cei.13081-BIB0146|cei13081-cit-0146", "doi-asserted-by": "crossref", "first-page": "925", "DOI": "10.1056/NEJMoa1112824", "article-title": "Immunologic correlates of the abscopal effect in a patient with melanoma", "volume": "366", "author": "Postow", "year": "2012", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0147|cei13081-cit-0147", "doi-asserted-by": "crossref", "first-page": "50", "DOI": "10.1186/s40425-015-0095-8", "article-title": "Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review", "volume": "3", "author": "Schoenfeld", "year": "2015", "journal-title": "J Immunother Cancer"}, {"key": "10.1111/cei.13081-BIB0148|cei13081-cit-0148", "first-page": "545", "article-title": "Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies", "volume": "4", "author": "Simone", "year": "2015", "journal-title": "Transl Lung Cancer Res"}, {"key": "10.1111/cei.13081-BIB0149|cei13081-cit-0149", "doi-asserted-by": "crossref", "first-page": "5198", "DOI": "10.1158/1078-0432.CCR-15-0822", "article-title": "New strategies in stereotactic radiotherapy for oligometastases", "volume": "21", "author": "Palma", "year": "2015", "journal-title": "Clin Cancer Res"}, {"key": "10.1111/cei.13081-BIB0150|cei13081-cit-0150", "doi-asserted-by": "crossref", "first-page": "119", "DOI": "10.1097/COC.0b013e3182940dc3", "article-title": "Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma", "volume": "38", "author": "Okwan-Duodu", "year": "2015", "journal-title": "Am J Clin Oncol"}, {"key": "10.1111/cei.13081-BIB0151|cei13081-cit-0151", "unstructured": "Immune checkpoint inhibition in combination with radiation therapy in pancreatic cancer patients (CheckPAC) https://clinicaltrials.gov/ct2/show/NCT02866383?term=pancreas+AND+ipilimumab&rank=5"}, {"key": "10.1111/cei.13081-BIB0152|cei13081-cit-0152", "unstructured": "Combination Adenovirus\u2009+\u2009Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE) https://clinicaltrials.gov/ct2/show/NCT02798406?term=checkpoint+inhibitors&rank=5"}, {"key": "10.1111/cei.13081-BIB0153|cei13081-cit-0153", "doi-asserted-by": "crossref", "first-page": "249", "DOI": "10.1038/nature15520", "article-title": "Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy", "volume": "527", "author": "Peng", "year": "2015", "journal-title": "Nature"}, {"key": "10.1111/cei.13081-BIB0154|cei13081-cit-0154", "doi-asserted-by": "crossref", "first-page": "832", "DOI": "10.1016/j.ccell.2016.04.014", "article-title": "CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma", "volume": "29", "author": "Steele", "year": "2016", "journal-title": "Cancer Cell"}, {"key": "10.1111/cei.13081-BIB0155|cei13081-cit-0155", "doi-asserted-by": "crossref", "first-page": "577", "DOI": "10.1016/j.immuni.2017.03.013", "article-title": "Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors", "volume": "46", "author": "Arce Vargas", "year": "2017", "journal-title": "Immunity"}, {"key": "10.1111/cei.13081-BIB0156|cei13081-cit-0156", "doi-asserted-by": "crossref", "first-page": "56", "DOI": "10.1126/science.aaa8172", "article-title": "The future of immune checkpoint therapy", "volume": "348", "author": "Sharma", "year": "2015", "journal-title": "Science"}, {"key": "10.1111/cei.13081-BIB0157|cei13081-cit-0157", "doi-asserted-by": "crossref", "first-page": "819", "DOI": "10.1056/NEJMoa1604958", "article-title": "Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma", "volume": "375", "author": "Zaretsky", "year": "2016", "journal-title": "N Engl J Med"}, {"key": "10.1111/cei.13081-BIB0158|cei13081-cit-0158", "unstructured": "Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies (SPECIAL) https://clinicaltrials.gov/ct2/show/NCT02724488?term=checkpoint+inhibitors&rank=1"}, {"key": "10.1111/cei.13081-BIB0159|cei13081-cit-0159", "doi-asserted-by": "crossref", "first-page": "47", "DOI": "10.1186/s13045-016-0277-y", "article-title": "Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy", "volume": "9", "author": "Ma", "year": "2016", "journal-title": "J Hematol Oncol"}, {"key": "10.1111/cei.13081-BIB0160|cei13081-cit-0160", "doi-asserted-by": "crossref", "first-page": "273", "DOI": "10.1038/nrclinonc.2016.25", "article-title": "The future of cancer treatment: immunomodulation, CARs and combination immunotherapy", "volume": "13", "author": "Khalil", "year": "2016", "journal-title": "Nature Rev Clin Oncol"}], "container-title": ["Clinical & Experimental Immunology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fcei.13081", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://onlinelibrary.wiley.com/wol1/doi/10.1111/cei.13081/fullpdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 10, 6]], "date-time": "2019-10-06T05:13:59Z", "timestamp": 1570338839000}, "score": 29.270868, "subtitle": ["Immune checkpoint inhibitors"], "issued": {"date-parts": [[2017, 12, 27]]}, "references-count": 160, "journal-issue": {"published-print": {"date-parts": [[2018, 2]]}, "issue": "2"}, "URL": "http://dx.doi.org/10.1111/cei.13081", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["0009-9104"], "issn-type": [{"value": "0009-9104", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T23:42:01Z", "timestamp": 1575502921293}, "reference-count": 0, "publisher": "American Thoracic Society", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2019, 5]]}, "DOI": "10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3092", "type": "proceedings-article", "created": {"date-parts": [[2019, 8, 26]], "date-time": "2019-08-26T16:37:28Z", "timestamp": 1566837448000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Diagnostic Challenges and Management Considerations of Immune-Related Hypersensitivity Pneumonitis Associated with Immune Checkpoint Inhibitors"], "prefix": "10.1164", "author": [{"given": "B.", "family": "Bagley", "sequence": "first", "affiliation": [{"name": "Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States"}]}, {"given": "N.L.", "family": "Sigua", "sequence": "additional", "affiliation": [{"name": "Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indiana University School of Medicine, Indianapolis, IN, United States"}]}, {"given": "M.", "family": "Bikak", "sequence": "additional", "affiliation": [{"name": "Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indiana University School of Medicine, Indianapolis, IN, United States"}]}], "member": "19", "published-online": {"date-parts": [[2019, 5, 1]]}, "event": {"name": "American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX"}, "container-title": ["B40. AUTOIMMUNE LUNG DISEASE CASE REPORTS"], "deposited": {"date-parts": [[2019, 8, 26]], "date-time": "2019-08-26T16:37:46Z", "timestamp": 1566837466000}, "score": 28.06494, "issued": {"date-parts": [[2019, 5]]}, "references-count": 0, "alternative-id": ["10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A3092", "10.1164/ajrccm-conference.2019.B40"], "URL": "http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3092"}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T07:22:22Z", "timestamp": 1575444142498}, "reference-count": 14, "publisher": "American Medical Association (AMA)", "issue": "7", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JAMA Oncol"], "published-print": {"date-parts": [[2019, 7, 1]]}, "DOI": "10.1001/jamaoncol.2019.0413", "type": "journal-article", "created": {"date-parts": [[2019, 4, 25]], "date-time": "2019-04-25T15:36:36Z", "timestamp": 1556206596000}, "page": "942", "source": "Crossref", "is-referenced-by-count": 3, "title": ["PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events"], "prefix": "10.1001", "volume": "5", "author": [{"given": "Diwakar", "family": "Davar", "sequence": "first", "affiliation": [{"name": "Division of Hematology-Oncology, Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania"}]}, {"given": "John M.", "family": "Kirkwood", "sequence": "additional", "affiliation": [{"name": "Division of Hematology-Oncology, Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania"}]}], "member": "10", "container-title": ["JAMA Oncology"], "language": "en", "link": [{"URL": "http:///jamaoncology/article-pdf/5/7/942/17712391/jamaoncology_davar_2019_ed_190008.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 7, 11]], "date-time": "2019-07-11T15:02:32Z", "timestamp": 1562857352000}, "score": 27.797825, "subtitle": ["Understanding the Upside of the Downside of Checkpoint Blockade"], "issued": {"date-parts": [[2019, 7, 1]]}, "references-count": 14, "journal-issue": {"published-print": {"date-parts": [[2019, 7, 1]]}, "issue": "7"}, "URL": "http://dx.doi.org/10.1001/jamaoncol.2019.0413", "ISSN": ["2374-2437"], "issn-type": [{"value": "2374-2437", "type": "print"}], "subject": ["General Medicine"]}, {"indexed": {"date-parts": [[2019, 12, 3]], "date-time": "2019-12-03T07:38:28Z", "timestamp": 1575358708794}, "publisher-location": "Cham", "reference-count": 50, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319935294", "type": "print"}, {"value": "9783319935300", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2018, 11, 28]], "date-time": "2018-11-28T00:00:00Z", "timestamp": 1543363200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "published-print": {"date-parts": [[2019]]}, "DOI": "10.1007/978-3-319-93530-0_7", "type": "book-chapter", "created": {"date-parts": [[2018, 11, 27]], "date-time": "2018-11-27T19:13:13Z", "timestamp": 1543345993000}, "page": "125-137", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Immune Checkpoint Inhibitors in Sarcoma"], "prefix": "10.1007", "author": [{"given": "Sandra P.", "family": "D\u2019Angelo", "sequence": "first", "affiliation": []}, {"given": "Ciara M.", "family": "Kelly", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2018, 11, 28]]}, "reference": [{"key": "7_CR1", "doi-asserted-by": "publisher", "first-page": "252", "DOI": "10.1038/nrc3239", "volume": "12", "author": "DM Pardoll", "year": "2012", "unstructured": "Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.", "journal-title": "Nat Rev Cancer"}, {"key": "7_CR2", "doi-asserted-by": "publisher", "first-page": "367", "DOI": "10.2217/imt.10.21", "volume": "2", "author": "DB Page", "year": "2010", "unstructured": "Page DB, Yuan J, Wolchok JD. Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers. Immunotherapy. 2010;2:367\u201379.", "journal-title": "Immunotherapy"}, {"key": "7_CR3", "doi-asserted-by": "publisher", "first-page": "76", "DOI": "10.1038/366076a0", "volume": "366", "author": "M Azuma", "year": "1993", "unstructured": "Azuma M, Ito D, Yagita H, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993;366:76\u20139.", "journal-title": "Nature"}, {"key": "7_CR4", "doi-asserted-by": "publisher", "first-page": "905", "DOI": "10.1126/science.7694361", "volume": "262", "author": "KS Hathcock", "year": "1993", "unstructured": "Hathcock KS, Laszlo G, Dickler HB, Bradshaw J, Linsley P, Hodes RJ. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science. 1993;262:905\u20137.", "journal-title": "Science"}, {"key": "7_CR5", "doi-asserted-by": "publisher", "first-page": "793", "DOI": "10.1016/S1074-7613(94)80021-9", "volume": "1", "author": "PS Linsley", "year": "1994", "unstructured": "Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994;1:793\u2013801.", "journal-title": "Immunity"}, {"key": "7_CR6", "doi-asserted-by": "publisher", "first-page": "1972", "DOI": "10.1126/science.1131078", "volume": "313", "author": "H Schneider", "year": "2006", "unstructured": "Schneider H, Downey J, Smith A, et al. Reversal of the TCR stop signal by CTLA-4. Science. 2006;313:1972\u20135.", "journal-title": "Science"}, {"key": "7_CR7", "doi-asserted-by": "publisher", "first-page": "9543", "DOI": "10.1128/MCB.25.21.9543-9553.2005", "volume": "25", "author": "RV Parry", "year": "2005", "unstructured": "Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25:9543\u201353.", "journal-title": "Mol Cell Biol"}, {"key": "7_CR8", "doi-asserted-by": "publisher", "first-page": "8968", "DOI": "10.1200/JCO.2005.01.109", "volume": "23", "author": "A Ribas", "year": "2005", "unstructured": "Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005;23:8968\u201377.", "journal-title": "J Clin Oncol"}, {"key": "7_CR9", "doi-asserted-by": "publisher", "first-page": "450", "DOI": "10.1053/j.seminoncol.2010.09.010", "volume": "37", "author": "A Ribas", "year": "2010", "unstructured": "Ribas A. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol. 2010;37:450\u20134.", "journal-title": "Semin Oncol"}, {"key": "7_CR10", "doi-asserted-by": "publisher", "first-page": "711", "DOI": "10.1056/NEJMoa1003466", "volume": "363", "author": "FS Hodi", "year": "2010", "unstructured": "Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.", "journal-title": "N Engl J Med"}, {"key": "7_CR11", "doi-asserted-by": "publisher", "first-page": "1889", "DOI": "10.1200/JCO.2014.56.2736", "volume": "33", "author": "D Schadendorf", "year": "2015", "unstructured": "Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889\u201394.", "journal-title": "J Clin Oncol"}, {"key": "7_CR12", "doi-asserted-by": "publisher", "first-page": "168145", "DOI": "10.1155/2013/168145", "volume": "2013", "author": "RG Maki", "year": "2013", "unstructured": "Maki RG, Jungbluth AA, Gnjatic S, et al. A pilot study of Anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma. 2013;2013:168145.", "journal-title": "Sarcoma"}, {"key": "7_CR13", "doi-asserted-by": "publisher", "first-page": "793", "DOI": "10.1038/nm730", "volume": "8", "author": "H Dong", "year": "2002", "unstructured": "Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793\u2013800.", "journal-title": "Nat Med"}, {"key": "7_CR14", "doi-asserted-by": "publisher", "first-page": "1140", "DOI": "10.1158/0008-5472.CAN-03-3259", "volume": "64", "author": "C Blank", "year": "2004", "unstructured": "Blank C, Brown I, Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004;64:1140\u20135.", "journal-title": "Cancer Res"}, {"key": "7_CR15", "doi-asserted-by": "publisher", "first-page": "3887", "DOI": "10.1002/j.1460-2075.1992.tb05481.x", "volume": "11", "author": "Y Ishida", "year": "1992", "unstructured": "Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887\u201395.", "journal-title": "EMBO J"}, {"key": "7_CR16", "doi-asserted-by": "publisher", "first-page": "1027", "DOI": "10.1084/jem.192.7.1027", "volume": "192", "author": "GJ Freeman", "year": "2000", "unstructured": "Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027\u201334.", "journal-title": "J Exp Med"}, {"key": "7_CR17", "doi-asserted-by": "publisher", "first-page": "3015", "DOI": "10.1084/jem.20090847", "volume": "206", "author": "LM Francisco", "year": "2009", "unstructured": "Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015\u201329.", "journal-title": "J Exp Med"}, {"key": "7_CR18", "doi-asserted-by": "publisher", "first-page": "157", "DOI": "10.1001/jamaoncol.2017.4182", "volume": "4", "author": "V Prasad", "year": "2018", "unstructured": "Prasad V, Kaestner V, Mailankody S. Cancer drugs approved based on biomarkers and not tumor type-FDA approval of pembrolizumab for mismatch repair-deficient solid cancers. JAMA Oncol. 2018;4:157\u20138.", "journal-title": "JAMA Oncol"}, {"key": "7_CR19", "doi-asserted-by": "publisher", "first-page": "3285", "DOI": "10.1002/cncr.30738", "volume": "123", "author": "E Ben-Ami", "year": "2017", "unstructured": "Ben-Ami E, Barysauskas CM, Solomon S, et al. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study. Cancer. 2017;123:3285\u201390.", "journal-title": "Cancer"}, {"key": "7_CR20", "doi-asserted-by": "publisher", "first-page": "1493", "DOI": "10.1016/S1470-2045(17)30624-1", "volume": "18", "author": "HA Tawbi", "year": "2017", "unstructured": "Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18:1493\u2013501.", "journal-title": "Lancet Oncol"}, {"key": "7_CR21", "doi-asserted-by": "publisher", "first-page": "2006", "DOI": "10.1056/NEJMoa1414428", "volume": "372", "author": "MA Postow", "year": "2015", "unstructured": "Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006\u201317.", "journal-title": "N Engl J Med"}, {"issue": "15_suppl", "key": "7_CR22", "doi-asserted-by": "publisher", "first-page": "11007", "DOI": "10.1200/JCO.2017.35.15_suppl.11007", "volume": "35", "author": "Sandra P. D'Angelo", "year": "2017", "unstructured": "D\u2019Angelo SP Mahoney MR, Van Tine BA, et al. A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401). American Society of Clinical Oncology Annual Meeting, Chicago, USA. 2017.", "journal-title": "Journal of Clinical Oncology"}, {"key": "7_CR23", "doi-asserted-by": "publisher", "first-page": "925", "DOI": "10.1056/NEJMoa1112824", "volume": "366", "author": "MA Postow", "year": "2012", "unstructured": "Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925\u201331.", "journal-title": "N Engl J Med"}, {"key": "7_CR24", "doi-asserted-by": "publisher", "first-page": "4843", "DOI": "10.1158/1078-0432.CCR-13-0352", "volume": "19", "author": "A Sharma", "year": "2013", "unstructured": "Sharma A, Bode B, Studer G, et al. Radiotherapy of human sarcoma promotes an intratumoral immune effector signature. Clin Cancer Res. 2013;19:4843\u201353.", "journal-title": "Clin Cancer Res"}, {"key": "7_CR25", "doi-asserted-by": "publisher", "first-page": "2514", "DOI": "10.1158/0008-5472.CAN-08-4709", "volume": "69", "author": "J Ozao-Choy", "year": "2009", "unstructured": "Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009;69:2514\u201322.", "journal-title": "Cancer Res"}, {"key": "7_CR26", "doi-asserted-by": "publisher", "first-page": "896", "DOI": "10.1038/leu.2010.11", "volume": "24", "author": "KC Lee", "year": "2010", "unstructured": "Lee KC, Ouwehand I, Giannini AL, Thomas NS, Dibb NJ, Bijlmakers MJ. Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia. 2010;24:896\u2013900.", "journal-title": "Leukemia"}, {"key": "7_CR27", "doi-asserted-by": "publisher", "first-page": "772", "DOI": "10.1182/blood-2009-12-256800", "volume": "116", "author": "A Kreutzman", "year": "2010", "unstructured": "Kreutzman A, Juvonen V, Kairisto V, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116:772\u201382.", "journal-title": "Blood"}, {"key": "7_CR28", "doi-asserted-by": "publisher", "first-page": "472", "DOI": "10.1056/NEJMoa020461", "volume": "347", "author": "GD Demetri", "year": "2002", "unstructured": "Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472\u201380.", "journal-title": "N Engl J Med"}, {"key": "7_CR29", "doi-asserted-by": "publisher", "first-page": "295", "DOI": "10.1016/S0140-6736(12)61857-1", "volume": "381", "author": "GD Demetri", "year": "2013", "unstructured": "Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295\u2013302.", "journal-title": "Lancet"}, {"key": "7_CR30", "doi-asserted-by": "publisher", "first-page": "1329", "DOI": "10.1016/S0140-6736(06)69446-4", "volume": "368", "author": "GD Demetri", "year": "2006", "unstructured": "Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329\u201338.", "journal-title": "Lancet"}, {"key": "7_CR31", "doi-asserted-by": "publisher", "first-page": "2972", "DOI": "10.1158/1078-0432.CCR-16-2349", "volume": "23", "author": "SP D\u2019Angelo", "year": "2017", "unstructured": "D\u2019Angelo SP, Shoushtari AN, Keohan ML, et al. Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: a phase Ib Study of dasatinib plus ipilimumab. Clin Cancer Res. 2017;23:2972\u201380.", "journal-title": "Clin Cancer Res"}, {"key": "7_CR32", "doi-asserted-by": "publisher", "first-page": "1094", "DOI": "10.1038/nm.2438", "volume": "17", "author": "VP Balachandran", "year": "2011", "unstructured": "Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17:1094\u2013100.", "journal-title": "Nat Med"}, {"issue": "15_suppl", "key": "7_CR33", "doi-asserted-by": "publisher", "DOI": "10.1200/jco.2011.29.15_suppl.10006", "volume": "29", "author": "JC Trent", "year": "2011", "unstructured": "Trent JC, Wathen K, von Mehren M, et al. A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol. 2011;29(15_suppl):10006.", "journal-title": "J Clin Oncol"}, {"key": "7_CR34", "doi-asserted-by": "publisher", "first-page": "1879", "DOI": "10.1016/S0140-6736(12)60651-5", "volume": "379", "author": "WT Graaf van der", "year": "2012", "unstructured": "van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879\u201386.", "journal-title": "Lancet"}, {"key": "7_CR35", "doi-asserted-by": "publisher", "first-page": "488", "DOI": "10.1016/S0140-6736(16)30587-6", "volume": "388", "author": "WD Tap", "year": "2016", "unstructured": "Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388:488\u201397.", "journal-title": "Lancet"}, {"key": "7_CR36", "doi-asserted-by": "publisher", "first-page": "263", "DOI": "10.1385/IR:23:2-3:263", "volume": "23", "author": "JE Ohm", "year": "2001", "unstructured": "Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res. 2001;23:263\u201372.", "journal-title": "Immunol Res"}, {"key": "7_CR37", "doi-asserted-by": "publisher", "first-page": "2205", "DOI": "10.1200/JCO.2012.46.3653", "volume": "31", "author": "RK Jain", "year": "2013", "unstructured": "Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31:2205\u201318.", "journal-title": "J Clin Oncol"}, {"key": "7_CR38", "unstructured": "Breelyn A, Wilky EA. A phase II study of concurrent Axitinib and Pembrolizumab in subjects with advanced alveolar soft part sarcoma and other soft tissue sarcomas. Connective Tissue Oncology Society, Maui, Hawaii. 2017."}, {"key": "7_CR39", "doi-asserted-by": "publisher", "first-page": "436", "DOI": "10.1158/2326-6066.CIR-15-0064", "volume": "3", "author": "LA Emens", "year": "2015", "unstructured": "Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3:436\u201343.", "journal-title": "Cancer Immunol Res"}, {"key": "7_CR40", "doi-asserted-by": "publisher", "first-page": "7477", "DOI": "10.1158/0008-5472.CAN-06-4639", "volume": "67", "author": "HJ Ko", "year": "2007", "unstructured": "Ko HJ, Kim YJ, Kim YS, et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 2007;67:7477\u201386.", "journal-title": "Cancer Res"}, {"key": "7_CR41", "doi-asserted-by": "publisher", "first-page": "1947", "DOI": "10.1038/mt.2010.159", "volume": "18", "author": "ZG Fridlender", "year": "2010", "unstructured": "Fridlender ZG, Sun J, Singhal S, et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther. 2010;18:1947\u201359.", "journal-title": "Mol Ther"}, {"key": "7_CR42", "doi-asserted-by": "publisher", "first-page": "6713", "DOI": "10.1158/1078-0432.CCR-05-0883", "volume": "11", "author": "E Suzuki", "year": "2005", "unstructured": "Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11:6713\u201321.", "journal-title": "Clin Cancer Res"}, {"key": "7_CR43", "doi-asserted-by": "publisher", "first-page": "247", "DOI": "10.1186/s12967-015-0613-y", "volume": "13", "author": "Z Guo", "year": "2015", "unstructured": "Guo Z, Wang H, Meng F, Li J, Zhang S. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. J Transl Med. 2015;13:247.", "journal-title": "J Transl Med"}, {"key": "7_CR44", "doi-asserted-by": "publisher", "first-page": "7448", "DOI": "10.1158/1078-0432.CCR-17-0898", "volume": "23", "author": "A Barone", "year": "2017", "unstructured": "Barone A, Chi DC, Theoret MR, et al. FDA approval summary: trabectedin for unresectable or metastatic liposarcoma or leiomyosarcoma following an anthracycline-containing regimen. Clin Cancer Res. 2017;23:7448\u201353.", "journal-title": "Clin Cancer Res"}, {"key": "7_CR45", "doi-asserted-by": "publisher", "first-page": "2443", "DOI": "10.1056/NEJMoa1200690", "volume": "366", "author": "SL Topalian", "year": "2012", "unstructured": "Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.", "journal-title": "N Engl J Med"}, {"key": "7_CR46", "first-page": "3000", "volume": "31", "author": "RS Herbst", "year": "2013", "unstructured": "Herbst RS, Gordon M, Fine GD, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol. 2013;31:3000.", "journal-title": "J Clin Oncol"}, {"issue": "4", "key": "7_CR47", "doi-asserted-by": "publisher", "first-page": "383", "DOI": "10.1200/JCO.2016.71.8023", "volume": "36", "author": "James Larkin", "year": "2018", "unstructured": "Larkin J, Minor D, D\u2019Angelo S, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in checkmate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018;36:383\u201390.", "journal-title": "Journal of Clinical Oncology"}, {"key": "7_CR48", "doi-asserted-by": "publisher", "first-page": "122", "DOI": "10.1056/NEJMoa1302369", "volume": "369", "author": "JD Wolchok", "year": "2013", "unstructured": "Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122\u201333.", "journal-title": "N Engl J Med"}, {"key": "7_CR49", "doi-asserted-by": "publisher", "first-page": "357", "DOI": "10.1016/j.humpath.2014.11.001", "volume": "46", "author": "SP D\u2019Angelo", "year": "2015", "unstructured": "D\u2019Angelo SP, Shoushtari AN, Agaram NP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46:357\u201365.", "journal-title": "Hum Pathol"}, {"issue": "suppl 4", "key": "7_CR50", "doi-asserted-by": "publisher", "first-page": "iv498", "DOI": "10.1093/annonc/mdu354.10", "volume": "25", "author": "SBM Raj", "year": "2014", "unstructured": "Raj SBM, Gonzales R, et al. Impact of PD-L1 expression on clinical outcomes in subtypes of sarcoma. Ann Oncol. 2014;25(suppl 4):iv498.", "journal-title": "Ann Oncol"}], "container-title": ["Immunotherapy of Sarcoma"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-93530-0_7", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 11, 27]], "date-time": "2018-11-27T19:15:13Z", "timestamp": 1543346113000}, "score": 27.617388, "issued": {"date-parts": [[2018, 11, 28]]}, "ISBN": ["9783319935294", "9783319935300"], "references-count": 50, "URL": "http://dx.doi.org/10.1007/978-3-319-93530-0_7", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T03:43:23Z", "timestamp": 1576727003316}, "reference-count": 100, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2018, 9, 1]], "date-time": "2018-09-01T00:00:00Z", "timestamp": 1535760000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["International Immunopharmacology"], "published-print": {"date-parts": [[2018, 9]]}, "DOI": "10.1016/j.intimp.2018.06.001", "type": "journal-article", "created": {"date-parts": [[2018, 7, 2]], "date-time": "2018-07-02T14:24:15Z", "timestamp": 1530541455000}, "page": "29-39", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 83, "title": ["Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors"], "prefix": "10.1016", "volume": "62", "author": [{"ORCID": "http://orcid.org/0000-0002-8668-5228", "authenticated-orcid": false, "given": "Kristian M.", "family": "Hargadon", "sequence": "first", "affiliation": []}, {"given": "Coleman E.", "family": "Johnson", "sequence": "additional", "affiliation": []}, {"given": "Corey J.", "family": "Williams", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["International Immunopharmacology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1567576918302522?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1567576918302522?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 8, 4]], "date-time": "2018-08-04T11:11:49Z", "timestamp": 1533381109000}, "score": 27.220722, "issued": {"date-parts": [[2018, 9]]}, "references-count": 100, "alternative-id": ["S1567576918302522"], "URL": "http://dx.doi.org/10.1016/j.intimp.2018.06.001", "ISSN": ["1567-5769"], "issn-type": [{"value": "1567-5769", "type": "print"}], "subject": ["Immunology", "Immunology and Allergy", "Pharmacology"], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors", "name": "articletitle", "label": "Article Title"}, {"value": "International Immunopharmacology", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.intimp.2018.06.001", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "\u00a9 2018 Elsevier B.V. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 12, 16]], "date-time": "2019-12-16T21:56:02Z", "timestamp": 1576533362663}, "reference-count": 68, "publisher": "Informa UK Limited", "issue": "11", "license": [{"URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "start": {"date-parts": [[2019, 7, 25]], "date-time": "2019-07-25T00:00:00Z", "timestamp": 1564012800000}, "delay-in-days": 0, "content-version": "vor"}], "content-domain": {"domain": ["www.tandfonline.com"], "crossmark-restriction": true}, "short-container-title": ["OncoImmunology"], "published-print": {"date-parts": [[2019, 11, 2]]}, "DOI": "10.1080/2162402x.2019.1644109", "type": "journal-article", "created": {"date-parts": [[2019, 7, 25]], "date-time": "2019-07-25T12:04:16Z", "timestamp": 1564056256000}, "page": "e1644109", "update-policy": "http://dx.doi.org/10.1080/tandf_crossmark_01", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives"], "prefix": "10.1080", "volume": "8", "author": [{"given": "H.", "family": "Taghizadeh", "sequence": "first", "affiliation": [{"name": "Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria"}, {"name": "Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}]}, {"ORCID": "http://orcid.org/0000-0001-8439-3312", "authenticated-orcid": false, "given": "M.", "family": "Marhold", "sequence": "additional", "affiliation": [{"name": "Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria"}, {"name": "Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}]}, {"given": "E.", "family": "Tomasich", "sequence": "additional", "affiliation": [{"name": "Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria"}, {"name": "Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}]}, {"given": "S.", "family": "Udovica", "sequence": "additional", "affiliation": [{"name": "Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria"}, {"name": "Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}]}, {"given": "A.", "family": "Merchant", "sequence": "additional", "affiliation": [{"name": "Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria"}, {"name": "Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}]}, {"ORCID": "http://orcid.org/0000-0002-7011-4957", "authenticated-orcid": false, "given": "M.", "family": "Krainer", "sequence": "additional", "affiliation": [{"name": "Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria"}, {"name": "Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}]}], "member": "301", "published-online": {"date-parts": [[2019, 7, 25]]}, "reference": [{"key": "CIT0006", "DOI": "10.1016/j.jaut.2013.06.006", "doi-asserted-by": "publisher"}, {"key": "CIT0007", "DOI": "10.1111/j.1600-065X.2011.01011.x", "doi-asserted-by": "publisher"}, {"key": "CIT0008", "DOI": "10.1146/annurev.immunol.14.1.233", "doi-asserted-by": "publisher"}, {"key": "CIT0009", "DOI": "10.1046/j.1365-2567.2000.00121.x", "doi-asserted-by": "publisher"}, {"key": "CIT0010", "DOI": "10.1016/S1074-7613(00)80480-X", "doi-asserted-by": "publisher"}, {"key": "CIT0011", "DOI": "10.1182/blood-2011-11-388918", "doi-asserted-by": "publisher"}, {"key": "CIT0012", "DOI": "10.1634/theoncologist.13-S4-2", "doi-asserted-by": "publisher"}, {"key": "CIT0013", "DOI": "10.1126/science.271.5256.1734", "doi-asserted-by": "publisher"}, {"key": "CIT0014", "DOI": "10.1016/j.coi.2006.01.011", "doi-asserted-by": "publisher"}, {"key": "CIT0015", "DOI": "10.1517/14712590802643347", "doi-asserted-by": "publisher"}, {"key": "CIT0016", "DOI": "10.1053/j.seminoncol.2010.09.015", "doi-asserted-by": "publisher"}, {"key": "CIT0017", "DOI": "10.1016/j.it.2013.07.003", "doi-asserted-by": "publisher"}, {"key": "CIT0018", "DOI": "10.1146/annurev.immunol.26.021607.090331", "doi-asserted-by": "publisher"}, {"key": "CIT0019", "DOI": "10.1084/jem.20090847", "doi-asserted-by": "publisher"}, {"key": "CIT0020", "DOI": "10.4049/jimmunol.181.10.6738", "doi-asserted-by": "publisher"}, {"key": "CIT0021", "DOI": "10.1111/j.1600-065X.2009.00767.x", "doi-asserted-by": "publisher"}, {"key": "CIT0022", "DOI": "10.1073/pnas.192461099", "doi-asserted-by": "publisher"}, {"key": "CIT0023", "DOI": "10.1080/17512433.2018.1464388", "doi-asserted-by": "publisher"}, {"key": "CIT0024", "DOI": "10.3389/fphar.2017.00561", "doi-asserted-by": "publisher"}, {"key": "CIT0025", "DOI": "10.1182/blood-2009-05-223412", "doi-asserted-by": "publisher"}, {"key": "CIT0026", "DOI": "10.1097/COC.0000000000000239", "doi-asserted-by": "publisher"}, {"key": "CIT0027", "DOI": "10.3389/fonc.2018.00086", "doi-asserted-by": "publisher"}, {"key": "CIT0028", "DOI": "10.1371/journal.pmed.1000097", "doi-asserted-by": "publisher"}, {"key": "CIT0029", "DOI": "10.1016/S1470-2045(14)70189-5", "doi-asserted-by": "publisher"}, {"key": "CIT0030", "DOI": "10.1200/jco.2014.32.4_suppl.2", "doi-asserted-by": "publisher"}, {"key": "CIT0031", "DOI": "10.1200/JCO.2016.69.1584", "doi-asserted-by": "publisher"}, {"key": "CIT0033", "DOI": "10.1186/s40425-018-0349-3", "doi-asserted-by": "publisher"}, {"key": "CIT0034", "DOI": "10.1158/0008-5472.CAN-12-4100", "doi-asserted-by": "publisher"}, {"key": "CIT0035", "DOI": "10.18632/oncotarget.2429", "doi-asserted-by": "publisher"}, {"key": "CIT0036", "DOI": "10.1158/1078-0432.CCR-07-4025", "doi-asserted-by": "publisher"}, {"key": "CIT0037", "DOI": "10.1002/ijc.28070", "doi-asserted-by": "publisher"}, {"key": "CIT0039", "DOI": "10.1016/S1470-2045(12)70006-2", "doi-asserted-by": "publisher"}, {"key": "CIT0041", "DOI": "10.1093/annonc/mdy232", "doi-asserted-by": "publisher"}, {"key": "CIT0042", "DOI": "10.1200/JCO.2018.36.15_suppl.5007", "doi-asserted-by": "publisher"}, {"key": "CIT0045", "DOI": "10.18632/oncotarget.v6i1", "doi-asserted-by": "publisher"}, {"key": "CIT0046", "DOI": "10.1200/JCO.2018.36.15_suppl.5047", "doi-asserted-by": "publisher"}, {"key": "CIT0049", "DOI": "10.18632/oncotarget.25387", "doi-asserted-by": "publisher"}, {"key": "CIT0050", "DOI": "10.1158/2326-6066.CIR-14-0206", "doi-asserted-by": "publisher"}, {"key": "CIT0051", "DOI": "10.1158/2326-6066.CIR-16-0374", "doi-asserted-by": "publisher"}, {"key": "CIT0052", "DOI": "10.1080/2162402X.2016.1165377", "doi-asserted-by": "publisher"}, {"key": "CIT0057", "DOI": "10.1124/jpet.106.119040", "doi-asserted-by": "publisher"}, {"key": "CIT0066", "DOI": "10.1158/0008-5472.CAN-04-4409", "doi-asserted-by": "publisher"}, {"key": "CIT0067", "DOI": "10.1186/s12943-017-0665-0", "doi-asserted-by": "publisher"}, {"key": "CIT0068", "DOI": "10.1016/j.csbj.2015.03.008", "doi-asserted-by": "publisher"}, {"key": "CIT0069", "unstructured": "CinicalTrials.gov. A dose escalation and confirmation study of PT-112 in advanced solid tumors in combination with avelumab (PAVE-1). [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT03409458?term=PAVE-1&rank=1."}, {"key": "CIT0070", "DOI": "10.1016/S1470-2045(17)30239-5", "doi-asserted-by": "publisher"}, {"key": "CIT0071", "unstructured": "CinicalTrials.gov. Javelin Parp Medley: Avelumab plus talazoparib in locally advanced or metastatic solid tumors. https://clinicaltrials.gov/ct2/show/NCT03330405?term=Parp+Medley&rank=1."}, {"key": "CIT0072", "unstructured": "CinicalTrials.gov. Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor. https://clinicaltrials.gov/ct2/show/NCT02814669?term=BO30013&rank=1."}, {"key": "CIT0073", "unstructured": "CinicalTrials.gov. Clinical study of atezolizumab (Anti-PD-L1) and Sipuleucel-T in patients who have asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT03024216?term=Rosser-2015-4&rank=1."}, {"key": "CIT0074", "unstructured": "CinicalTrials.gov. A study of atezolizumab (Anti-PD-L1 Antibody) in combination with enzalutamide in participants with metastatic castration-resistant prostrate cancer (mCRPC) after failure of an androgen synthesis inhibitor and failure of, ineligibility for, or refusal of a taxane regimen (IMbassador250). [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT03016312?term=IMbassador250&rank=1."}, {"key": "CIT0077", "DOI": "10.1200/JCO.2015.65.5597", "doi-asserted-by": "publisher"}, {"key": "CIT0078", "unstructured": "CinicalTrials.gov. Study of cabozantinib in combination with atezolizumab to subjects with locally advanced or metastatic solid tumors. [accessed 2019 Jun 28]. https://clinicaltrials.gov/ct2/show/NCT03170960?term=XL184-021&rank=1."}, {"key": "CIT0079", "DOI": "10.21037/jtd.2017.12.51", "doi-asserted-by": "publisher"}, {"key": "CIT0080", "DOI": "10.5114/wo.2018.73889", "doi-asserted-by": "publisher"}, {"key": "CIT0081", "DOI": "10.1016/j.ctrv.2018.04.004", "doi-asserted-by": "publisher"}, {"key": "CIT0082", "DOI": "10.1159/000477852", "doi-asserted-by": "publisher"}, {"key": "CIT0083", "DOI": "10.1016/j.urolonc.2018.05.008", "doi-asserted-by": "publisher"}, {"key": "CIT0084", "DOI": "10.4103/1008-682X.178852", "doi-asserted-by": "publisher"}, {"key": "CIT0085", "DOI": "10.1038/nrurol.2012.185", "doi-asserted-by": "publisher"}, {"key": "CIT0086", "DOI": "10.1172/JCI64096", "doi-asserted-by": "publisher"}, {"key": "CIT0088", "DOI": "10.1038/35094091", "doi-asserted-by": "publisher"}, {"key": "CIT0089", "DOI": "10.1111/j.1365-4632.2010.04474.x", "doi-asserted-by": "publisher"}, {"key": "CIT0090", "DOI": "10.1016/j.sder.2011.08.003", "doi-asserted-by": "publisher"}, {"key": "CIT0091", "author": "Correa P", "volume": "7", "first-page": "59", "year": "2011", "journal-title": "US Gastroenterol Hepatol Rev"}, {"key": "CIT0093", "DOI": "10.1186/s40425-018-0341-y", "doi-asserted-by": "publisher"}, {"key": "CIT0094", "DOI": "10.18632/oncotarget.12697", "doi-asserted-by": "publisher"}, {"key": "CIT0095", "DOI": "10.1186/s12967-017-1119-6", "doi-asserted-by": "publisher"}, {"key": "CIT0096", "DOI": "10.1093/jjco/hyu210", "doi-asserted-by": "publisher"}], "container-title": ["OncoImmunology"], "language": "en", "link": [{"URL": "https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2019.1644109", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 12, 16]], "date-time": "2019-12-16T04:53:00Z", "timestamp": 1576471980000}, "score": 26.847422, "issued": {"date-parts": [[2019, 7, 25]]}, "references-count": 68, "journal-issue": {"published-print": {"date-parts": [[2019, 11, 2]]}, "issue": "11"}, "alternative-id": ["10.1080/2162402X.2019.1644109"], "URL": "http://dx.doi.org/10.1080/2162402x.2019.1644109", "relation": {"cites": []}, "ISSN": ["2162-402X"], "issn-type": [{"value": "2162-402X", "type": "electronic"}], "subject": ["Immunology", "Immunology and Allergy", "Oncology"], "assertion": [{"value": "The publishing and review policy for this title is described in its Aims & Scope.", "order": 1, "name": "peerreview_statement", "label": "Peer Review Statement"}, {"value": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=koni20", "URL": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=koni20", "order": 2, "name": "aims_and_scope_url", "label": "Aim & Scope"}, {"value": "2019-05-15", "order": 0, "name": "received", "label": "Received", "group": {"name": "publication_history", "label": "Publication History"}}, {"value": "2019-07-02", "order": 1, "name": "revised", "label": "Revised", "group": {"name": "publication_history", "label": "Publication History"}}, {"value": "2019-07-04", "order": 2, "name": "accepted", "label": "Accepted", "group": {"name": "publication_history", "label": "Publication History"}}, {"value": "2019-07-25", "order": 3, "name": "published", "label": "Published", "group": {"name": "publication_history", "label": "Publication History"}}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T15:43:51Z", "timestamp": 1575474231687}, "reference-count": 48, "publisher": "Springer Science and Business Media LLC", "issue": "4", "license": [{"URL": "https://creativecommons.org/licenses/by/4.0", "start": {"date-parts": [[2019, 7, 10]], "date-time": "2019-07-10T00:00:00Z", "timestamp": 1562716800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Curr Colorectal Cancer Rep"], "published-print": {"date-parts": [[2019, 8]]}, "DOI": "10.1007/s11888-019-00437-z", "type": "journal-article", "created": {"date-parts": [[2019, 7, 10]], "date-time": "2019-07-10T06:27:00Z", "timestamp": 1562740020000}, "page": "112-121", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer: Current Status, Recent Advances, and Future Directions"], "prefix": "10.1007", "volume": "15", "author": [{"given": "Saivaishnavi", "family": "Kamatham", "sequence": "first", "affiliation": []}, {"given": "Faisal", "family": "Shahjehan", "sequence": "additional", "affiliation": []}, {"given": "Pashtoon M.", "family": "Kasi", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2019, 7, 10]]}, "reference": [{"issue": "1", "key": "437_CR1", "doi-asserted-by": "publisher", "first-page": "7", "DOI": "10.3322/caac.21442", "volume": "68", "author": "RL Siegel", "year": "2018", "unstructured": "Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330.", "journal-title": "CA Cancer J Clin"}, {"key": "437_CR2", "unstructured": "Koopman M, Kortman GAM, Mekenkamp L, Ligtenberg MJL, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100:266\u201373.", "DOI": "10.1038/sj.bjc.6604867", "doi-asserted-by": "crossref"}, {"key": "437_CR3", "unstructured": "Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20(20):5322\u201330. \n                                 https://doi.org/10.1158/1078-0432.CCR-14-0332\n                                 \n                              .", "DOI": "10.1158/1078-0432.CCR-14-0332", "doi-asserted-by": "publisher"}, {"key": "437_CR4", "unstructured": "Tougeron D, Cohen R, Sueur B, Sefrioui D, Gentilhomme L, Lecomte T, et al. 533PA large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability. Ann Oncol. 2017;28(suppl_5):v158\u2013208. \n                                 https://doi.org/10.1093/annonc/mdx393\n                                 \n                              .", "DOI": "10.1093/annonc/mdx393", "doi-asserted-by": "publisher"}, {"key": "437_CR5", "unstructured": "Nebot-Bral L, Coutzac C, Kannouche PL, Chaput N. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors? Bull Cancer. 2019;106(2):105\u201313. \n                                 https://doi.org/10.1016/j.bulcan.2018.08.007\n                                 \n                              .", "DOI": "10.1016/j.bulcan.2018.08.007", "doi-asserted-by": "publisher"}, {"key": "437_CR6", "unstructured": "Cohen R, Pellat A, Boussion H, Svrcek M, Lopez-Trabada D, Trouilloud I, et al. Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency. Bull Cancer. 2019;106(2):137\u201342. \n                                 https://doi.org/10.1016/j.bulcan.2018.09.004\n                                 \n                              .", "DOI": "10.1016/j.bulcan.2018.09.004", "doi-asserted-by": "publisher"}, {"key": "437_CR7", "unstructured": "Chu JN, Choi J, Ostvar S, Torchia JA, Reynolds KL, Tramontano A, et al. Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. NCCN Guidelines Version 1.2018 Genetic/Familial High-Risk Assessment: Colorectal. Cancer. 2019; 15;125(2):278\u2013289. \n                                 https://doi.org/10.1002/cncr.31795\n                                 \n                              .", "DOI": "10.1002/cncr.31795", "doi-asserted-by": "publisher"}, {"key": "437_CR8", "unstructured": "Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43\u201351.", "DOI": "10.1158/2159-8290.CD-14-0863", "doi-asserted-by": "crossref"}, {"key": "437_CR9", "unstructured": "NCCN Guidelines Version 1.2018 Genetic/Familial High-Risk Assessment: Colorectal. \n                                 https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf\n                                 \n                              ."}, {"key": "437_CR10", "unstructured": "Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219\u201326.", "DOI": "10.1200/JCO.2009.27.1825", "doi-asserted-by": "crossref"}, {"issue": "26", "key": "437_CR11", "doi-asserted-by": "publisher", "first-page": "2509", "DOI": "10.1056/NEJMoa1500596", "volume": "372", "author": "DT Le", "year": "2015", "unstructured": "Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320.", "journal-title": "N Engl J Med"}, {"issue": "12", "key": "437_CR12", "doi-asserted-by": "publisher", "first-page": "e0189848", "DOI": "10.1371/journal.pone.0189848", "volume": "12", "author": "BH O\u2019Neil", "year": "2017", "unstructured": "O\u2019Neil BH, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS One. 2017;12(12):e0189848.", "journal-title": "PLoS One"}, {"key": "437_CR13", "unstructured": "\u2022\u2022 Diaz LA, et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. J Clin Oncol. 2017;35(15_suppl):3071\u20131. The early results of the KEYNOTE-164 study affirmed the robust antitumor activity of pembrolizumab in patients with pretreated MSI-H colorectal cancer.", "DOI": "10.1200/JCO.2017.35.15_suppl.3071", "doi-asserted-by": "crossref"}, {"key": "437_CR14", "unstructured": "Overman MJ, et al. Nivolumab \u00b1 ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J Clin Oncol. 2016;34(15_suppl):3501\u20131.", "DOI": "10.1200/JCO.2016.34.15_suppl.3501", "doi-asserted-by": "crossref"}, {"key": "437_CR15", "unstructured": "\u2022\u2022 Overman MJ, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773\u20139. CheckMate-142 is the largest single-study report of combination immunotherpy with nivolumab and ipilimumab demonstrating high response rate and safety profile."}, {"key": "437_CR16", "unstructured": "\u2022\u2022 Lenz HJ, van Cutsem E, Limon ML, Wong KY, Hendlisz A, Aglietta M, et al. LBA18_PR durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Ann Oncol. 2018;29(Suppl 8). This study reports the first results of clinical efficacy and safety of nivolumab plus a low dose of ipilimumab as a new first-line therapy for dMMR/MSI-H mCRC.", "DOI": "10.1093/annonc/mdy424.019", "doi-asserted-by": "crossref"}, {"key": "437_CR17", "unstructured": "\u2022\u2022 Chalabi M, Fanchi LF, Van den Berg JG, Beets GL, Lopez-Yurda M, Aalbers AG, et al. LBA37_PRNeoadjuvant ipilimumab plus nivolumab in early stage colon cancer. Ann Oncol. 2018;29(suppl_8). \n                                 https://doi.org/10.1093/annonc/mdy424.047\n                                 \n                              . The first study to suggest short-term neoadjuvant nivolumab plus ipilimumab combination therapy has the potential to change current standard of care in dMMR early satge colon cancers.", "DOI": "10.1093/annonc/mdy424.047", "doi-asserted-by": "publisher"}, {"key": "437_CR18", "unstructured": "NCCN Guidelines Version 2.2019 Colon Cancer. Systemic therapy for advanced or metastatic disease - chemotherapy regimens. \n                                 https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf\n                                 \n                              ."}, {"key": "437_CR19", "unstructured": "\u2022 Bendell J, Ciardiello F, Tabernero J, Tebbutt N, Eng C, Di Bartolomeo M, et al. LBA-004 efficacy and safety results from IMblaze370, a randomised phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. Ann Oncol. 2018;29(suppl_5). \n                                 https://doi.org/10.1093/annonc/mdy208.003\n                                 \n                              . A global, multi-center study whose primary analysis validated that atezolizumab plus cobimetinib combination or atezolizumab monotherapy had no statistically significant outcomes in efficay for MSS mCRC.", "DOI": "10.1093/annonc/mdy208.003", "doi-asserted-by": "publisher"}, {"key": "437_CR20", "unstructured": "Chen EX, Jonker DJ, Kennecke HF, Berry SR, Couture F, Ahmad CE, et al. 26 trial: a phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC). J Clin Oncol. 2019;37(4_suppl):481\u20131. \n                                 https://doi.org/10.1200/JCO.2019.37.4\n                                 \n                              .", "DOI": "10.1200/JCO.2019.37.4", "doi-asserted-by": "publisher"}, {"issue": "4", "key": "437_CR21", "doi-asserted-by": "publisher", "first-page": "256", "DOI": "10.1093/jnci/djs629", "volume": "105", "author": "SC Formenti", "year": "2013", "unstructured": "Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256\u201365.", "journal-title": "J Natl Cancer Inst"}, {"key": "437_CR22", "unstructured": "Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, K.Wansley E, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259\u201371.", "DOI": "10.1084/jem.20052494", "doi-asserted-by": "crossref"}, {"key": "437_CR23", "unstructured": "NIH U.S. National Library of Medicine ClinicalTrials.gov. Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors. ClinicalTrials.gov Identifier: NCT01876511. \n                                 https://clinicaltrials.gov/ct2/show/NCT01876511\n                                 \n                              ."}, {"key": "437_CR24", "unstructured": "NIH U.S. National Library of Medicine ClinicalTrials.gov. Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) ClinicalTrials.gov Identifier: NCT02460198. \n                                 https://clinicaltrials.gov/ct2/show/NCT02460198\n                                 \n                              ."}, {"key": "437_CR25", "unstructured": "\u2022 NIH U.S. National Library of Medicine ClinicalTrials.gov. Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) ClinicalTrials.gov Identifier: NCT02563002. \n                                 https://clinicaltrials.gov/ct2/show/NCT02563002\n                                 \n                              . An ongoing clinical trial that compares progression free survival and overall survival in dMMR/MSI-H stage IV CRC patients receiving pembrolizumab vs those receiving standard chemotherapy."}, {"key": "437_CR26", "unstructured": "\u2022 NIH U.S. National Library of Medicine ClinicalTrials.gov. Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer ClinicalTrials.gov Identifier: NCT02873195. \n                                 https://clinicaltrials.gov/ct2/show/NCT02873195\n                                 \n                              . BACCI study is an ongoing clinical trial to estimate the efficacy of atezolizumab plus capecitabine/bevacizumab therapy in refractory mCRC patients."}, {"key": "437_CR27", "unstructured": "NIH U.S. National Library of Medicine ClinicalTrials.gov. An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (CheckMate 9X8) ClinicalTrials.gov Identifier: NCT03414983. \n                                 https://clinicaltrials.gov/ct2/show/NCT03414983\n                                 \n                              ."}, {"key": "437_CR28", "unstructured": "\u2022\u2022 NIH U.S. National Library of Medicine ClinicalTrials.gov. Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer ClinicalTrials.gov Identifier: NCT02997228. \n                                 https://clinicaltrials.gov/ct2/show/NCT02997228\n                                 \n                              . This phase III randomized clinical trial is currently recruiting patients to study the efficacy of atezolizumab plus combination chemotherapy/bevacizumab as first line tresatment of patients with dMMR mCRC."}, {"key": "437_CR29", "unstructured": "\u2022\u2022 NIH U.S. National Library of Medicine ClinicalTrials.gov. Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair ClinicalTrials.gov Identifier: NCT02912559. \n                                 https://clinicaltrials.gov/ct2/show/NCT02912559\n                                 \n                              . Atomic study is an ongoing phase III clinical trial to assess efficacy of combination chemotherapy and atezolizumab in patients with stage III dMMR colon cancer."}, {"key": "437_CR30", "unstructured": "NIH U.S. National Library of Medicine ClinicalTrials.gov. Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX) ClinicalTrials.gov Identifier: NCT02777710. \n                                 https://clinicaltrials.gov/ct2/show/NCT02777710\n                                 \n                              ."}, {"key": "437_CR31", "unstructured": "NIH U.S. National Library of Medicine ClinicalTrials.gov. Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers. ClinicalTrials.gov Identifier: NCT02484404. \n                                 https://clinicaltrials.gov/ct2/show/NCT02484404\n                                 \n                              ."}, {"key": "437_CR32", "unstructured": "\u2022 NIH U.S. National Library of Medicine ClinicalTrials.gov. Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer (AVETUXIRI). ClinicalTrials.gov Identifier: NCT03608046. \n                                 https://clinicaltrials.gov/ct2/show/NCT03608046\n                                 \n                              . A new clinical trial to assess tumor response rate in MSI stable metastatic colorectal cancer patients on treatment with avelumab combined with cetuximab and irinotecan."}, {"key": "437_CR33", "unstructured": "\u2022\u2022 NIH U.S. National Library of Medicine ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC). ClinicalTrials.gov Identifier: NCT03555149. \n                                 https://clinicaltrials.gov/ct2/show/NCT03555149\n                                 \n                              . Morpheus-CRC is a phase Ib/II, open-label, multicenter, randomized study designed to evaluate safety and efficacay of multiple immunotherapy based therapy combinations."}, {"key": "437_CR34", "unstructured": "NIH U.S. National Library of Medicine ClinicalTrials.gov. An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread (CheckMate 9N9). ClinicalTrials.gov Identifier: NCT03377361. \n                                 https://clinicaltrials.gov/ct2/show/NCT03377361\n                                 \n                              ."}, {"key": "437_CR35", "unstructured": "NIH U.S. National Library of Medicine ClinicalTrials.gov. Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer ClinicalTrials.gov Identifier: NCT03711058. \n                                 https://clinicaltrials.gov/ct2/show/NCT03711058\n                                 \n                              ."}, {"key": "437_CR36", "unstructured": "NIH U.S. National Library of Medicine ClinicalTrials.gov. Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer ClinicalTrials.gov Identifier: NCT03642067. \n                                 https://clinicaltrials.gov/ct2/show/NCT03642067\n                                 \n                              ."}, {"key": "437_CR37", "unstructured": "\u2022\u2022 NIH U.S. National Library of Medicine ClinicalTrials.gov. Synergism of Immunomodulation and Tumor Ablation (ILOC) ClinicalTrials.gov Identifier: NCT03101475. \n                                 https://clinicaltrials.gov/ct2/show/NCT03101475\n                                 \n                              . ILOC- a phase II single arm, multicenter trial to study the synergism of immunotherapy (durvalumab, tremelimumab) and local tumor ablation with radiofrequency ablation (RFA) or stereotactic body radiation therapy (SBRT) in colorectal cancer with liver metastases."}, {"key": "437_CR38", "unstructured": "\u2022\u2022 NIH U.S. National Library of Medicine ClinicalTrials.gov. Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases ClinicalTrials.gov Identifier: NCT03802747. \n                                 https://clinicaltrials.gov/ct2/show/NCT03802747\n                                 \n                              . A new phse I clinical trial to evaluate the efficacy of combination of dual immune checkpoint blockade (durvalumab, Tremelimumab) plus Yttrium-90 (Y-90) radioembolization & stereotactic body radiation therapy (SBRT) in refractory metastatic MSS colorectal cancer with liver metastases."}, {"key": "437_CR39", "unstructured": "NIH U.S. National Library of Medicine ClinicalTrials.gov. Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer ClinicalTrials.gov Identifier: NCT03507699. \n                                 https://clinicaltrials.gov/ct2/show/NCT03507699\n                                 \n                              ."}, {"key": "437_CR40", "unstructured": "NIH U.S. National Library of Medicine ClinicalTrials.gov. Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer ClinicalTrials.gov Identifier: NCT03104439. \n                                 https://clinicaltrials.gov/ct2/show/NCT03104439\n                                 \n                              ."}, {"key": "437_CR41", "unstructured": "\u2022\u2022 NIH U.S. National Library of Medicine ClinicalTrials.gov. QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC ClinicalTrials.gov Identifier: NCT03169777. \n                                 https://clinicaltrials.gov/ct2/show/NCT03169777\n                                 \n                              . QUILT-3.050 - phase 1b/2 study to assess the safety and efficacy of NANT colorectal cancer vaccine: combination immunotherapy in recurrent or metastatic colorectal cancer."}, {"key": "437_CR42", "unstructured": "NIH U.S. National Library of Medicine ClinicalTrials.gov. CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors ClinicalTrials.gov Identifier: NCT02757391. \n                                 https://clinicaltrials.gov/ct2/show/NCT02757391\n                                 \n                              ."}, {"key": "437_CR43", "unstructured": "\u2022 NIH U.S. National Library of Medicine ClinicalTrials.gov. Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer ClinicalTrials.gov Identifier: NCT03800602. \n                                 https://clinicaltrials.gov/ct2/show/NCT03800602\n                                 \n                              . A phse II trial to determine the efficacy of nivolumab and metformin in treatment refractory microsatellite stable (MSS) colorectal cancer."}, {"issue": "2", "key": "437_CR44", "doi-asserted-by": "publisher", "first-page": "138", "DOI": "10.1016/j.bbcan.2017.12.002", "volume": "1869", "author": "R Fletcher", "year": "2018", "unstructured": "Fletcher R, Wang YJ, Schoen RE, Finn OJ, Yu J, Zhang L. Colorectal cancer prevention: immune modulation taking the stage. Biochim Biophys Acta Rev Cancer. 2018;1869(2):138\u201348.", "journal-title": "Biochim Biophys Acta Rev Cancer"}, {"key": "437_CR45", "unstructured": "Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila). 2013;6(1):18\u201326.", "DOI": "10.1158/1940-6207.CAPR-12-0275", "doi-asserted-by": "crossref"}, {"key": "437_CR46", "unstructured": "Morse MA, Chaudhry A, Gabitzsch ES, Hobeika AC, Osada T, Clay TM, et al. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother. 2013;62(8):1293\u2013301.", "DOI": "10.1007/s00262-013-1400-3", "doi-asserted-by": "crossref"}, {"key": "437_CR47", "unstructured": "Koblansky AA, Truax AD, Liu R, Montgomery SA, Ding S, Wilson JE, et al. The innate immune receptor NLRX1 functions as a tumor suppressor by reducing colon tumorigenesis and key tumor-promoting signals. Cell Rep. 2016;14(11):2562\u201375.", "DOI": "10.1016/j.celrep.2016.02.064", "doi-asserted-by": "crossref"}, {"key": "437_CR48", "unstructured": "Zelenay S, van der Veen AG, B\u00f6ttcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162(6):1257\u201370.", "DOI": "10.1016/j.cell.2015.08.015", "doi-asserted-by": "crossref"}], "container-title": ["Current Colorectal Cancer Reports"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s11888-019-00437-z.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s11888-019-00437-z/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s11888-019-00437-z.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 9, 8]], "date-time": "2019-09-08T02:08:29Z", "timestamp": 1567908509000}, "score": 26.828762, "issued": {"date-parts": [[2019, 7, 10]]}, "references-count": 48, "journal-issue": {"published-print": {"date-parts": [[2019, 8]]}, "issue": "4"}, "alternative-id": ["437"], "URL": "http://dx.doi.org/10.1007/s11888-019-00437-z", "relation": {"cites": []}, "ISSN": ["1556-3790", "1556-3804"], "issn-type": [{"value": "1556-3790", "type": "print"}, {"value": "1556-3804", "type": "electronic"}], "subject": ["Hepatology", "Gastroenterology", "Oncology"], "assertion": [{"value": "10 July 2019", "order": 1, "name": "first_online", "label": "First Online", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"order": 1, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Compliance With Ethical Standards"}}, {"value": "The authors declare that they have no conflicts of interest.", "order": 2, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Conflict of Interest"}}, {"value": "This article does not contain any studies with human or animal subjects performed by any of the authors.", "order": 3, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Human and Animal Rights and Informed Consent"}}]}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T23:43:50Z", "timestamp": 1574725430783}, "reference-count": 98, "publisher": "Wiley", "issue": "10", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Eur. J. Immunol."], "published-print": {"date-parts": [[2015, 10]]}, "DOI": "10.1002/eji.201545759", "type": "journal-article", "created": {"date-parts": [[2015, 9, 8]], "date-time": "2015-09-08T10:06:44Z", "timestamp": 1441706804000}, "page": "2712-2720", "source": "Crossref", "is-referenced-by-count": 12, "title": ["Neurons and T\u00a0cells: Understanding this interaction for inflammatory neurological diseases"], "prefix": "10.1002", "volume": "45", "author": [{"given": "Lidia", "family": "Yshii", "sequence": "first", "affiliation": [{"name": "INSERM U1043 - CNRS UMR 5282; Centre de Physiopathologie Toulouse-Purpan; Toulouse France"}, {"name": "Universit\u00e9 Toulouse III; Toulouse France"}, {"name": "Institute of Biomedical Sciences I; University of Sao Paulo; Sao Paulo Brazil"}]}, {"given": "Christina", "family": "Gebauer", "sequence": "additional", "affiliation": [{"name": "INSERM U1043 - CNRS UMR 5282; Centre de Physiopathologie Toulouse-Purpan; Toulouse France"}, {"name": "Universit\u00e9 Toulouse III; Toulouse France"}]}, {"given": "Rapha\u00ebl", "family": "Bernard-Valnet", "sequence": "additional", "affiliation": [{"name": "INSERM U1043 - CNRS UMR 5282; Centre de Physiopathologie Toulouse-Purpan; Toulouse France"}, {"name": "Universit\u00e9 Toulouse III; Toulouse France"}]}, {"given": "Roland", "family": "Liblau", "sequence": "additional", "affiliation": [{"name": "INSERM U1043 - CNRS UMR 5282; Centre de Physiopathologie Toulouse-Purpan; Toulouse France"}, {"name": "Universit\u00e9 Toulouse III; Toulouse France"}]}], "member": "311", "published-online": {"date-parts": [[2015, 9, 23]]}, "reference": [{"key": "10.1002/eji.201545759-BIB0001|eji3443-cit-0001", "doi-asserted-by": "crossref", "first-page": "5", "DOI": "10.1016/j.it.2006.11.007", "article-title": "What is the blood-brain barrier (not)?", "volume": "28", "author": "Bechmann", "year": "2007", "journal-title": "Trends Immunol."}, {"key": "10.1002/eji.201545759-BIB0002|eji3443-cit-0002", "doi-asserted-by": "crossref", "first-page": "392", "DOI": "10.1098/rspb.1953.0049", "article-title": "Studies on the problem of corneal homografts", "volume": "141", "author": "Billingham", "year": "1953", "journal-title": "Proc. R Soc. Lond. B Biol. Sci."}, {"key": "10.1002/eji.201545759-BIB0003|eji3443-cit-0003", "doi-asserted-by": "crossref", "first-page": "1695", "DOI": "10.2353/ajpath.2007.060677", "article-title": "Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration", "volume": "170", "author": "Chitnis", "year": "2007", "journal-title": "Am. J. Pathol."}, {"key": "10.1002/eji.201545759-BIB0004|eji3443-cit-0004", "doi-asserted-by": "crossref", "first-page": "623", "DOI": "10.1038/nri3265", "article-title": "The anatomical and cellular basis of immune surveillance in the central nervous system", "volume": "12", "author": "Ransohoff", "year": "2012", "journal-title": "Nat. Rev. Immunol."}, {"key": "10.1002/eji.201545759-BIB0005|eji3443-cit-0005", "doi-asserted-by": "crossref", "first-page": "337", "DOI": "10.1038/nature14432", "article-title": "Structural and functional features of central nervous system lymphatic vessels", "volume": "523", "author": "Louveau", "year": "2015", "journal-title": "Nature"}, {"key": "10.1002/eji.201545759-BIB0006|eji3443-cit-0006", "doi-asserted-by": "crossref", "first-page": "991", "DOI": "10.1084/jem.20142290", "article-title": "A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules", "volume": "212", "author": "Aspelund", "year": "2015", "journal-title": "J. Exp. Med."}, {"key": "10.1002/eji.201545759-BIB0007|eji3443-cit-0007", "doi-asserted-by": "crossref", "first-page": "315", "DOI": "10.1016/j.tins.2013.01.008", "article-title": "Neurons as targets for T\u00a0cells in the nervous system", "volume": "36", "author": "Liblau", "year": "2013", "journal-title": "Trends Neurosci."}, {"key": "10.1002/eji.201545759-BIB0008|eji3443-cit-0008", "doi-asserted-by": "crossref", "first-page": "945", "DOI": "10.1016/S1474-4422(15)00141-6", "article-title": "Innate and adaptive immune responses in the CNS", "volume": "14", "author": "Waisman", "year": "2015", "journal-title": "Lancet Neurol."}, {"key": "10.1002/eji.201545759-BIB0009|eji3443-cit-0009", "doi-asserted-by": "crossref", "first-page": "183", "DOI": "10.1016/S1474-4422(14)70256-X", "article-title": "Pathological mechanisms in progressive multiple sclerosis", "volume": "14", "author": "Mahad", "year": "2015", "journal-title": "Lancet Neurol."}, {"key": "10.1002/eji.201545759-BIB0010|eji3443-cit-0010", "doi-asserted-by": "crossref", "first-page": "6784", "DOI": "10.1073/pnas.0902018106", "article-title": "H2-K(b) and H2-D(b) regulate cerebellar long-term depression and limit motor learning", "volume": "106", "author": "McConnell", "year": "2009", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "10.1002/eji.201545759-BIB0011|eji3443-cit-0011", "doi-asserted-by": "crossref", "first-page": "16999", "DOI": "10.1073/pnas.1006087107", "article-title": "MHC class I molecules are present both pre- and postsynaptically in the visual cortex during postnatal development and in adulthood", "volume": "107", "author": "Needleman", "year": "2010", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "10.1002/eji.201545759-BIB0012|eji3443-cit-0012", "doi-asserted-by": "crossref", "first-page": "1185", "DOI": "10.1016/0896-6273(92)90138-4", "article-title": "Neuronal cells are deficient in loading peptides onto MHC class I molecules", "volume": "8", "author": "Joly", "year": "1992", "journal-title": "Neuron"}, {"key": "10.1002/eji.201545759-BIB0013|eji3443-cit-0013", "doi-asserted-by": "crossref", "first-page": "43", "DOI": "10.1111/j.1750-3639.2004.tb00496.x", "article-title": "Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions", "volume": "14", "author": "Hoftberger", "year": "2004", "journal-title": "Brain Pathol."}, {"key": "10.1002/eji.201545759-BIB0014|eji3443-cit-0014", "doi-asserted-by": "crossref", "first-page": "3633", "DOI": "10.1038/ncomms4633", "article-title": "MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration", "volume": "5", "author": "Cebrian", "year": "2014", "journal-title": "Nat. Commun."}, {"key": "10.1002/eji.201545759-BIB0015|eji3443-cit-0015", "doi-asserted-by": "crossref", "first-page": "e1002393", "DOI": "10.1371/journal.ppat.1002393", "article-title": "Neurons are MHC class I-dependent targets for CD8 T\u00a0cells upon neurotropic viral infection", "volume": "7", "author": "Chevalier", "year": "2011", "journal-title": "PLoS Pathog."}, {"key": "10.1002/eji.201545759-BIB0016|eji3443-cit-0016", "doi-asserted-by": "crossref", "first-page": "579", "DOI": "10.1016/j.it.2012.07.004", "article-title": "Capture, crawl, cross: the T\u00a0cell code to breach the blood-brain barriers", "volume": "33", "author": "Engelhardt", "year": "2012", "journal-title": "Trends Immunol."}, {"key": "10.1002/eji.201545759-BIB0017|eji3443-cit-0017", "doi-asserted-by": "crossref", "first-page": "63", "DOI": "10.1038/356063a0", "article-title": "Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin", "volume": "356", "author": "Yednock", "year": "1992", "journal-title": "Nature"}, {"key": "10.1002/eji.201545759-BIB0018|eji3443-cit-0018", "doi-asserted-by": "crossref", "first-page": "1192", "DOI": "10.4049/jimmunol.1100695", "article-title": "CD8+ T\u00a0cells primed in the periphery provide time-bound immune-surveillance to the central nervous system", "volume": "187", "author": "Young", "year": "2011", "journal-title": "J. Immunol."}, {"key": "10.1002/eji.201545759-BIB0019|eji3443-cit-0019", "doi-asserted-by": "crossref", "first-page": "3560", "DOI": "10.1093/brain/awr268", "article-title": "Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on alpha4 integrin", "volume": "134", "author": "Ifergan", "year": "2011", "journal-title": "Brain"}, {"key": "10.1002/eji.201545759-BIB0020|eji3443-cit-0020", "doi-asserted-by": "crossref", "first-page": "6176", "DOI": "10.4049/jimmunol.1102515", "article-title": "Cutting edge: loss of alpha4 integrin expression differentially affects the homing of Th1 and Th17 cells", "volume": "187", "author": "Glatigny", "year": "2011", "journal-title": "J. Immunol."}, {"key": "10.1002/eji.201545759-BIB0021|eji3443-cit-0021", "doi-asserted-by": "crossref", "first-page": "1833", "DOI": "10.1084/jem.20140540", "article-title": "VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T\u00a0cells and MCAM-adhesion of TH17 cells", "volume": "211", "author": "Schneider-Hohendorf", "year": "2014", "journal-title": "J. Exp. Med."}, {"key": "10.1002/eji.201545759-BIB0022|eji3443-cit-0022", "doi-asserted-by": "crossref", "first-page": "2465", "DOI": "10.1084/jem.20110434", "article-title": "Th17 lymphocytes traffic to the central nervous system independently of alpha4 integrin expression during EAE", "volume": "208", "author": "Rothhammer", "year": "2011", "journal-title": "J. Exp. Med."}, {"key": "10.1002/eji.201545759-BIB0023|eji3443-cit-0023", "doi-asserted-by": "crossref", "first-page": "514", "DOI": "10.1038/ni.1716", "article-title": "C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE", "volume": "10", "author": "Reboldi", "year": "2009", "journal-title": "Nat. Immunol."}, {"key": "10.1002/eji.201545759-BIB0024|eji3443-cit-0024", "doi-asserted-by": "crossref", "first-page": "7834", "DOI": "10.1038/srep07834", "article-title": "Integrin alpha L controls the homing of regulatory T\u00a0cells during CNS autoimmunity in the absence of integrin alpha 4", "volume": "5", "author": "Glatigny", "year": "2015", "journal-title": "Sci. Rep."}, {"key": "10.1002/eji.201545759-BIB0025|eji3443-cit-0025", "doi-asserted-by": "crossref", "first-page": "463", "DOI": "10.1007/s00401-015-1383-6", "article-title": "Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8(+) T\u00a0cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome", "volume": "129", "author": "Martin-Blondel", "year": "2015", "journal-title": "Acta Neuropathol."}, {"key": "10.1002/eji.201545759-BIB0026|eji3443-cit-0026", "doi-asserted-by": "crossref", "first-page": "486", "DOI": "10.1056/NEJMc1304828", "article-title": "Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome", "volume": "370", "author": "Giacomini", "year": "2014", "journal-title": "N. Engl. J. Med."}, {"key": "10.1002/eji.201545759-BIB0027|eji3443-cit-0027", "doi-asserted-by": "crossref", "first-page": "35", "DOI": "10.1084/jem.20051970", "article-title": "CCR5 deficiency increases risk of symptomatic West Nile virus infection", "volume": "203", "author": "Glass", "year": "2006", "journal-title": "J. Exp. Med."}, {"key": "10.1002/eji.201545759-BIB0028|eji3443-cit-0028", "doi-asserted-by": "crossref", "first-page": "5283", "DOI": "10.1523/JNEUROSCI.20-14-05283.2000", "article-title": "Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells", "volume": "20", "author": "Hammarberg", "year": "2000", "journal-title": "J. Neurosci."}, {"key": "10.1002/eji.201545759-BIB0029|eji3443-cit-0029", "doi-asserted-by": "crossref", "first-page": "654", "DOI": "10.1007/s12031-012-9790-9", "article-title": "Role of neurotrophins in the development and function of neural circuits that regulate energy homeostasis", "volume": "48", "author": "Fargali", "year": "2012", "journal-title": "J. Mol. Neurosci."}, {"key": "10.1002/eji.201545759-BIB0030|eji3443-cit-0030", "doi-asserted-by": "crossref", "first-page": "865", "DOI": "10.1084/jem.189.5.865", "article-title": "Activated human T\u00a0cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?", "volume": "189", "author": "Kerschensteiner", "year": "1999", "journal-title": "J. Exp. Med."}, {"key": "10.1002/eji.201545759-BIB0031|eji3443-cit-0031", "doi-asserted-by": "crossref", "first-page": "353", "DOI": "10.1111/j.1750-3639.2000.tb00267.x", "article-title": "Neuronal FasL induces cell death of encephalitogenic T lymphocytes", "volume": "10", "author": "Flugel", "year": "2000", "journal-title": "Brain Pathol."}, {"key": "10.1002/eji.201545759-BIB0032|eji3443-cit-0032", "doi-asserted-by": "crossref", "first-page": "518", "DOI": "10.1038/nm1402", "article-title": "Neuron-mediated generation of regulatory T\u00a0cells from encephalitogenic T\u00a0cells suppresses EAE", "volume": "12", "author": "Liu", "year": "2006", "journal-title": "Nat. Med."}, {"key": "10.1002/eji.201545759-BIB0033|eji3443-cit-0033", "doi-asserted-by": "crossref", "first-page": "1132", "DOI": "10.1002/1521-4141(200104)31:4<1132::AID-IMMU1132>3.0.CO;2-N", "article-title": "Essential role of TGF-beta in the natural resistance to experimental allergic encephalomyelitis in rats", "volume": "31", "author": "Cautain", "year": "2001", "journal-title": "Eur. J. Immunol."}, {"key": "10.1002/eji.201545759-BIB0034|eji3443-cit-0034", "doi-asserted-by": "crossref", "first-page": "3025", "DOI": "10.4049/jimmunol.175.5.3025", "article-title": "Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system", "volume": "175", "author": "McGeachy", "year": "2005", "journal-title": "J. Immunol."}, {"key": "10.1002/eji.201545759-BIB0035|eji3443-cit-0035", "doi-asserted-by": "crossref", "first-page": "423", "DOI": "10.1038/nm1564", "article-title": "Myelin-specific regulatory T\u00a0cells accumulate in the CNS but fail to control autoimmune inflammation", "volume": "13", "author": "Korn", "year": "2007", "journal-title": "Nat. Med."}, {"key": "10.1002/eji.201545759-BIB0036|eji3443-cit-0036", "doi-asserted-by": "crossref", "first-page": "272", "DOI": "10.1038/nm.3485", "article-title": "FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T\u00a0cell population in EAE and MS", "volume": "20", "author": "Liu", "year": "2014", "journal-title": "Nat. Med."}, {"key": "10.1002/eji.201545759-BIB0037|eji3443-cit-0037", "doi-asserted-by": "crossref", "first-page": "825", "DOI": "10.4049/jimmunol.180.2.825", "article-title": "Essential role of CD8+CD122+ regulatory T\u00a0cells in the recovery from experimental autoimmune encephalomyelitis", "volume": "180", "author": "Lee", "year": "2008", "journal-title": "J. Immunol."}, {"key": "10.1002/eji.201545759-BIB0038|eji3443-cit-0038", "doi-asserted-by": "crossref", "first-page": "699", "DOI": "10.1172/JCI76210", "article-title": "MHCII-independent CD4+ T\u00a0cells protect injured CNS neurons via IL-4", "volume": "125", "author": "Walsh", "year": "2015", "journal-title": "J. Clin. Invest."}, {"key": "10.1002/eji.201545759-BIB0039|eji3443-cit-0039", "doi-asserted-by": "crossref", "first-page": "10141", "DOI": "10.1523/JNEUROSCI.0076-14.2014", "article-title": "CNS repair requires both effector and regulatory T\u00a0cells with distinct temporal and spatial profiles", "volume": "34", "author": "Raposo", "year": "2014", "journal-title": "J. Neurosci."}, {"key": "10.1002/eji.201545759-BIB0040|eji3443-cit-0040", "doi-asserted-by": "crossref", "first-page": "6381", "DOI": "10.1523/JNEUROSCI.3644-14.2015", "article-title": "Immunization with a myelin-derived antigen activates the brain's choroid plexus for recruitment of immunoregulatory cells to the CNS and attenuates disease progression in a mouse model of ALS", "volume": "35", "author": "Kunis", "year": "2015", "journal-title": "J. Neurosci."}, {"key": "10.1002/eji.201545759-BIB0041|eji3443-cit-0041", "doi-asserted-by": "crossref", "first-page": "592", "DOI": "10.1016/j.celrep.2015.03.053", "article-title": "Astrocyte-derived TGF-beta1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T\u00a0cells", "volume": "11", "author": "Endo", "year": "2015", "journal-title": "Cell Rep."}, {"key": "10.1002/eji.201545759-BIB0042|eji3443-cit-0042", "doi-asserted-by": "crossref", "first-page": "1056", "DOI": "10.1126/science.2434993", "article-title": "RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons", "volume": "235", "author": "Stevens", "year": "1987", "journal-title": "Science"}, {"key": "10.1002/eji.201545759-BIB0043|eji3443-cit-0043", "doi-asserted-by": "crossref", "first-page": "2179", "DOI": "10.1016/S0002-9440(10)63575-4", "article-title": "Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response", "volume": "163", "author": "Theil", "year": "2003", "journal-title": "Am. J. Pathol."}, {"key": "10.1002/eji.201545759-BIB0044|eji3443-cit-0044", "doi-asserted-by": "crossref", "first-page": "e1003547", "DOI": "10.1371/journal.ppat.1003547", "article-title": "Local CD4 and CD8 T-cell reactivity to HSV-1 antigens documents broad viral protein expression and immune competence in latently infected human trigeminal ganglia", "volume": "9", "author": "Velzen", "year": "2013", "journal-title": "PLoS Pathog."}, {"key": "10.1002/eji.201545759-BIB0045|eji3443-cit-0045", "doi-asserted-by": "crossref", "first-page": "268", "DOI": "10.1126/science.1164164", "article-title": "Noncytotoxic lytic granule-mediated CD8+ T\u00a0cell inhibition of HSV-1 reactivation from neuronal latency", "volume": "322", "author": "Knickelbein", "year": "2008", "journal-title": "Science"}, {"key": "10.1002/eji.201545759-BIB0046|eji3443-cit-0046", "doi-asserted-by": "crossref", "first-page": "8312", "DOI": "10.1128/JVI.78.15.8312-8321.2004", "article-title": "Role of CD8+ T\u00a0cells in control of West Nile virus infection", "volume": "78", "author": "Shrestha", "year": "2004", "journal-title": "J. Virol."}, {"key": "10.1002/eji.201545759-BIB0047|eji3443-cit-0047", "doi-asserted-by": "crossref", "first-page": "11749", "DOI": "10.1128/JVI.01136-07", "article-title": "Fas ligand interactions contribute to CD8+ T-cell-mediated control of West Nile virus infection in the central nervous system", "volume": "81", "author": "Shrestha", "year": "2007", "journal-title": "J. Virol."}, {"key": "10.1002/eji.201545759-BIB0048|eji3443-cit-0048", "doi-asserted-by": "crossref", "first-page": "8937", "DOI": "10.1128/JVI.00673-12", "article-title": "CD8+ T\u00a0cells use TRAIL to restrict West Nile virus pathogenesis by controlling infection in neurons", "volume": "86", "author": "Shrestha", "year": "2012", "journal-title": "J. Virol."}, {"key": "10.1002/eji.201545759-BIB0049|eji3443-cit-0049", "doi-asserted-by": "crossref", "first-page": "2641", "DOI": "10.4049/jimmunol.180.4.2641", "article-title": "CXCR3 mediates region-specific antiviral T\u00a0cell trafficking within the central nervous system during West Nile virus encephalitis", "volume": "180", "author": "Zhang", "year": "2008", "journal-title": "J. Immunol."}, {"key": "10.1002/eji.201545759-BIB0050|eji3443-cit-0050", "doi-asserted-by": "crossref", "first-page": "2087", "DOI": "10.1084/jem.20122143", "article-title": "Neuroprotective intervention by interferon-gamma blockade prevents CD8+ T\u00a0cell-mediated dendrite and synapse loss", "volume": "210", "author": "Kreutzfeldt", "year": "2013", "journal-title": "J. Exp. Med."}, {"key": "10.1002/eji.201545759-BIB0051|eji3443-cit-0051", "doi-asserted-by": "crossref", "first-page": "1797", "DOI": "10.1096/fj.07-099499", "article-title": "Interferon-gamma directly induces neurotoxicity through a neuron specific, calcium-permeable complex of IFN-gamma receptor and AMPA GluR1 receptor", "volume": "22", "author": "Mizuno", "year": "2008", "journal-title": "FASEB J."}, {"key": "10.1002/eji.201545759-BIB0052|eji3443-cit-0052", "doi-asserted-by": "crossref", "first-page": "3201", "DOI": "10.1002/eji.201445191", "article-title": "Conflicting consequences of immunity to cancer versus autoimmunity to neurons: insights from paraneoplastic disease", "volume": "44", "author": "Steinman", "year": "2014", "journal-title": "Eur. J. Immunol."}, {"key": "10.1002/eji.201545759-BIB0053|eji3443-cit-0053", "doi-asserted-by": "crossref", "first-page": "3240", "DOI": "10.1002/eji.201444624", "article-title": "T\u00a0cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation", "volume": "44", "author": "Blachere", "year": "2014", "journal-title": "Eur. J. Immunol."}, {"key": "10.1002/eji.201545759-BIB0054|eji3443-cit-0054", "doi-asserted-by": "crossref", "first-page": "389", "DOI": "10.1002/ana.1123", "article-title": "Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions", "volume": "50", "author": "Peterson", "year": "2001", "journal-title": "Ann. Neurol."}, {"key": "10.1002/eji.201545759-BIB0055|eji3443-cit-0055", "doi-asserted-by": "crossref", "first-page": "1321", "DOI": "10.1038/3315", "article-title": "Tumor-specific killer cells in paraneoplastic cerebellar degeneration", "volume": "4", "author": "Albert", "year": "1998", "journal-title": "Nat. Med."}, {"key": "10.1002/eji.201545759-BIB0056|eji3443-cit-0056", "doi-asserted-by": "crossref", "first-page": "1353", "DOI": "10.1038/ng.2770", "article-title": "Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis", "volume": "45", "author": "Beecham", "year": "2013", "journal-title": "Nat. Genet."}, {"key": "10.1002/eji.201545759-BIB0057|eji3443-cit-0057", "doi-asserted-by": "crossref", "first-page": "602", "DOI": "10.1038/nrneurol.2012.198", "article-title": "The initiation and prevention of multiple sclerosis", "volume": "8", "author": "Ascherio", "year": "2012", "journal-title": "Nat. Rev. Neurol."}, {"key": "10.1002/eji.201545759-BIB0058|eji3443-cit-0058", "doi-asserted-by": "crossref", "first-page": "428", "DOI": "10.1111/j.1750-3639.2010.00466.x", "article-title": "Axonal loss and neurofilament phosphorylation changes accompany lesion development and clinical progression in multiple sclerosis", "volume": "21", "author": "Schirmer", "year": "2011", "journal-title": "Brain Pathol."}, {"key": "10.1002/eji.201545759-BIB0059|eji3443-cit-0059", "doi-asserted-by": "crossref", "first-page": "33", "DOI": "10.1016/j.jaut.2014.06.004", "article-title": "From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development", "volume": "54", "author": "Ben-Nun", "year": "2014", "journal-title": "J. Autoimmun."}, {"key": "10.1002/eji.201545759-BIB0060|eji3443-cit-0060", "doi-asserted-by": "crossref", "first-page": "2188", "DOI": "10.1056/NEJMoa1100648", "article-title": "Inflammatory cortical demyelination in early multiple sclerosis", "volume": "365", "author": "Lucchinetti", "year": "2011", "journal-title": "N. Engl. J. Med."}, {"key": "10.1002/eji.201545759-BIB0061|eji3443-cit-0061", "doi-asserted-by": "crossref", "first-page": "393", "DOI": "10.1084/jem.192.3.393", "article-title": "Clonal expansions of CD8(+) T\u00a0cells dominate the T\u00a0cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction", "volume": "192", "author": "Babbe", "year": "2000", "journal-title": "J. Exp. Med."}, {"key": "10.1002/eji.201545759-BIB0062|eji3443-cit-0062", "doi-asserted-by": "crossref", "first-page": "181", "DOI": "10.1111/sji.12147", "article-title": "IL-17 and glutamate excitotoxicity in the pathogenesis of multiple sclerosis", "volume": "79", "author": "Kostic", "year": "2014", "journal-title": "Scand. J. Immunol."}, {"key": "10.1002/eji.201545759-BIB0063|eji3443-cit-0063", "doi-asserted-by": "crossref", "first-page": "146", "DOI": "10.2353/ajpath.2008.070690", "article-title": "Interleukin-17 production in central nervous system-infiltrating T\u00a0cells and glial cells is associated with active disease in multiple sclerosis", "volume": "172", "author": "Tzartos", "year": "2008", "journal-title": "Am. J. Pathol."}, {"key": "10.1002/eji.201545759-BIB0064|eji3443-cit-0064", "doi-asserted-by": "crossref", "first-page": "424", "DOI": "10.1016/j.immuni.2010.08.018", "article-title": "In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis", "volume": "33", "author": "Siffrin", "year": "2010", "journal-title": "Immunity"}, {"key": "10.1002/eji.201545759-BIB0065|eji3443-cit-0065", "doi-asserted-by": "crossref", "first-page": "421", "DOI": "10.1016/j.neuron.2005.03.018", "article-title": "Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL", "volume": "46", "author": "Aktas", "year": "2005", "journal-title": "Neuron"}, {"key": "10.1002/eji.201545759-BIB0066|eji3443-cit-0066", "doi-asserted-by": "crossref", "first-page": "3758", "DOI": "10.1016/j.febslet.2011.08.047", "article-title": "Role of CD8 T\u00a0cell subsets in the pathogenesis of multiple sclerosis", "volume": "585", "author": "Saxena", "year": "2011", "journal-title": "FEBS Lett."}, {"key": "10.1002/eji.201545759-BIB0067|eji3443-cit-0067", "doi-asserted-by": "crossref", "first-page": "669", "DOI": "10.1084/jem.194.5.669", "article-title": "A pathogenic role for myelin-specific CD8(+) T\u00a0cells in a model for multiple sclerosis", "volume": "194", "author": "Huseby", "year": "2001", "journal-title": "J. Exp. Med."}, {"key": "10.1002/eji.201545759-BIB0068|eji3443-cit-0068", "doi-asserted-by": "crossref", "first-page": "1227", "DOI": "10.1038/nm.1881", "article-title": "Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T\u00a0cells in multiple sclerosis", "volume": "14", "author": "Friese", "year": "2008", "journal-title": "Nat. Med."}, {"key": "10.1002/eji.201545759-BIB0069|eji3443-cit-0069", "doi-asserted-by": "crossref", "first-page": "1183", "DOI": "10.1016/j.neuron.2014.11.006", "article-title": "Pervasive axonal transport deficits in multiple sclerosis models", "volume": "84", "author": "Sorbara", "year": "2014", "journal-title": "Neuron"}, {"key": "10.1002/eji.201545759-BIB0070|eji3443-cit-0070", "first-page": "2136", "article-title": "Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors", "volume": "60", "author": "Darnell", "year": "2000", "journal-title": "Cancer Res."}, {"key": "10.1002/eji.201545759-BIB0071|eji3443-cit-0071", "doi-asserted-by": "crossref", "first-page": "519", "DOI": "10.1007/s004010050460", "article-title": "Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration", "volume": "91", "author": "Verschuuren", "year": "1996", "journal-title": "Acta Neuropathol."}, {"key": "10.1002/eji.201545759-BIB0072|eji3443-cit-0072", "doi-asserted-by": "crossref", "first-page": "327", "DOI": "10.1016/S1474-4422(08)70060-7", "article-title": "Paraneoplastic syndromes of the CNS", "volume": "7", "author": "Dalmau", "year": "2008", "journal-title": "Lancet Neurol."}, {"key": "10.1002/eji.201545759-BIB0073|eji3443-cit-0073", "doi-asserted-by": "crossref", "first-page": "835", "DOI": "10.1007/s00401-014-1351-6", "article-title": "Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis", "volume": "128", "author": "Schubert", "year": "2014", "journal-title": "Acta Neuropathol."}, {"key": "10.1002/eji.201545759-BIB0074|eji3443-cit-0074", "doi-asserted-by": "crossref", "first-page": "330", "DOI": "10.1001/archneurol.2009.341", "article-title": "Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers", "volume": "67", "author": "Giometto", "year": "2010", "journal-title": "Arch. Neurol."}, {"key": "10.1002/eji.201545759-BIB0075|eji3443-cit-0075", "doi-asserted-by": "crossref", "first-page": "136", "DOI": "10.1016/j.jneuroim.2009.01.017", "article-title": "CD8 positive T-cell infiltration in the dentate nucleus of paraneoplastic cerebellar degeneration", "volume": "208", "author": "Aye", "year": "2009", "journal-title": "J. Neuroimmunol."}, {"key": "10.1002/eji.201545759-BIB0076|eji3443-cit-0076", "doi-asserted-by": "crossref", "first-page": "9", "DOI": "10.1002/1531-8249(200001)47:1<9::AID-ANA5>3.0.CO;2-I", "article-title": "Detection and treatment of activated T\u00a0cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration", "volume": "47", "author": "Albert", "year": "2000", "journal-title": "Ann. Neurol."}, {"key": "10.1002/eji.201545759-BIB0077|eji3443-cit-0077", "first-page": "182", "article-title": "Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease", "volume": "119", "author": "Brochard", "year": "2009", "journal-title": "J. Clin. Invest."}, {"key": "10.1002/eji.201545759-BIB0078|eji3443-cit-0078", "doi-asserted-by": "crossref", "first-page": "841", "DOI": "10.1002/glia.22654", "article-title": "What is microglia neurotoxicity (Not)?", "volume": "62", "author": "Biber", "year": "2014", "journal-title": "Glia"}, {"key": "10.1002/eji.201545759-BIB0079|eji3443-cit-0079", "doi-asserted-by": "crossref", "first-page": "1819", "DOI": "10.1016/S0140-6736(12)61769-3", "article-title": "Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial", "volume": "380", "author": "Cohen", "year": "2012", "journal-title": "Lancet"}, {"key": "10.1002/eji.201545759-BIB0080|eji3443-cit-0080", "doi-asserted-by": "crossref", "first-page": "1829", "DOI": "10.1016/S0140-6736(12)61768-1", "article-title": "Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial", "volume": "380", "author": "Coles", "year": "2012", "journal-title": "Lancet"}, {"key": "10.1002/eji.201545759-BIB0081|eji3443-cit-0081", "doi-asserted-by": "crossref", "first-page": "298", "DOI": "10.1136/jnnp-2011-300826", "article-title": "Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis", "volume": "83", "author": "Hill-Cawthorne", "year": "2012", "journal-title": "J. Neurol. Neurosurg. Psychiatry"}, {"key": "10.1002/eji.201545759-BIB0082|eji3443-cit-0082", "doi-asserted-by": "crossref", "first-page": "5867", "DOI": "10.4049/jimmunol.1301926", "article-title": "Differential reconstitution of T\u00a0cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis", "volume": "191", "author": "Zhang", "year": "2013", "journal-title": "J. Immunol."}, {"key": "10.1002/eji.201545759-BIB0083|eji3443-cit-0083", "doi-asserted-by": "crossref", "first-page": "2232", "DOI": "10.1093/brain/awq176", "article-title": "Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity", "volume": "133", "author": "Jones", "year": "2010", "journal-title": "Brain"}, {"key": "10.1002/eji.201545759-BIB0084|eji3443-cit-0084", "doi-asserted-by": "crossref", "first-page": "44", "DOI": "10.1016/j.expneurol.2014.04.015", "article-title": "Daclizumab (anti-CD25) in multiple sclerosis", "volume": "262", "author": "Pfender", "year": "2014", "journal-title": "Exp. Neurol."}, {"key": "10.1002/eji.201545759-BIB0085|eji3443-cit-0085", "doi-asserted-by": "crossref", "first-page": "2167", "DOI": "10.1016/S0140-6736(12)62190-4", "article-title": "Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial", "volume": "381", "author": "Gold", "year": "2013", "journal-title": "Lancet"}, {"key": "10.1002/eji.201545759-BIB0086|eji3443-cit-0086", "doi-asserted-by": "crossref", "first-page": "5941", "DOI": "10.1073/pnas.0601335103", "article-title": "Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis", "volume": "103", "author": "Bielekova", "year": "2006", "journal-title": "Proc. Natl. Acad. Sci. USA"}, {"key": "10.1002/eji.201545759-BIB0087|eji3443-cit-0087", "doi-asserted-by": "crossref", "first-page": "899", "DOI": "10.1056/NEJMoa044397", "article-title": "A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis", "volume": "354", "author": "Polman", "year": "2006", "journal-title": "N. Engl. J. Med."}, {"key": "10.1002/eji.201545759-BIB0088|eji3443-cit-0088", "doi-asserted-by": "crossref", "first-page": "387", "DOI": "10.1056/NEJMoa0909494", "article-title": "A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis", "volume": "362", "author": "Kappos", "year": "2010", "journal-title": "N. Engl. J. Med."}, {"key": "10.1002/eji.201545759-BIB0089|eji3443-cit-0089", "author": "Constantinescu CS", "year": "2014", "article-title": "Safety and pharmacokinetics of MOR103, a human antibody to granulocyte-macrophage colonystimulating factor, in patients with multiple sclerosis", "journal-title": "ACTRIMS-ECTRIMS"}, {"key": "10.1002/eji.201545759-BIB0090|eji3443-cit-0090", "first-page": "513", "article-title": "Positive proof of concept of AIN457, an antibody against interleukin-17A, in relapsing-remitting multiple sclerosis Actrims", "volume": "18", "author": "Havrdova", "year": "2012", "journal-title": "Multiple Scler. J."}, {"key": "10.1002/eji.201545759-BIB0091|eji3443-cit-0091", "doi-asserted-by": "crossref", "first-page": "893", "DOI": "10.1016/S0140-6736(87)92863-7", "article-title": "Exacerbations of multiple sclerosis in patients treated with gamma interferon", "volume": "1", "author": "Panitch", "year": "1987", "journal-title": "Lancet"}, {"key": "10.1002/eji.201545759-BIB0092|eji3443-cit-0092", "unstructured": "Agency , E. M. Public summary of opinion on orphan designation: Recombinant human anti-interferon gamma monoclonal antibody for the treatment of haemophagocytic lymphohistiocytosis European Medicines Agency"}, {"key": "10.1002/eji.201545759-BIB0093|eji3443-cit-0093", "doi-asserted-by": "crossref", "first-page": "725", "DOI": "10.1056/NEJMoa1111160", "article-title": "Adult-onset immunodeficiency in Thailand and Taiwan", "volume": "367", "author": "Browne", "year": "2012", "journal-title": "N. Engl. J. Med."}, {"key": "10.1002/eji.201545759-BIB0094|eji3443-cit-0094", "doi-asserted-by": "crossref", "first-page": "537", "DOI": "10.1038/nrd3141", "article-title": "Aptamers as therapeutics", "volume": "9", "author": "Keefe", "year": "2010", "journal-title": "Nat. Rev. Drug Discov."}, {"key": "10.1002/eji.201545759-BIB0095|eji3443-cit-0095", "doi-asserted-by": "crossref", "first-page": "713", "DOI": "10.1016/j.jaci.2013.04.036", "article-title": "A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders", "volume": "132", "author": "Wang", "year": "2013", "journal-title": "J. Allergy Clin. Immunol."}, {"key": "10.1002/eji.201545759-BIB0096|eji3443-cit-0096", "doi-asserted-by": "crossref", "first-page": "123", "DOI": "10.1111/j.1600-065X.1999.tb01311.x", "article-title": "Mechanisms of central and peripheral T-cell tolerance: lessons from experimental models of multiple sclerosis", "volume": "169", "author": "Anderton", "year": "1999", "journal-title": "Immunol. Rev."}, {"key": "10.1002/eji.201545759-BIB0097|eji3443-cit-0097", "doi-asserted-by": "crossref", "first-page": "188ra175", "DOI": "10.1126/scitranslmed.3006168", "article-title": "Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis", "volume": "5", "author": "Lutterotti", "year": "2013", "journal-title": "Sci. Transl. Med."}, {"key": "10.1002/eji.201545759-BIB0098|eji3443-cit-0098", "doi-asserted-by": "crossref", "first-page": "419", "DOI": "10.1016/j.it.2015.05.007", "article-title": "Harnessing nanoparticles for immune modulation", "volume": "36", "author": "Getts", "year": "2015", "journal-title": "Trends Immunol."}], "container-title": ["European Journal of Immunology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Feji.201545759", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Feji.201545759", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/eji.201545759", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 8, 30]], "date-time": "2019-08-30T07:55:04Z", "timestamp": 1567151704000}, "score": 26.17845, "subtitle": ["Highlights"], "issued": {"date-parts": [[2015, 9, 23]]}, "references-count": 98, "journal-issue": {"published-print": {"date-parts": [[2015, 10]]}, "issue": "10"}, "URL": "http://dx.doi.org/10.1002/eji.201545759", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["0014-2980"], "issn-type": [{"value": "0014-2980", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T01:41:05Z", "timestamp": 1575250865182}, "reference-count": 0, "publisher": "Impact Journals, LLC", "issue": "18", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Oncotarget"], "published-print": {"date-parts": [[2018, 3, 6]]}, "DOI": "10.18632/oncotarget.24553", "type": "journal-article", "created": {"date-parts": [[2018, 2, 22]], "date-time": "2018-02-22T05:37:36Z", "timestamp": 1519277856000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status"], "prefix": "10.18632", "volume": "9", "author": [{"given": "Aman", "family": "Chauhan", "sequence": "first", "affiliation": []}, {"given": "Susanne M.", "family": "Arnold", "sequence": "additional", "affiliation": []}, {"given": "Jill", "family": "Kolesar", "sequence": "additional", "affiliation": []}, {"given": "Hala Elnakat", "family": "Thomas", "sequence": "additional", "affiliation": []}, {"given": "Mark", "family": "Evers", "sequence": "additional", "affiliation": []}, {"given": "Lowell", "family": "Anthony", "sequence": "additional", "affiliation": []}], "member": "7892", "published-online": {"date-parts": [[2018, 2, 22]]}, "container-title": ["Oncotarget"], "language": "en", "link": [{"URL": "http://www.oncotarget.com/fulltext/24553", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 3, 13]], "date-time": "2018-03-13T16:09:42Z", "timestamp": 1520957382000}, "score": 26.103346, "issued": {"date-parts": [[2018, 2, 22]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2018, 3, 6]]}, "issue": "18"}, "alternative-id": ["24553"], "URL": "http://dx.doi.org/10.18632/oncotarget.24553", "ISSN": ["1949-2553"], "issn-type": [{"value": "1949-2553", "type": "electronic"}], "subject": ["Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T00:19:00Z", "timestamp": 1574813940213}, "reference-count": 50, "publisher": "Wiley", "issue": "7", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"], "published-print": {"date-parts": [[2016, 7]]}, "DOI": "10.1111/ddg.13012", "type": "journal-article", "created": {"date-parts": [[2016, 7, 4]], "date-time": "2016-07-04T06:06:46Z", "timestamp": 1467612406000}, "page": "685-695", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Immune checkpoint inhibitors: a milestone in the treatment of melanoma"], "prefix": "10.1111", "volume": "14", "author": [{"given": "Sophia M.", "family": "Wilden", "sequence": "first", "affiliation": [{"name": "Department of Dermatology; University Medical Center Mainz; Mainz Germany"}]}, {"given": "Berenice M.", "family": "Lang", "sequence": "additional", "affiliation": [{"name": "Department of Dermatology; University Medical Center Mainz; Mainz Germany"}]}, {"given": "Peter", "family": "Mohr", "sequence": "additional", "affiliation": [{"name": "Department of Dermatology; Elbe Hospital; Buxtehude Germany"}]}, {"given": "Stephan", "family": "Grabbe", "sequence": "additional", "affiliation": [{"name": "Department of Dermatology; University Medical Center Mainz; Mainz Germany"}]}], "member": "311", "published-online": {"date-parts": [[2016, 7, 4]]}, "reference": [{"key": "10.1111/ddg.13012-BIB0001|ddg13012-cit-0001", "first-page": "28", "article-title": "Immuntherapie des Melanoms: Wirksamkeit und Wirkungsmechanismen", "volume": "14", "author": "Wieder", "year": "2016", "journal-title": "J Dtsch Dermatol Ges"}, {"key": "10.1111/ddg.13012-BIB0002|ddg13012-cit-0002", "first-page": "1223", "article-title": "Systemtherapie des metastasierten malignen Melanoms", "volume": "13", "author": "Rauschenberg", "year": "2015", "journal-title": "J Dtsch Dermatol Ges"}, {"key": "10.1111/ddg.13012-BIB0003|ddg13012-cit-0003", "doi-asserted-by": "crossref", "first-page": "23", "DOI": "10.1111/ddg.12557", "article-title": "Exploiting natural killer cells for therapy of melanoma", "volume": "13", "author": "Holsken", "year": "2015", "journal-title": "J Dtsch Dermatol Ges"}, {"key": "10.1111/ddg.13012-BIB0004|ddg13012-cit-0004", "doi-asserted-by": "crossref", "first-page": "252", "DOI": "10.1667/RR13707.1", "article-title": "Immunotherapy and radiation therapy: considerations for successfully combining radiation into the paradigm of immuno-oncology drug development", "volume": "182", "author": "Sharon", "year": "2014", "journal-title": "Radiat Res"}, {"issue": "Suppl 5", "key": "10.1111/ddg.13012-BIB0005|ddg13012-cit-0005", "doi-asserted-by": "crossref", "first-page": "S1", "DOI": "10.1053/j.seminoncol.2014.09.002", "article-title": "Immuno-oncology comes of age-introduction", "volume": "41", "author": "Weber", "year": "2014", "journal-title": "Semin Oncol"}, {"key": "10.1111/ddg.13012-BIB0006|ddg13012-cit-0006", "doi-asserted-by": "crossref", "first-page": "45", "DOI": "10.1038/nri3790", "article-title": "Clinical blockade of PD1 and LAG3 - potential mechanisms of action", "volume": "15", "author": "Nguyen", "year": "2015", "journal-title": "Nat Rev Immunol"}, {"key": "10.1111/ddg.13012-BIB0007|ddg13012-cit-0007", "doi-asserted-by": "crossref", "first-page": "1123", "DOI": "10.4049/jimmunol.1200695", "article-title": "Cutting edge: CTLA-4 on effector T-cells inhibits in trans", "volume": "189", "author": "Corse", "year": "2012", "journal-title": "J Immunol"}, {"key": "10.1111/ddg.13012-BIB0008|ddg13012-cit-0008", "doi-asserted-by": "crossref", "first-page": "205", "DOI": "10.1016/j.cell.2015.03.030", "article-title": "Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential", "volume": "161", "author": "Sharma", "year": "2015", "journal-title": "Cell"}, {"key": "10.1111/ddg.13012-BIB0009|ddg13012-cit-0009", "doi-asserted-by": "crossref", "first-page": "677", "DOI": "10.1146/annurev.immunol.26.021607.090331", "article-title": "PD-1 and its ligands in tolerance and immunity", "volume": "26", "author": "Keir", "year": "2008", "journal-title": "Annu Rev Immunol"}, {"key": "10.1111/ddg.13012-BIB0010|ddg13012-cit-0010", "first-page": "393", "article-title": "Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma", "volume": "19", "author": "Metcalfe", "year": "2015", "journal-title": "Discov Med"}, {"key": "10.1111/ddg.13012-BIB0011|ddg13012-cit-0011", "doi-asserted-by": "crossref", "first-page": "711", "DOI": "10.1056/NEJMoa1003466", "article-title": "Improved survival with ipilimumab in patients with metastatic melanoma", "volume": "363", "author": "Hodi", "year": "2010", "journal-title": "N Engl J Med"}, {"key": "10.1111/ddg.13012-BIB0012|ddg13012-cit-0012", "doi-asserted-by": "crossref", "first-page": "351", "DOI": "10.1186/s12967-015-0716-5", "article-title": "Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma", "volume": "13", "author": "Zimmer", "year": "2015", "journal-title": "J Transl Med"}, {"key": "10.1111/ddg.13012-BIB0013|ddg13012-cit-0013", "doi-asserted-by": "crossref", "first-page": "e0118564", "DOI": "10.1371/journal.pone.0118564", "article-title": "Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma", "volume": "10", "author": "Zimmer", "year": "2015", "journal-title": "PloS one"}, {"key": "10.1111/ddg.13012-BIB0014|ddg13012-cit-0014", "doi-asserted-by": "crossref", "first-page": "1120", "DOI": "10.1016/j.ejca.2013.12.015", "article-title": "Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma", "volume": "50", "author": "Gaudy-Marqueste", "year": "2014", "journal-title": "Eur J Cancer"}, {"key": "10.1111/ddg.13012-BIB0015|ddg13012-cit-0015", "doi-asserted-by": "crossref", "first-page": "116", "DOI": "10.1186/1479-5876-12-116", "article-title": "Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort", "volume": "12", "author": "Ascierto", "year": "2014", "journal-title": "J Transl Med"}, {"key": "10.1111/ddg.13012-BIB0016|ddg13012-cit-0016", "doi-asserted-by": "crossref", "first-page": "1889", "DOI": "10.1200/JCO.2014.56.2736", "article-title": "Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma", "volume": "33", "author": "Schadendorf", "year": "2015", "journal-title": "J Clin Oncol"}, {"key": "10.1111/ddg.13012-BIB0017|ddg13012-cit-0017", "doi-asserted-by": "crossref", "first-page": "522", "DOI": "10.1016/S1470-2045(15)70122-1", "article-title": "Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial", "volume": "16", "author": "Eggermont", "year": "2015", "journal-title": "The Lancet Oncology"}, {"key": "10.1111/ddg.13012-BIB0018|ddg13012-cit-0018", "doi-asserted-by": "crossref", "first-page": "1365", "DOI": "10.1056/NEJMc1302338", "article-title": "Hepatotoxicity with combination of vemurafenib and ipilimumab", "volume": "368", "author": "Ribas", "year": "2013", "journal-title": "N Engl J Med"}, {"key": "10.1111/ddg.13012-BIB0019|ddg13012-cit-0019", "doi-asserted-by": "crossref", "first-page": "5s", "DOI": "10.1200/jco.2014.32.15_suppl.2511", "article-title": "Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)", "volume": "32", "author": "Puzanov", "year": "2014", "journal-title": "J Clin Oncol"}, {"key": "10.1111/ddg.13012-BIB0020|ddg13012-cit-0020", "doi-asserted-by": "crossref", "first-page": "899", "DOI": "10.1002/cam4.140", "article-title": "Ipilimumab and radiation therapy for melanoma brain metastases", "volume": "2", "author": "Silk", "year": "2013", "journal-title": "Cancer med"}, {"key": "10.1111/ddg.13012-BIB0021|ddg13012-cit-0021", "doi-asserted-by": "crossref", "first-page": "925", "DOI": "10.1056/NEJMoa1112824", "article-title": "Immunologic correlates of the abscopal effect in a patient with melanoma", "volume": "366", "author": "Postow", "year": "2012", "journal-title": "N Engl J Med"}, {"key": "10.1111/ddg.13012-BIB0022|ddg13012-cit-0022", "doi-asserted-by": "crossref", "first-page": "375", "DOI": "10.1016/S1470-2045(15)70076-8", "article-title": "Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial", "volume": "16", "author": "Weber", "year": "2015", "journal-title": "The Lancet Oncology"}, {"key": "10.1111/ddg.13012-BIB0023|ddg13012-cit-0023", "doi-asserted-by": "crossref", "first-page": "1020", "DOI": "10.1200/JCO.2013.53.0105", "article-title": "Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab", "volume": "32", "author": "Topalian", "year": "2014", "journal-title": "J Clin Oncol"}, {"key": "10.1111/ddg.13012-BIB0024|ddg13012-cit-0024", "doi-asserted-by": "crossref", "first-page": "1109", "DOI": "10.1016/S0140-6736(14)60958-2", "article-title": "Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial", "volume": "384", "author": "Robert", "year": "2014", "journal-title": "Lancet"}, {"key": "10.1111/ddg.13012-BIB0025|ddg13012-cit-0025", "doi-asserted-by": "crossref", "first-page": "2521", "DOI": "10.1056/NEJMoa1503093", "article-title": "Pembrolizumab versus Ipilimumab in Advanced Melanoma", "volume": "372", "author": "Robert", "year": "2015", "journal-title": "N Engl J Med"}, {"key": "10.1111/ddg.13012-BIB0026|ddg13012-cit-0026", "doi-asserted-by": "crossref", "first-page": "2443", "DOI": "10.1056/NEJMoa1200690", "article-title": "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", "volume": "366", "author": "Topalian", "year": "2012", "journal-title": "N Engl J Med"}, {"key": "10.1111/ddg.13012-BIB0027|ddg13012-cit-0027", "doi-asserted-by": "crossref", "first-page": "2006", "DOI": "10.1056/NEJMoa1414428", "article-title": "Nivolumab and ipilimumab versus ipilimumab in untreated melanoma", "volume": "372", "author": "Postow", "year": "2015", "journal-title": "N Engl J Med"}, {"key": "10.1111/ddg.13012-BIB0028|ddg13012-cit-0028", "doi-asserted-by": "crossref", "first-page": "1867", "DOI": "10.1056/NEJMoa1408868", "article-title": "Combined vemurafenib and cobimetinib in BRAF-mutated melanoma", "volume": "371", "author": "Larkin", "year": "2014", "journal-title": "N Engl J Med"}, {"key": "10.1111/ddg.13012-BIB0029|ddg13012-cit-0029", "doi-asserted-by": "crossref", "first-page": "954", "DOI": "10.1016/S1470-2045(14)70301-8", "article-title": "Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study", "volume": "15", "author": "Ribas", "year": "2014", "journal-title": "The Lancet Oncology"}, {"key": "10.1111/ddg.13012-BIB0030|ddg13012-cit-0030", "doi-asserted-by": "crossref", "first-page": "3697", "DOI": "10.1200/JCO.2014.57.3535", "article-title": "Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor", "volume": "32", "author": "Johnson", "year": "2014", "journal-title": "J Clin Oncol"}, {"key": "10.1111/ddg.13012-BIB0031|ddg13012-cit-0031", "doi-asserted-by": "crossref", "first-page": "30", "DOI": "10.1056/NEJMoa1412690", "article-title": "Improved overall survival in melanoma with combined dabrafenib and trametinib", "volume": "372", "author": "Robert", "year": "2015", "journal-title": "N Engl J Med"}, {"key": "10.1111/ddg.13012-BIB0032|ddg13012-cit-0032", "doi-asserted-by": "crossref", "first-page": "122", "DOI": "10.1056/NEJMoa1302369", "article-title": "Nivolumab plus ipilimumab in advanced melanoma", "volume": "369", "author": "Wolchok", "year": "2013", "journal-title": "N Engl J Med"}, {"key": "10.1111/ddg.13012-BIB0033|ddg13012-cit-0033", "doi-asserted-by": "crossref", "first-page": "23", "DOI": "10.1056/NEJMoa1504030", "article-title": "Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma", "volume": "373", "author": "Larkin", "year": "2015", "journal-title": "N Engl J Med"}, {"issue": "8", "key": "10.1111/ddg.13012-BIB0034|ddg13012-cit-0034", "doi-asserted-by": "crossref", "first-page": "908", "DOI": "10.1016/S1470-2045(15)00083-2", "article-title": "Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial", "volume": "16", "author": "Ribas", "year": "2015", "journal-title": "Lancet Oncol"}, {"key": "10.1111/ddg.13012-BIB0035|ddg13012-cit-0035", "doi-asserted-by": "crossref", "first-page": "1675", "DOI": "10.1002/cncr.27969", "article-title": "Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma", "volume": "119", "author": "Weber", "year": "2013", "journal-title": "Cancer"}, {"key": "10.1111/ddg.13012-BIB0036|ddg13012-cit-0036", "doi-asserted-by": "crossref", "first-page": "277", "DOI": "10.1111/j.1610-0387.2010.07568.x", "article-title": "Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma", "volume": "9", "author": "Kahler", "year": "2011", "journal-title": "J Dtsch Dermatol Ges"}, {"key": "10.1111/ddg.13012-BIB0037|ddg13012-cit-0037", "doi-asserted-by": "crossref", "first-page": "19", "DOI": "10.1186/s40425-015-0064-2", "article-title": "Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis", "volume": "3", "author": "Bostwick", "year": "2015", "journal-title": "J Immunother Cancer"}, {"key": "10.1111/ddg.13012-BIB0038|ddg13012-cit-0038", "doi-asserted-by": "crossref", "first-page": "2283", "DOI": "10.1200/JCO.2005.04.5716", "article-title": "Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4", "volume": "24", "author": "Beck", "year": "2006", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "10.1111/ddg.13012-BIB0039|ddg13012-cit-0039", "doi-asserted-by": "crossref", "first-page": "234", "DOI": "10.1001/jamaoncol.2015.4368", "article-title": "Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders", "volume": "2", "author": "Johnson", "year": "2016", "journal-title": "JAMA Oncol"}, {"key": "10.1111/ddg.13012-BIB0040|ddg13012-cit-0040", "doi-asserted-by": "crossref", "first-page": "473", "DOI": "10.1053/j.seminoncol.2010.09.001", "article-title": "Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy", "volume": "37", "author": "Callahan", "year": "2010", "journal-title": "Semin Oncol"}, {"key": "10.1111/ddg.13012-BIB0041|ddg13012-cit-0041", "doi-asserted-by": "crossref", "first-page": "675", "DOI": "10.1007/s00262-014-1545-8", "article-title": "Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma", "volume": "63", "author": "Simeone", "year": "2014", "journal-title": "Cancer Immunol Immunother"}, {"key": "10.1111/ddg.13012-BIB0042|ddg13012-cit-0042", "doi-asserted-by": "crossref", "first-page": "1767", "DOI": "10.1002/cncr.24951", "article-title": "Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival", "volume": "116", "author": "Ku", "year": "2010", "journal-title": "Cancer"}, {"key": "10.1111/ddg.13012-BIB0043|ddg13012-cit-0043", "doi-asserted-by": "crossref", "first-page": "16723", "DOI": "10.1073/pnas.1110814108", "article-title": "Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab", "volume": "108", "author": "Yuan", "year": "2011", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "10.1111/ddg.13012-BIB0044|ddg13012-cit-0044", "doi-asserted-by": "crossref", "first-page": "207", "DOI": "10.1126/science.aad0095", "article-title": "Genomic correlates of response to CTLA-4 blockade in metastatic melanoma", "volume": "350", "author": "Allen", "year": "2015", "journal-title": "Science"}, {"key": "10.1111/ddg.13012-BIB0045|ddg13012-cit-0045", "first-page": "1021", "article-title": "Myeloid-derived suppressor cells in malignant melanoma", "volume": "12", "author": "Umansky", "year": "2014", "journal-title": "J Dtsch Dermatol Ges"}, {"key": "10.1111/ddg.13012-BIB0046|ddg13012-cit-0046", "doi-asserted-by": "crossref", "first-page": "241", "DOI": "10.3109/1547691X.2012.678021", "article-title": "Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1", "volume": "9", "author": "Simeone", "year": "2012", "journal-title": "J Immunotoxicol"}, {"key": "10.1111/ddg.13012-BIB0047|ddg13012-cit-0047", "author": "Tsai", "volume": "33", "year": "2015", "article-title": "Clinical characteristics predictive of response to pembrolizumab in advanced melanoma", "journal-title": "J Clin Oncol", "DOI": "10.1200/jco.2015.33.15_suppl.9031", "doi-asserted-by": "crossref"}, {"key": "10.1111/ddg.13012-BIB0048|ddg13012-cit-0048", "doi-asserted-by": "crossref", "first-page": "448", "DOI": "10.1053/j.seminoncol.2015.02.016", "article-title": "Immunologic correlates in the course of treatment with immunomodulating antibodies", "volume": "42", "author": "Weide", "year": "2015", "journal-title": "Semin Oncol"}, {"issue": "3", "key": "10.1111/ddg.13012-BIB0049|ddg13012-cit-0049", "doi-asserted-by": "crossref", "first-page": "385", "DOI": "10.1016/j.critrevonc.2015.08.021", "article-title": "Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma", "volume": "96", "author": "Carlino", "year": "2015", "journal-title": "Crit Rev Oncol Hematol"}, {"key": "10.1111/ddg.13012-BIB0050|ddg13012-cit-0050", "doi-asserted-by": "crossref", "first-page": "320", "DOI": "10.1056/NEJMoa1412082", "article-title": "Nivolumab in previously untreated melanoma without BRAF mutation", "volume": "372", "author": "Robert", "year": "2015", "journal-title": "N Engl J Med"}], "container-title": ["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fddg.13012", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 9, 10]], "date-time": "2019-09-10T16:47:18Z", "timestamp": 1568134038000}, "score": 26.095905, "subtitle": ["Immune checkpoint inhibitors in the treatment of melanoma"], "issued": {"date-parts": [[2016, 7]]}, "references-count": 50, "journal-issue": {"published-print": {"date-parts": [[2016, 7]]}, "issue": "7"}, "URL": "http://dx.doi.org/10.1111/ddg.13012", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["1610-0379"], "issn-type": [{"value": "1610-0379", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T21:30:02Z", "timestamp": 1574803802269}, "reference-count": 174, "publisher": "Springer Science and Business Media LLC", "issue": "1", "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["J Hematol Oncol"], "published-print": {"date-parts": [[2016, 12]]}, "DOI": "10.1186/s13045-016-0277-y", "type": "journal-article", "created": {"date-parts": [[2016, 5, 27]], "date-time": "2016-05-27T11:44:35Z", "timestamp": 1464349475000}, "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 120, "title": ["Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy"], "prefix": "10.1186", "volume": "9", "author": [{"given": "Weijie", "family": "Ma", "sequence": "first", "affiliation": []}, {"given": "Barbara M.", "family": "Gilligan", "sequence": "additional", "affiliation": []}, {"given": "Jianda", "family": "Yuan", "sequence": "additional", "affiliation": []}, {"given": "Tianhong", "family": "Li", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 5, 27]]}, "reference": [{"issue": "12", "key": "277_CR1", "doi-asserted-by": "crossref", "first-page": "883", "DOI": "10.1038/nrd4476", "volume": "13", "author": "RM Webster", "year": "2014", "unstructured": "Webster RM. The immune checkpoint inhibitors: where are we now? Nat Rev Drug Discov. 2014;13(12):883\u20134.", "journal-title": "Nat Rev Drug Discov"}, {"issue": "23", "key": "277_CR2", "doi-asserted-by": "crossref", "first-page": "7412", "DOI": "10.1158/1078-0432.CCR-09-1624", "volume": "15", "author": "JD Wolchok", "year": "2009", "unstructured": "Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412\u201320.", "journal-title": "Clin Cancer Res"}, {"issue": "13", "key": "277_CR3", "doi-asserted-by": "crossref", "first-page": "1510", "DOI": "10.1200/JCO.2015.64.0391", "volume": "34", "author": "FS Hodi", "year": "2016", "unstructured": "Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34(13):1510\u20137.", "journal-title": "J Clin Oncol"}, {"issue": "21", "key": "277_CR4", "doi-asserted-by": "crossref", "first-page": "2006", "DOI": "10.1056/NEJMoa1414428", "volume": "372", "author": "MA Postow", "year": "2015", "unstructured": "Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006\u201317.", "journal-title": "N Engl J Med"}, {"issue": "21", "key": "277_CR5", "doi-asserted-by": "crossref", "first-page": "2018", "DOI": "10.1056/NEJMoa1501824", "volume": "372", "author": "EB Garon", "year": "2015", "unstructured": "Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u201328.", "journal-title": "N Engl J Med"}, {"key": "277_CR6", "doi-asserted-by": "crossref", "first-page": "70", "DOI": "10.1186/s13045-014-0070-8", "volume": "7", "author": "AD Smith", "year": "2014", "unstructured": "Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014;7:70.", "journal-title": "J Hematol Oncol"}, {"issue": "8", "key": "277_CR7", "doi-asserted-by": "crossref", "first-page": "482", "DOI": "10.1016/j.molmed.2015.05.005", "volume": "21", "author": "Y Pico de Coana", "year": "2015", "unstructured": "Pico de Coana Y, Choudhury A, Kiessling R. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends Mol Med. 2015;21(8):482\u201391.", "journal-title": "Trends Mol Med"}, {"issue": "2", "key": "277_CR8", "doi-asserted-by": "crossref", "first-page": "205", "DOI": "10.1016/j.cell.2015.03.030", "volume": "161", "author": "P Sharma", "year": "2015", "unstructured": "Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205\u201314.", "journal-title": "Cell"}, {"issue": "4", "key": "277_CR9", "doi-asserted-by": "crossref", "first-page": "462", "DOI": "10.1016/j.ccell.2015.02.015", "volume": "27", "author": "B Ruffell", "year": "2015", "unstructured": "Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27(4):462\u201372.", "journal-title": "Cancer Cell"}, {"issue": "4", "key": "277_CR10", "doi-asserted-by": "crossref", "first-page": "198", "DOI": "10.1016/j.it.2015.02.006", "volume": "36", "author": "SB Coffelt", "year": "2015", "unstructured": "Coffelt SB, de Visser KE. Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends Immunol. 2015;36(4):198\u2013216.", "journal-title": "Trends Immunol"}, {"issue": "4", "key": "277_CR11", "doi-asserted-by": "crossref", "first-page": "250", "DOI": "10.1016/j.it.2015.02.003", "volume": "36", "author": "SR Woo", "year": "2015", "unstructured": "Woo SR, Corrales L, Gajewski TF. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 2015;36(4):250\u20136.", "journal-title": "Trends Immunol"}, {"key": "277_CR12", "doi-asserted-by": "crossref", "first-page": "86", "DOI": "10.1186/s13045-015-0185-6", "volume": "8", "author": "G Goel", "year": "2015", "unstructured": "Goel G, Sun W. Advances in the management of gastrointestinal cancers\u2014an upcoming role of immune checkpoint blockade. J Hematol Oncol. 2015;8:86.", "journal-title": "J Hematol Oncol"}, {"issue": "24", "key": "277_CR13", "doi-asserted-by": "crossref", "first-page": "6580", "DOI": "10.1158/1078-0432.CCR-12-1362", "volume": "18", "author": "DS Chen", "year": "2012", "unstructured": "Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy\u2014inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580\u20137.", "journal-title": "Clin Cancer Res"}, {"issue": "36", "key": "277_CR14", "doi-asserted-by": "crossref", "first-page": "4828", "DOI": "10.1200/JCO.2011.38.0899", "volume": "29", "author": "SL Topalian", "year": "2011", "unstructured": "Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011;29(36):4828\u201336.", "journal-title": "J Clin Oncol"}, {"key": "277_CR15", "doi-asserted-by": "crossref", "first-page": "329", "DOI": "10.1146/annurev.immunol.22.012703.104803", "volume": "22", "author": "GP Dunn", "year": "2004", "unstructured": "Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329\u201360.", "journal-title": "Annu Rev Immunol"}, {"issue": "1", "key": "277_CR16", "doi-asserted-by": "crossref", "first-page": "11", "DOI": "10.1158/2326-6066.CIR-13-0022", "volume": "1", "author": "N Hacohen", "year": "2013", "unstructured": "Hacohen N, Fritsch EF, Carter TA, Lander ES, Wu CJ. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol Res. 2013;1(1):11\u20135.", "journal-title": "Cancer Immunol Res"}, {"issue": "1", "key": "277_CR17", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1111/j.1365-2567.2007.02587.x", "volume": "121", "author": "R Kim", "year": "2007", "unstructured": "Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121(1):1\u201314.", "journal-title": "Immunology"}, {"issue": "45", "key": "277_CR18", "doi-asserted-by": "crossref", "first-page": "5894", "DOI": "10.1038/onc.2008.268", "volume": "27", "author": "TJ Stewart", "year": "2008", "unstructured": "Stewart TJ, Abrams SI. How tumours escape mass destruction. Oncogene. 2008;27(45):5894\u2013903.", "journal-title": "Oncogene"}, {"issue": "2", "key": "277_CR19", "doi-asserted-by": "crossref", "first-page": "539", "DOI": "10.1158/0008-5472.CAN-12-2325", "volume": "73", "author": "M Terme", "year": "2013", "unstructured": "Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013;73(2):539\u201349.", "journal-title": "Cancer Res"}, {"issue": "7077", "key": "277_CR20", "doi-asserted-by": "crossref", "first-page": "682", "DOI": "10.1038/nature04444", "volume": "439", "author": "DL Barber", "year": "2006", "unstructured": "Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682\u20137.", "journal-title": "Nature"}, {"issue": "2", "key": "277_CR21", "doi-asserted-by": "crossref", "first-page": "223", "DOI": "10.1016/j.coi.2010.02.005", "volume": "22", "author": "PS Kim", "year": "2010", "unstructured": "Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol. 2010;22(2):223\u201330.", "journal-title": "Curr Opin Immunol"}, {"key": "277_CR22", "doi-asserted-by": "crossref", "first-page": "211", "DOI": "10.1186/s12916-015-0455-8", "volume": "13", "author": "A Bertrand", "year": "2015", "unstructured": "Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211.", "journal-title": "BMC Med"}, {"issue": "4", "key": "277_CR23", "doi-asserted-by": "crossref", "first-page": "1361", "DOI": "10.1210/jc.2012-4075", "volume": "98", "author": "SM Corsello", "year": "2013", "unstructured": "Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98(4):1361\u201375.", "journal-title": "J Clin Endocrinol Metab"}, {"issue": "2", "key": "277_CR24", "doi-asserted-by": "crossref", "first-page": "234", "DOI": "10.1001/jamaoncol.2015.4368", "volume": "2", "author": "DB Johnson", "year": "2016", "unstructured": "Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2(2):234\u201340.", "journal-title": "JAMA Oncol"}, {"key": "277_CR25", "doi-asserted-by": "crossref", "first-page": "677", "DOI": "10.1146/annurev.immunol.26.021607.090331", "volume": "26", "author": "ME Keir", "year": "2008", "unstructured": "Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.", "journal-title": "Annu Rev Immunol"}, {"issue": "7", "key": "277_CR26", "doi-asserted-by": "crossref", "first-page": "802", "DOI": "10.1097/01.pas.0000209855.28282.ce", "volume": "30", "author": "DM Dorfman", "year": "2006", "unstructured": "Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30(7):802\u201310.", "journal-title": "Am J Surg Pathol"}, {"issue": "1", "key": "277_CR27", "doi-asserted-by": "crossref", "first-page": "24", "DOI": "10.1016/j.molmed.2014.10.009", "volume": "21", "author": "KC Ohaegbulam", "year": "2015", "unstructured": "Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24\u201333.", "journal-title": "Trends Mol Med"}, {"issue": "10", "key": "277_CR28", "doi-asserted-by": "crossref", "first-page": "5538", "DOI": "10.4049/jimmunol.169.10.5538", "volume": "169", "author": "T Yamazaki", "year": "2002", "unstructured": "Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002;169(10):5538\u201345.", "journal-title": "J Immunol"}, {"issue": "2", "key": "277_CR29", "doi-asserted-by": "crossref", "first-page": "133", "DOI": "10.1080/713774061", "volume": "9", "author": "MJ Eppihimer", "year": "2002", "unstructured": "Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, Erickson J, et al. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation. 2002;9(2):133\u201345.", "journal-title": "Microcirculation"}, {"issue": "1-2", "key": "277_CR30", "doi-asserted-by": "crossref", "first-page": "172", "DOI": "10.1016/j.jneuroim.2004.06.013", "volume": "155", "author": "B Schreiner", "year": "2004", "unstructured": "Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M, et al. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol. 2004;155(1-2):172\u201382.", "journal-title": "J Neuroimmunol"}, {"issue": "4", "key": "277_CR31", "doi-asserted-by": "crossref", "first-page": "256", "DOI": "10.1093/jnci/djs629", "volume": "105", "author": "SC Formenti", "year": "2013", "unstructured": "Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256\u201365.", "journal-title": "J Natl Cancer Inst"}, {"issue": "7547", "key": "277_CR32", "doi-asserted-by": "crossref", "first-page": "373", "DOI": "10.1038/nature14292", "volume": "520", "author": "C Twyman-Saint Victor", "year": "2015", "unstructured": "Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373\u20137.", "journal-title": "Nature"}, {"issue": "12", "key": "277_CR33", "doi-asserted-by": "crossref", "first-page": "1685", "DOI": "10.1097/JTO.0000000000000686", "volume": "10", "author": "ME Daly", "year": "2015", "unstructured": "Daly ME, Monjazeb AM, Kelly K. Clinical trials integrating immunotherapy and radiation for non-small-cell lung cancer. J Thorac Oncol. 2015;10(12):1685\u201393.", "journal-title": "J Thorac Oncol"}, {"issue": "4", "key": "277_CR34", "doi-asserted-by": "crossref", "first-page": "1111", "DOI": "10.1172/JCI40269", "volume": "120", "author": "R Ramakrishnan", "year": "2010", "unstructured": "Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest. 2010;120(4):1111\u201324.", "journal-title": "J Clin Invest"}, {"issue": "1", "key": "277_CR35", "doi-asserted-by": "crossref", "first-page": "74", "DOI": "10.1016/j.immuni.2013.06.014", "volume": "39", "author": "L Zitvogel", "year": "2013", "unstructured": "Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013;39(1):74\u201388.", "journal-title": "Immunity"}, {"issue": "4", "key": "277_CR36", "doi-asserted-by": "crossref", "first-page": "729", "DOI": "10.1016/j.immuni.2013.03.003", "volume": "38", "author": "Y Ma", "year": "2013", "unstructured": "Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38(4):729\u201341.", "journal-title": "Immunity"}, {"issue": "8", "key": "277_CR37", "doi-asserted-by": "crossref", "first-page": "3052", "DOI": "10.1158/0008-5472.CAN-09-3690", "volume": "70", "author": "J Vincent", "year": "2010", "unstructured": "Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052\u201361.", "journal-title": "Cancer Res"}, {"issue": "21", "key": "277_CR38", "doi-asserted-by": "crossref", "first-page": "6022", "DOI": "10.1158/0008-5472.CAN-14-0657", "volume": "74", "author": "J Kanterman", "year": "2014", "unstructured": "Kanterman J, Sade-Feldman M, Biton M, Ish-Shalom E, Lasry A, Goldshtein A, et al. Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res. 2014;74(21):6022\u201335.", "journal-title": "Cancer Res"}, {"issue": "1", "key": "277_CR39", "doi-asserted-by": "crossref", "first-page": "111", "DOI": "10.1016/j.immuni.2007.05.016", "volume": "27", "author": "MJ Butte", "year": "2007", "unstructured": "Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111\u201322.", "journal-title": "Immunity"}, {"issue": "13", "key": "277_CR40", "doi-asserted-by": "crossref", "first-page": "2286", "DOI": "10.1182/blood-2010-02-271874", "volume": "116", "author": "DM Benson Jr", "year": "2010", "unstructured": "Benson Jr DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116(13):2286\u201394.", "journal-title": "Blood"}, {"issue": "19", "key": "277_CR41", "doi-asserted-by": "crossref", "first-page": "12293", "DOI": "10.1073/pnas.192461099", "volume": "99", "author": "Y Iwai", "year": "2002", "unstructured": "Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293\u20137.", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "1", "key": "277_CR42", "doi-asserted-by": "crossref", "first-page": "296", "DOI": "10.1182/blood-2006-10-051482", "volume": "110", "author": "J Liu", "year": "2007", "unstructured": "Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007;110(1):296\u2013304.", "journal-title": "Blood"}, {"issue": "4", "key": "277_CR43", "doi-asserted-by": "crossref", "first-page": "450", "DOI": "10.1016/j.ccell.2015.03.001", "volume": "27", "author": "SL Topalian", "year": "2015", "unstructured": "Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450\u201361.", "journal-title": "Cancer Cell"}, {"issue": "8", "key": "277_CR44", "doi-asserted-by": "crossref", "first-page": "860", "DOI": "10.1158/2159-8290.CD-14-1236", "volume": "5", "author": "F Skoulidis", "year": "2015", "unstructured": "Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015;5(8):860\u201377.", "journal-title": "Cancer Discov"}, {"issue": "6", "key": "277_CR45", "doi-asserted-by": "crossref", "first-page": "910", "DOI": "10.1097/JTO.0000000000000500", "volume": "10", "author": "N Chen", "year": "2015", "unstructured": "Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol. 2015;10(6):910\u201323.", "journal-title": "J Thorac Oncol"}, {"issue": "10", "key": "277_CR46", "doi-asserted-by": "crossref", "first-page": "1935", "DOI": "10.1093/annonc/mdu242", "volume": "25", "author": "K Azuma", "year": "2014", "unstructured": "Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol. 2014;25(10):1935\u201340.", "journal-title": "Ann Oncol"}, {"issue": "17", "key": "277_CR47", "doi-asserted-by": "crossref", "first-page": "4014", "DOI": "10.1158/1078-0432.CCR-15-0016", "volume": "21", "author": "K Ota", "year": "2015", "unstructured": "Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, et al. Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin Cancer Res. 2015;21(17):4014\u201321.", "journal-title": "Clin Cancer Res"}, {"issue": "2", "key": "277_CR48", "doi-asserted-by": "crossref", "first-page": "227", "DOI": "10.1158/0008-5472.CAN-14-3362", "volume": "76", "author": "KJ Lastwika", "year": "2016", "unstructured": "Lastwika KJ, Wilson 3rd W, Li QK, Norris J, Xu H, Ghazarian SR, et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. 2016;76(2):227\u201338.", "journal-title": "Cancer Res"}, {"key": "277_CR49", "unstructured": "Lou Y, Diao L, Parra Cuentas ER, Denning WL, Chen L, Fan YH, et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res. 2016. doi: 10.1158/1078-0432.CCR-15-1434 .", "DOI": "10.1158/1078-0432.CCR-15-1434", "doi-asserted-by": "crossref"}, {"issue": "9", "key": "277_CR50", "doi-asserted-by": "crossref", "first-page": "915", "DOI": "10.1158/2159-8290.CD-15-0563", "volume": "5", "author": "A Ribas", "year": "2015", "unstructured": "Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015;5(9):915\u20139.", "journal-title": "Cancer Discov"}, {"key": "277_CR51", "doi-asserted-by": "crossref", "first-page": "3", "DOI": "10.1186/2051-1426-2-3", "volume": "2", "author": "S Spranger", "year": "2014", "unstructured": "Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer. 2014;2:3.", "journal-title": "J Immunother Cancer"}, {"issue": "12", "key": "277_CR52", "doi-asserted-by": "crossref", "first-page": "2965", "DOI": "10.1158/1055-9965.EPI-14-0654", "volume": "23", "author": "Z Gatalica", "year": "2014", "unstructured": "Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2965\u201370.", "journal-title": "Cancer Epidemiol Biomarkers Prev"}, {"key": "277_CR53", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1016/j.jaut.2014.06.005", "volume": "53", "author": "N Okiyama", "year": "2014", "unstructured": "Okiyama N, Katz SI. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes. J Autoimmun. 2014;53:1\u20139.", "journal-title": "J Autoimmun"}, {"issue": "7", "key": "277_CR54", "doi-asserted-by": "crossref", "first-page": "1757", "DOI": "10.1002/cncr.24899", "volume": "116", "author": "R Hino", "year": "2010", "unstructured": "Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116(7):1757\u201366.", "journal-title": "Cancer"}, {"issue": "1", "key": "277_CR55", "doi-asserted-by": "crossref", "first-page": "29", "DOI": "10.1038/ni.1679", "volume": "10", "author": "SD Blackburn", "year": "2009", "unstructured": "Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10(1):29\u201337.", "journal-title": "Nat Immunol"}, {"issue": "2", "key": "277_CR56", "doi-asserted-by": "crossref", "first-page": "141", "DOI": "10.1016/S1074-7613(00)80089-8", "volume": "11", "author": "H Nishimura", "year": "1999", "unstructured": "Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141\u201351.", "journal-title": "Immunity"}, {"issue": "5502", "key": "277_CR57", "doi-asserted-by": "crossref", "first-page": "319", "DOI": "10.1126/science.291.5502.319", "volume": "291", "author": "H Nishimura", "year": "2001", "unstructured": "Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502):319\u201322.", "journal-title": "Science"}, {"issue": "5", "key": "277_CR58", "doi-asserted-by": "crossref", "first-page": "562", "DOI": "10.1038/nm863", "volume": "9", "author": "TJ Curiel", "year": "2003", "unstructured": "Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9(5):562\u20137.", "journal-title": "Nat Med"}, {"issue": "3", "key": "277_CR59", "first-page": "1089", "volume": "65", "author": "F Hirano", "year": "2005", "unstructured": "Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65(3):1089\u201396.", "journal-title": "Cancer Res"}, {"issue": "9", "key": "277_CR60", "doi-asserted-by": "crossref", "first-page": "4275", "DOI": "10.1073/pnas.0915174107", "volume": "107", "author": "MA Curran", "year": "2010", "unstructured": "Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107(9):4275\u201380.", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "4", "key": "277_CR61", "doi-asserted-by": "crossref", "first-page": "917", "DOI": "10.1158/0008-5472.CAN-11-1620", "volume": "72", "author": "SR Woo", "year": "2012", "unstructured": "Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72(4):917\u201327.", "journal-title": "Cancer Res"}, {"issue": "1", "key": "277_CR62", "doi-asserted-by": "crossref", "first-page": "123", "DOI": "10.1186/s13045-015-0219-0", "volume": "8", "author": "KK Tsai", "year": "2015", "unstructured": "Tsai KK, Daud AI. Nivolumab plus ipilimumab in the treatment of advanced melanoma. J Hematol Oncol. 2015;8(1):123.", "journal-title": "J Hematol Oncol"}, {"issue": "12", "key": "277_CR63", "doi-asserted-by": "crossref", "first-page": "2433", "DOI": "10.1093/annonc/mdu452", "volume": "25", "author": "D Massi", "year": "2014", "unstructured": "Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol. 2014;25(12):2433\u201342.", "journal-title": "Ann Oncol"}, {"issue": "10", "key": "277_CR64", "doi-asserted-by": "crossref", "first-page": "1223", "DOI": "10.1093/intimm/dxm091", "volume": "19", "author": "RM Wong", "year": "2007", "unstructured": "Wong RM, Scotland RR, Lau RL, Wang C, Korman AJ, Kast WM, et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol. 2007;19(10):1223\u201334.", "journal-title": "Int Immunol"}, {"issue": "9", "key": "277_CR65", "doi-asserted-by": "crossref", "first-page": "1065", "DOI": "10.1093/intimm/dxp072", "volume": "21", "author": "W Wang", "year": "2009", "unstructured": "Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol. 2009;21(9):1065\u201377.", "journal-title": "Int Immunol"}, {"issue": "12", "key": "277_CR66", "doi-asserted-by": "crossref", "first-page": "6104", "DOI": "10.4049/jimmunol.1201617", "volume": "190", "author": "JJ Charlton", "year": "2013", "unstructured": "Charlton JJ, Chatzidakis I, Tsoukatou D, Boumpas DT, Garinis GA, Mamalaki C. Programmed death-1 shapes memory phenotype CD8 T cell subsets in a cell-intrinsic manner. J Immunol. 2013;190(12):6104\u201314.", "journal-title": "J Immunol"}, {"issue": "10", "key": "277_CR67", "doi-asserted-by": "crossref", "first-page": "1020", "DOI": "10.1200/JCO.2013.53.0105", "volume": "32", "author": "SL Topalian", "year": "2014", "unstructured": "Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020\u201330.", "journal-title": "J Clin Oncol"}, {"key": "277_CR68", "author": "MERCK", "year": "2015", "unstructured": "MERCK. FDA approves KEYTRUDA\u00ae (pembrolizumab) for the treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 with disease progression on or after platinum-containing chemotherapy. 2015. http://www.mercknewsroom.com/news-release/prescription-medicine-news/fda-approves-keytruda-pembrolizumab-treatment-patients-metas .", "volume-title": "FDA approves KEYTRUDA\u00ae (pembrolizumab) for the treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 with disease progression on or after platinum-containing chemotherapy"}, {"key": "277_CR69", "doi-asserted-by": "crossref", "first-page": "214", "DOI": "10.1186/1479-5876-9-214", "volume": "9", "author": "BA Fox", "year": "2011", "unstructured": "Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, et al. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011;9:214.", "journal-title": "J Transl Med"}, {"key": "277_CR70", "doi-asserted-by": "crossref", "first-page": "130", "DOI": "10.1186/1479-5876-8-130", "volume": "8", "author": "LH Butterfield", "year": "2010", "unstructured": "Butterfield LH, Disis ML, Khleif SN, Balwit JM, Marincola FM. Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med. 2010;8:130.", "journal-title": "J Transl Med"}, {"key": "277_CR71", "doi-asserted-by": "crossref", "first-page": "155", "DOI": "10.1186/1479-5876-9-155", "volume": "9", "author": "D Bedognetti", "year": "2011", "unstructured": "Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG, et al. SITC/iSBTc cancer immunotherapy biomarkers resource document: online resources and useful tools\u2014a compass in the land of biomarker discovery. J Transl Med. 2011;9:155.", "journal-title": "J Transl Med"}, {"key": "277_CR72", "doi-asserted-by": "crossref", "first-page": "3", "DOI": "10.1186/s40425-016-0107-3", "volume": "4", "author": "J Yuan", "year": "2016", "unstructured": "Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer. 2016;4:3.", "journal-title": "J Immunother Cancer"}, {"issue": "1", "key": "277_CR73", "doi-asserted-by": "crossref", "first-page": "15", "DOI": "10.1001/jamaoncol.2015.4685", "volume": "2", "author": "AR Hansen", "year": "2016", "unstructured": "Hansen AR, Siu LL. PD-L1 testing in cancer: challenges in companion diagnostic development. JAMA Oncol. 2016;2(1):15\u20136.", "journal-title": "JAMA Oncol"}, {"key": "277_CR74", "author": "MJ Ratcliffe", "year": "2016", "unstructured": "Ratcliffe MJ, Sharpe A, Midha A, Barker C, Scorer P, Walker J. A comparative study of PD-L1 diagnostic assays and the classification of patients at PD-L1 positive and PD-L1 negative [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20. New Orleans, LA Philadelphia (PA): AACR; 2016. Abstract nr LB-094.", "volume-title": "Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20"}, {"key": "277_CR75", "doi-asserted-by": "crossref", "first-page": "88", "DOI": "10.1016/j.critrevonc.2016.02.001", "volume": "100", "author": "S Gandini", "year": "2016", "unstructured": "Gandini S, Massi D, Mandala M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016;100:88\u201398.", "journal-title": "Crit Rev Oncol Hematol"}, {"issue": "3", "key": "277_CR76", "doi-asserted-by": "crossref", "first-page": "449", "DOI": "10.1007/s00262-008-0583-5", "volume": "58", "author": "N Leffers", "year": "2009", "unstructured": "Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 2009;58(3):449\u201359.", "journal-title": "Cancer Immunol Immunother"}, {"issue": "2", "key": "277_CR77", "doi-asserted-by": "crossref", "first-page": "192", "DOI": "10.1016/j.ygyno.2011.09.039", "volume": "124", "author": "WT Hwang", "year": "2012", "unstructured": "Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124(2):192\u20138.", "journal-title": "Gynecol Oncol"}, {"issue": "5", "key": "277_CR78", "doi-asserted-by": "crossref", "first-page": "1070", "DOI": "10.1158/0008-5472.CAN-11-3218", "volume": "72", "author": "G Erdag", "year": "2012", "unstructured": "Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012;72(5):1070\u201380.", "journal-title": "Cancer Res"}, {"key": "277_CR79", "doi-asserted-by": "crossref", "first-page": "47", "DOI": "10.1186/s40425-015-0091-z", "volume": "3", "author": "Z Feng", "year": "2015", "unstructured": "Feng Z, Puri S, Moudgil T, Wood W, Hoyt CC, Wang C, et al. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. J Immunother Cancer. 2015;3:47.", "journal-title": "J Immunother Cancer"}, {"issue": "1", "key": "277_CR80", "doi-asserted-by": "crossref", "first-page": "46", "DOI": "10.1016/j.ymeth.2014.08.016", "volume": "70", "author": "EC Stack", "year": "2014", "unstructured": "Stack EC, Wang C, Roman KA, Hoyt CC. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods. 2014;70(1):46\u201358.", "journal-title": "Methods"}, {"issue": "12", "key": "277_CR81", "first-page": "4404", "volume": "9", "author": "F Ichihara", "year": "2003", "unstructured": "Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003;9(12):4404\u20138.", "journal-title": "Clin Cancer Res"}, {"key": "277_CR82", "unstructured": "Basu S, Campbell HM, Dittel BN, Ray A. Purification of specific cell population by fluorescence activated cell sorting (FACS). J Vis Exp. 2010(41): e1546. doi: 10.3791/1546 .", "DOI": "10.3791/1546", "doi-asserted-by": "crossref"}, {"issue": "6", "key": "277_CR83", "doi-asserted-by": "crossref", "first-page": "601", "DOI": "10.1586/erv.10.49", "volume": "9", "author": "L Zaritskaya", "year": "2010", "unstructured": "Zaritskaya L, Shurin MR, Sayers TJ, Malyguine AM. New flow cytometric assays for monitoring cell-mediated cytotoxicity. Expert Rev Vaccines. 2010;9(6):601\u201316.", "journal-title": "Expert Rev Vaccines"}, {"issue": "51", "key": "277_CR84", "doi-asserted-by": "crossref", "first-page": "20410", "DOI": "10.1073/pnas.0810114105", "volume": "105", "author": "J Yuan", "year": "2008", "unstructured": "Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A. 2008;105(51):20410\u20135.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "277_CR85", "doi-asserted-by": "crossref", "first-page": "108", "DOI": "10.1186/1479-5876-9-108", "volume": "9", "author": "S Attig", "year": "2011", "unstructured": "Attig S, Price L, Janetzki S, Kalos M, Pride M, McNeil L, et al. A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols. J Transl Med. 2011;9:108.", "journal-title": "J Transl Med"}, {"issue": "8", "key": "277_CR86", "doi-asserted-by": "crossref", "first-page": "728", "DOI": "10.1002/cyto.a.22319", "volume": "83", "author": "LK McNeil", "year": "2013", "unstructured": "McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, Odunsi K, et al. A harmonized approach to intracellular cytokine staining gating: results from an international multiconsortia proficiency panel conducted by the cancer immunotherapy consortium (CIC/CRI). Cytometry A. 2013;83(8):728\u201338.", "journal-title": "Cytometry A"}, {"issue": "15", "key": "277_CR87", "doi-asserted-by": "crossref", "first-page": "4250", "DOI": "10.1093/emboj/18.15.4250", "volume": "18", "author": "M Vales-Gomez", "year": "1999", "unstructured": "Vales-Gomez M, Reyburn HT, Erskine RA, Lopez-Botet M, Strominger JL. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J. 1999;18(15):4250\u201360.", "journal-title": "EMBO J"}, {"key": "277_CR88", "doi-asserted-by": "crossref", "first-page": "44", "DOI": "10.1186/s40425-015-0085-x", "volume": "3", "author": "HT Maecker", "year": "2015", "unstructured": "Maecker HT, Harari A. Immune monitoring technology primer: flow and mass cytometry. J Immunother Cancer. 2015;3:44.", "journal-title": "J Immunother Cancer"}, {"issue": "7", "key": "277_CR89", "doi-asserted-by": "crossref", "first-page": "985", "DOI": "10.1097/JTO.0000000000000526", "volume": "10", "author": "KM Kerr", "year": "2015", "unstructured": "Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR, et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol. 2015;10(7):985\u20139.", "journal-title": "J Thorac Oncol"}, {"issue": "11", "key": "277_CR90", "doi-asserted-by": "crossref", "first-page": "5088", "DOI": "10.1073/pnas.0914213107", "volume": "107", "author": "S Gnjatic", "year": "2010", "unstructured": "Gnjatic S, Ritter E, Buchler MW, Giese NA, Brors B, Frei C, et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A. 2010;107(11):5088\u201393.", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "277_CR91", "doi-asserted-by": "crossref", "first-page": "2", "DOI": "10.1186/s40425-016-0106-4", "volume": "4", "author": "J Yuan", "year": "2016", "unstructured": "Yuan J, Wang E, Fox BA. Immune monitoring technology primer: protein microarray (\u2018seromics\u2019). J Immunother Cancer. 2016;4:2.", "journal-title": "J Immunother Cancer"}, {"key": "277_CR92", "author": "Inc. TFS", "year": "2015", "unstructured": "Inc. TFS. General information, technology overview, and applications using the ProtoArray\u00ae Human Protein Microarray. ProtoArray\u00ae Applications Guide. 2015. https://tools.thermofisher.com/content/sfs/manuals/protoarray_applicationsguide_man.pdf .", "volume-title": "General information, technology overview, and applications using the ProtoArray\u00ae Human Protein Microarray. ProtoArray\u00ae Applications Guide"}, {"issue": "7", "key": "277_CR93", "doi-asserted-by": "crossref", "first-page": "1098", "DOI": "10.1038/nprot.2015.068", "volume": "10", "author": "S Janetzki", "year": "2015", "unstructured": "Janetzki S, Price L, Schroeder H, Britten CM, Welters MJ, Hoos A. Guidelines for the automated evaluation of Elispot assays. Nat Protoc. 2015;10(7):1098\u2013115.", "journal-title": "Nat Protoc"}, {"issue": "2", "key": "277_CR94", "doi-asserted-by": "crossref", "first-page": "111", "DOI": "10.3390/cells1020111", "volume": "1", "author": "AM Malyguine", "year": "2012", "unstructured": "Malyguine AM, Strobl S, Dunham K, Shurin MR, Sayers TJ. ELISPOT assay for monitoring cytotoxic T lymphocytes (CTL) activity in cancer vaccine clinical trials. Cells. 2012;1(2):111\u201326.", "journal-title": "Cells"}, {"issue": "3", "key": "277_CR95", "doi-asserted-by": "crossref", "first-page": "303", "DOI": "10.1007/s00262-007-0380-6", "volume": "57", "author": "S Janetzki", "year": "2008", "unstructured": "Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the cancer vaccine consortium (CVC/SVI). Cancer Immunol Immunother. 2008;57(3):303\u201315.", "journal-title": "Cancer Immunol Immunother"}, {"key": "277_CR96", "doi-asserted-by": "crossref", "first-page": "71", "DOI": "10.1007/978-1-62703-727-3_5", "volume": "1102", "author": "LH Butterfield", "year": "2014", "unstructured": "Butterfield LH, Buffo MJ. Immunologic monitoring of cancer vaccine trials using the ELISPOT assay. Methods Mol Biol. 2014;1102:71\u201382.", "journal-title": "Methods Mol Biol"}, {"issue": "1", "key": "277_CR97", "first-page": "171", "volume": "24", "author": "S Gabrielsson", "year": "2004", "unstructured": "Gabrielsson S, Brichard V, Dhellin O, Dorval T, Bonnerot C. IFN-gamma responses in peptide-treated melanoma patients measured by an ELISPOT assay using allogeneic dendritic cells. Anticancer Res. 2004;24(1):171\u20137.", "journal-title": "Anticancer Res"}, {"issue": "6", "key": "277_CR98", "doi-asserted-by": "crossref", "first-page": "932", "DOI": "10.1002/(SICI)1097-0215(19970611)71:6<932::AID-IJC3>3.0.CO;2-Z", "volume": "71", "author": "C Scheibenbogen", "year": "1997", "unstructured": "Scheibenbogen C, Lee KH, Stevanovic S, Witzens M, Willhauck M, Waldmann V, et al. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer. 1997;71(6):932\u20136.", "journal-title": "Int J Cancer"}, {"key": "277_CR99", "doi-asserted-by": "crossref", "first-page": "30", "DOI": "10.1186/s40425-015-0074-0", "volume": "3", "author": "S Janetzki", "year": "2015", "unstructured": "Janetzki S. Immune monitoring technology primer: the enzyme-linked immunospot (Elispot) and fluorospot assay. J Immunother Cancer. 2015;3:30.", "journal-title": "J Immunother Cancer"}, {"issue": "214", "key": "277_CR100", "doi-asserted-by": "crossref", "first-page": "214ra169", "DOI": "10.1126/scitranslmed.3007247", "volume": "5", "author": "HS Robins", "year": "2013", "unstructured": "Robins HS, Ericson NG, Guenthoer J, O'Briant KC, Tewari M, Drescher CW, et al. Digital genomic quantification of tumor-infiltrating lymphocytes. Sci Transl Med. 2013;5(214):214ra169.", "journal-title": "Sci Transl Med"}, {"issue": "238", "key": "277_CR101", "first-page": "238ra270", "volume": "6", "author": "E Cha", "year": "2014", "unstructured": "Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med. 2014;6(238):238ra270.", "journal-title": "Sci Transl Med"}, {"issue": "6230", "key": "277_CR102", "doi-asserted-by": "crossref", "first-page": "69", "DOI": "10.1126/science.aaa4971", "volume": "348", "author": "TN Schumacher", "year": "2015", "unstructured": "Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69\u201374.", "journal-title": "Science"}, {"issue": "9", "key": "277_CR103", "doi-asserted-by": "crossref", "first-page": "3413", "DOI": "10.1172/JCI80008", "volume": "125", "author": "MM Gubin", "year": "2015", "unstructured": "Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015;125(9):3413\u201321.", "journal-title": "J Clin Invest"}, {"issue": "23", "key": "277_CR104", "doi-asserted-by": "crossref", "first-page": "2189", "DOI": "10.1056/NEJMoa1406498", "volume": "371", "author": "A Snyder", "year": "2014", "unstructured": "Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189\u201399.", "journal-title": "N Engl J Med"}, {"issue": "6230", "key": "277_CR105", "doi-asserted-by": "crossref", "first-page": "124", "DOI": "10.1126/science.aaa1348", "volume": "348", "author": "NA Rizvi", "year": "2015", "unstructured": "Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124\u20138.", "journal-title": "Science"}, {"issue": "1", "key": "277_CR106", "doi-asserted-by": "crossref", "first-page": "35", "DOI": "10.1016/j.cell.2016.02.065", "volume": "165", "author": "W Hugo", "year": "2016", "unstructured": "Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35\u201344.", "journal-title": "Cell"}, {"key": "277_CR107", "unstructured": "Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol. 2016. doi: 10.1200/JCO.2016.66.6552 .", "DOI": "10.1200/JCO.2016.66.6552", "doi-asserted-by": "crossref"}, {"issue": "2", "key": "277_CR108", "doi-asserted-by": "crossref", "first-page": "219", "DOI": "10.1016/j.ajhg.2008.07.006", "volume": "83", "author": "S Hoffmann", "year": "2008", "unstructured": "Hoffmann S, Cepok S, Grummel V, Lehmann-Horn K, Hackermuller J, Stadler PF, et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet. 2008;83(2):219\u201327.", "journal-title": "Am J Hum Genet"}, {"issue": "7359", "key": "277_CR109", "doi-asserted-by": "crossref", "first-page": "214", "DOI": "10.1038/nature10251", "volume": "476", "author": "C International Multiple Sclerosis Ge", "year": "2011", "unstructured": "International Multiple Sclerosis Genetics C, Wellcome Trust Case Control C, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214\u20139.", "journal-title": "Nature"}, {"issue": "15", "key": "277_CR110", "doi-asserted-by": "crossref", "first-page": "5094", "DOI": "10.1158/1078-0432.CCR-04-0428", "volume": "10", "author": "J Konishi", "year": "2004", "unstructured": "Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10(15):5094\u2013100.", "journal-title": "Clin Cancer Res"}, {"issue": "3", "key": "277_CR111", "doi-asserted-by": "crossref", "first-page": "147", "DOI": "10.1016/S1001-9294(13)60040-1", "volume": "28", "author": "YY Chen", "year": "2013", "unstructured": "Chen YY, Wang LB, Zhu HL, Li XY, Zhu YP, Yin YL, et al. Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients. Chin Med Sci J. 2013;28(3):147\u201351.", "journal-title": "Chin Med Sci J"}, {"issue": "9", "key": "277_CR112", "doi-asserted-by": "crossref", "first-page": "1980", "DOI": "10.1093/annonc/mdv255", "volume": "26", "author": "D Massi", "year": "2015", "unstructured": "Massi D, Brusa D, Merelli B, Falcone C, Xue G, Carobbio A, et al. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. Ann Oncol. 2015;26(9):1980\u20137.", "journal-title": "Ann Oncol"}, {"issue": "19", "key": "277_CR113", "doi-asserted-by": "crossref", "first-page": "5064", "DOI": "10.1158/1078-0432.CCR-13-3271", "volume": "20", "author": "JM Taube", "year": "2014", "unstructured": "Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064\u201374.", "journal-title": "Clin Cancer Res"}, {"issue": "26", "key": "277_CR114", "doi-asserted-by": "crossref", "first-page": "2509", "DOI": "10.1056/NEJMoa1500596", "volume": "372", "author": "DT Le", "year": "2015", "unstructured": "Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320.", "journal-title": "N Engl J Med"}, {"issue": "6266", "key": "277_CR115", "doi-asserted-by": "crossref", "first-page": "1387", "DOI": "10.1126/science.aad1253", "volume": "350", "author": "E Tran", "year": "2015", "unstructured": "Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350(6266):1387\u201390.", "journal-title": "Science"}, {"issue": "1", "key": "277_CR116", "doi-asserted-by": "crossref", "first-page": "124", "DOI": "10.1186/s13045-015-0222-5", "volume": "8", "author": "AY Lin", "year": "2015", "unstructured": "Lin AY, Lin E. Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors? J Hematol Oncol. 2015;8(1):124.", "journal-title": "J Hematol Oncol"}, {"issue": "6", "key": "277_CR117", "doi-asserted-by": "crossref", "first-page": "747", "DOI": "10.1038/nm.3161", "volume": "19", "author": "PF Robbins", "year": "2013", "unstructured": "Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747\u201352.", "journal-title": "Nat Med"}, {"issue": "4", "key": "277_CR118", "doi-asserted-by": "crossref", "first-page": "433", "DOI": "10.1038/nm.4051", "volume": "22", "author": "A Gros", "year": "2016", "unstructured": "Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016;22(4):433\u20138.", "journal-title": "Nat Med"}, {"issue": "1", "key": "277_CR119", "doi-asserted-by": "crossref", "first-page": "107", "DOI": "10.1038/labinvest.2013.130", "volume": "94", "author": "V Velcheti", "year": "2014", "unstructured": "Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014;94(1):107\u201316.", "journal-title": "Lab Invest"}, {"issue": "8", "key": "277_CR120", "doi-asserted-by": "crossref", "first-page": "1537", "DOI": "10.1182/blood-2008-12-195792", "volume": "114", "author": "M Ahmadzadeh", "year": "2009", "unstructured": "Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537\u201344.", "journal-title": "Blood"}, {"issue": "7528", "key": "277_CR121", "doi-asserted-by": "crossref", "first-page": "568", "DOI": "10.1038/nature13954", "volume": "515", "author": "PC Tumeh", "year": "2014", "unstructured": "Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.", "journal-title": "Nature"}, {"issue": "24", "key": "277_CR122", "doi-asserted-by": "crossref", "first-page": "4932", "DOI": "10.1093/hmg/ddr431", "volume": "20", "author": "S Yung", "year": "2011", "unstructured": "Yung S, Ledran M, Moreno-Gimeno I, Conesa A, Montaner D, Dopazo J, et al. Large-scale transcriptional profiling and functional assays reveal important roles for Rho-GTPase signalling and SCL during haematopoietic differentiation of human embryonic stem cells. Hum Mol Genet. 2011;20(24):4932\u201346.", "journal-title": "Hum Mol Genet"}, {"issue": "2", "key": "277_CR123", "doi-asserted-by": "crossref", "first-page": "199", "DOI": "10.1002/path.4287", "volume": "232", "author": "J Galon", "year": "2014", "unstructured": "Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Towards the introduction of the \u2018Immunoscore\u2019 in the classification of malignant tumours. J Pathol. 2014;232(2):199\u2013209.", "journal-title": "J Pathol"}, {"issue": "8", "key": "277_CR124", "doi-asserted-by": "crossref", "first-page": "2946", "DOI": "10.1073/pnas.1222738110", "volume": "110", "author": "T Shay", "year": "2013", "unstructured": "Shay T, Jojic V, Zuk O, Rothamel K, Puyraimond-Zemmour D, Feng T, et al. Conservation and divergence in the transcriptional programs of the human and mouse immune systems. Proc Natl Acad Sci U S A. 2013;110(8):2946\u201351.", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "2", "key": "277_CR125", "doi-asserted-by": "crossref", "first-page": "123", "DOI": "10.1056/NEJMoa1504627", "volume": "373", "author": "J Brahmer", "year": "2015", "unstructured": "Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123\u201335.", "journal-title": "N Engl J Med"}, {"issue": "17", "key": "277_CR126", "doi-asserted-by": "crossref", "first-page": "1627", "DOI": "10.1056/NEJMoa1507643", "volume": "373", "author": "H Borghaei", "year": "2015", "unstructured": "Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627\u201339.", "journal-title": "N Engl J Med"}, {"issue": "19", "key": "277_CR127", "doi-asserted-by": "crossref", "first-page": "1803", "DOI": "10.1056/NEJMoa1510665", "volume": "373", "author": "RJ Motzer", "year": "2015", "unstructured": "Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.", "journal-title": "N Engl J Med"}, {"issue": "4", "key": "277_CR128", "doi-asserted-by": "crossref", "first-page": "375", "DOI": "10.1016/S1470-2045(15)70076-8", "volume": "16", "author": "JS Weber", "year": "2015", "unstructured": "Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375\u201384.", "journal-title": "Lancet Oncol"}, {"issue": "4", "key": "277_CR129", "doi-asserted-by": "crossref", "first-page": "320", "DOI": "10.1056/NEJMoa1412082", "volume": "372", "author": "C Robert", "year": "2015", "unstructured": "Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.", "journal-title": "N Engl J Med"}, {"issue": "1", "key": "277_CR130", "doi-asserted-by": "crossref", "first-page": "23", "DOI": "10.1056/NEJMoa1504030", "volume": "373", "author": "J Larkin", "year": "2015", "unstructured": "Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.", "journal-title": "N Engl J Med"}, {"issue": "3", "key": "277_CR131", "doi-asserted-by": "crossref", "first-page": "257", "DOI": "10.1016/S1470-2045(15)70054-9", "volume": "16", "author": "NA Rizvi", "year": "2015", "unstructured": "Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257\u201365.", "journal-title": "Lancet Oncol"}, {"issue": "18", "key": "277_CR132", "doi-asserted-by": "crossref", "first-page": "2013", "DOI": "10.1200/JCO.2014.58.1041", "volume": "33", "author": "DF McDermott", "year": "2015", "unstructured": "McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015;33(18):2013\u201320.", "journal-title": "J Clin Oncol"}, {"issue": "18", "key": "277_CR133", "doi-asserted-by": "crossref", "first-page": "2004", "DOI": "10.1200/JCO.2014.58.3708", "volume": "33", "author": "SN Gettinger", "year": "2015", "unstructured": "Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004\u201312.", "journal-title": "J Clin Oncol"}, {"issue": "26", "key": "277_CR134", "doi-asserted-by": "crossref", "first-page": "2521", "DOI": "10.1056/NEJMoa1503093", "volume": "372", "author": "C Robert", "year": "2015", "unstructured": "Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332.", "journal-title": "N Engl J Med"}, {"issue": "8", "key": "277_CR135", "doi-asserted-by": "crossref", "first-page": "908", "DOI": "10.1016/S1470-2045(15)00083-2", "volume": "16", "author": "A Ribas", "year": "2015", "unstructured": "Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908\u201318.", "journal-title": "Lancet Oncol"}, {"issue": "15_suppl", "key": "277_CR136", "first-page": "9005", "volume": "33", "author": "A Daud", "year": "2015", "unstructured": "Daud A, Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. ASCO Meeting Abstr. 2015;33(15_suppl):9005.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "15", "key": "277_CR137", "doi-asserted-by": "crossref", "first-page": "1600", "DOI": "10.1001/jama.2016.4059", "volume": "315", "author": "A Ribas", "year": "2016", "unstructured": "Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315(15):1600\u20139.", "journal-title": "JAMA"}, {"issue": "9948", "key": "277_CR138", "doi-asserted-by": "crossref", "first-page": "1109", "DOI": "10.1016/S0140-6736(14)60958-2", "volume": "384", "author": "C Robert", "year": "2014", "unstructured": "Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109\u201317.", "journal-title": "Lancet"}, {"issue": "9 Supplement", "key": "277_CR139", "doi-asserted-by": "crossref", "first-page": "S1", "DOI": "10.1158/1538-7445.SABCS14-S1-09", "volume": "75", "author": "R Nanda", "year": "2015", "unstructured": "Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Abstract S1-09: a phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Res. 2015;75(9 Supplement):S1\u201309.", "journal-title": "Cancer Res"}, {"issue": "10027", "key": "277_CR140", "doi-asserted-by": "crossref", "first-page": "1540", "DOI": "10.1016/S0140-6736(15)01281-7", "volume": "387", "author": "RS Herbst", "year": "2015", "unstructured": "Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015;387(10027):1540\u201350.", "journal-title": "Lancet"}, {"key": "277_CR141", "unstructured": "Moskowitz C, Ribrag V, Michot J-M, Martinelli G, Zinzani PL, Gutierrez M, et al. PD-1 Blockade with the monoclonal antibody Pembrolizumab (M-3475) in patients with classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary results from a phase 1b study [abstract]. Blood. 2014;124:290. abstract."}, {"issue": "15_suppl", "key": "277_CR142", "first-page": "8028", "volume": "33", "author": "DR Spigel", "year": "2015", "unstructured": "Spigel DR, Chaft JE, Gettinger SN, Chao BH, Dirix LY, Schmid P, et al. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC). ASCO Meeting Abstr. 2015;33(15_suppl):8028.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "15_suppl", "key": "277_CR143", "first-page": "8010", "volume": "33", "author": "AI Spira", "year": "2015", "unstructured": "Spira AI, Park K, Mazieres J, Vansteenkiste JF, Rittmeyer A, Ballinger M, et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). ASCO Meeting Abstr. 2015;33(15_suppl):8010.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "15_suppl", "key": "277_CR144", "first-page": "9010", "volume": "31", "author": "O Hamid", "year": "2013", "unstructured": "Hamid O, Sosman JA, Lawrence DP, Sullivan RJ, Ibrahim N, Kluger HM, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). ASCO Meeting Abstr. 2013;31(15_suppl):9010.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "7528", "key": "277_CR145", "doi-asserted-by": "crossref", "first-page": "563", "DOI": "10.1038/nature14011", "volume": "515", "author": "RS Herbst", "year": "2014", "unstructured": "Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563\u20137.", "journal-title": "Nature"}, {"issue": "15_suppl", "key": "277_CR146", "first-page": "8030", "volume": "33", "author": "SV Liu", "year": "2015", "unstructured": "Liu SV, Powderly JD, Camidge DR, Ready N, Heist RS, Hodi FS, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstr. 2015;33(15_suppl):8030.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "3_suppl", "key": "277_CR147", "first-page": "704", "volume": "33", "author": "JC Bendell", "year": "2015", "unstructured": "Bendell JC, Powderly JD, Lieu CH, Eckhardt SG, Hurwitz H, Hochster HS, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). ASCO Meeting Abstr. 2015;33(3_suppl):704.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "7_suppl", "key": "277_CR148", "first-page": "410", "volume": "33", "author": "M Sznol", "year": "2015", "unstructured": "Sznol M, McDermott DF, Jones SF, Mier JW, Waterkamp D, Rossi C, et al. Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstr. 2015;33(7_suppl):410.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "15_suppl", "key": "277_CR149", "first-page": "8032", "volume": "33", "author": "NA Rizvi", "year": "2015", "unstructured": "Rizvi NA, Brahmer JR, Ou S-HI, Segal NH, Khleif S, Hwu W-J, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). ASCO Meeting Abstr. 2015;33(15_suppl):8032.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "15_suppl", "key": "277_CR150", "first-page": "8021", "volume": "32", "author": "JR Brahmer", "year": "2014", "unstructured": "Brahmer JR, Rizvi NA, Lutzky J, Khleif S, Blake-Haskins A, Li X, et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. ASCO Meeting Abstr. 2014;32(15_suppl):8021.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "15_suppl", "key": "277_CR151", "first-page": "3011", "volume": "33", "author": "NH Segal", "year": "2015", "unstructured": "Segal NH, Ou S-HI, Balmanoukian AS, Fury MG, Massarelli E, Brahmer JR, et al. Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. ASCO Meeting Abstr. 2015;33(15_suppl):3011.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "15_suppl", "key": "277_CR152", "first-page": "3001", "volume": "32", "author": "J Lutzky", "year": "2014", "unstructured": "Lutzky J, Antonia SJ, Blake-Haskins A, Li X, Robbins PB, Shalabi AM, et al. A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors. ASCO Meeting Abstr. 2014;32(15_suppl):3001.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "15_suppl", "key": "277_CR153", "first-page": "3047", "volume": "33", "author": "BC Creelan", "year": "2015", "unstructured": "Creelan BC, Chow LQ, Kim D-W, Kim S-W, Yeh T, Karakunnel JJ, et al. Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC). ASCO Meeting Abstr. 2015;33(15_suppl):3047.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "15_suppl", "key": "277_CR154", "first-page": "3014", "volume": "33", "author": "SJ Antonia", "year": "2015", "unstructured": "Antonia SJ, Goldberg SB, Balmanoukian AS, Sanborn RE, Steele K, Narwal R, et al. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. ASCO Meeting Abstr. 2015;33(15_suppl):3014.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "3", "key": "277_CR155", "doi-asserted-by": "crossref", "first-page": "299", "DOI": "10.1016/S1470-2045(15)00544-6", "volume": "17", "author": "S Antonia", "year": "2016", "unstructured": "Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17(3):299\u2013308.", "journal-title": "Lancet Oncol"}, {"issue": "18_suppl", "key": "277_CR156", "first-page": "LBA109", "volume": "33", "author": "L Paz-Ares", "year": "2015", "unstructured": "Paz-Ares L, Horn L, Borghaei H, Spigel DR, Steins M, Ready N, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). ASCO Meeting Abstr. 2015;33(18_suppl):LBA109.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "15_suppl", "key": "277_CR157", "first-page": "8025", "volume": "33", "author": "SN Gettinger", "year": "2015", "unstructured": "Gettinger SN, Hellmann MD, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQM, et al. First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. ASCO Meeting Abstr. 2015;33(15_suppl):8025.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "15_suppl", "key": "277_CR158", "first-page": "8023", "volume": "32", "author": "SJ Antonia", "year": "2014", "unstructured": "Antonia SJ, Gettinger SN, Chow LQM, Juergens RA, Borghaei H, Shen Y, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. ASCO Meeting Abstr. 2014;32(15_suppl):8023.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "15_suppl", "key": "277_CR159", "first-page": "8026", "volume": "33", "author": "NA Rizvi", "year": "2015", "unstructured": "Rizvi NA, Garon EB, Leighl N, Hellmann MD, Patnaik A, Gandhi L, et al. Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001. ASCO Meeting Abstr. 2015;33(15_suppl):8026.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "suppl 4", "key": "277_CR160", "first-page": "LBA43", "volume": "25", "author": "EB Garon", "year": "2014", "unstructured": "Garon EB, Gandhi L, Rizvi N, Hui R, Balmanoukian AS, Patnaik A, et al. Antitumor activity of pembrolizumab (pembro; mk-3475) and correlation with programmed death ligand 1 (pd-l1) expression in a pooled analysis of patients (pts) with advanced non\u2013small cell lung carcinoma (NSCLC). Ann Oncol. 2014;25 suppl 4:LBA43.", "journal-title": "Ann Oncol"}, {"issue": "15_suppl", "key": "277_CR161", "first-page": "8020", "volume": "32", "author": "EB Garon", "year": "2014", "unstructured": "Garon EB, Leighl NB, Rizvi NA, Blumenschein GR, Balmanoukian AS, Eder JP, et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). ASCO Meeting Abstr. 2014;32(15_suppl):8020.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "15_suppl", "key": "277_CR162", "first-page": "8029", "volume": "33", "author": "L Horn", "year": "2015", "unstructured": "Horn L, Spigel DR, Gettinger SN, Antonia SJ, Gordon MS, Herbst RS, et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. ASCO Meeting Abstr. 2015;33(15_suppl):8029.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "15_suppl", "key": "277_CR163", "first-page": "3002", "volume": "32", "author": "NH Segal", "year": "2014", "unstructured": "Segal NH, Antonia SJ, Brahmer JR, Maio M, Blake-Haskins A, Li X, et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. ASCO Meeting Abstr. 2014;32(15_suppl):3002.", "journal-title": "ASCO Meeting Abstr"}, {"issue": "1-2", "key": "277_CR164", "doi-asserted-by": "crossref", "first-page": "32", "DOI": "10.1016/j.jim.2007.01.012", "volume": "321", "author": "PM Loughlin", "year": "2007", "unstructured": "Loughlin PM, Cooke TG, George WD, Gray AJ, Stott DI, Going JJ. Quantifying tumour-infiltrating lymphocyte subsets: a practical immuno-histochemical method. J Immunol Methods. 2007;321(1-2):32\u201340.", "journal-title": "J Immunol Methods"}, {"issue": "4", "key": "277_CR165", "doi-asserted-by": "crossref", "first-page": "385", "DOI": "10.1038/labinvest.2014.157", "volume": "95", "author": "DE Carvajal-Hausdorf", "year": "2015", "unstructured": "Carvajal-Hausdorf DE, Schalper KA, Neumeister VM, Rimm DL. Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic. Lab Invest. 2015;95(4):385\u201396.", "journal-title": "Lab Invest"}, {"issue": "1", "key": "277_CR166", "doi-asserted-by": "crossref", "first-page": "29", "DOI": "10.1186/s13045-016-0259-0", "volume": "9", "author": "KH Chen", "year": "2016", "unstructured": "Chen KH, Yuan CT, Tseng LH, Shun CT, Yeh KH. Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance. J Hematol Oncol. 2016;9(1):29.", "journal-title": "J Hematol Oncol"}, {"issue": "3", "key": "277_CR167", "doi-asserted-by": "crossref", "first-page": "328", "DOI": "10.1097/01.cji.0000203079.35612.c8", "volume": "29", "author": "K Shafer-Weaver", "year": "2006", "unstructured": "Shafer-Weaver K, Rosenberg S, Strobl S, Gregory Alvord W, Baseler M, Malyguine A. Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials. J Immunother. 2006;29(3):328\u201335.", "journal-title": "J Immunother"}, {"issue": "9_suppl 2", "key": "277_CR168", "first-page": "S266", "volume": "10", "author": "L Barrera", "year": "2015", "unstructured": "Barrera L, Rodriguez OA, Morales-Flores R, Garcia-Vicente A, Serv\u00edn EM, Salinas-Parra F, et al. MINI 02.03 over expression of CD47, decrease of apoptosis and phagocytosis of neutrophils in advanced non-small cell lung cancer patients. J Thoracic Oncol. 2015;10(9_suppl 2):S266.", "journal-title": "J Thoracic Oncol"}, {"issue": "1", "key": "277_CR169", "doi-asserted-by": "crossref", "first-page": "17", "DOI": "10.1186/2047-1440-2-17", "volume": "2", "author": "M Streitz", "year": "2013", "unstructured": "Streitz M, Miloud T, Kapinsky M, Reed MR, Magari R, Geissler EK, et al. Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res. 2013;2(1):17.", "journal-title": "Transplant Res"}, {"issue": "9", "key": "277_CR170", "doi-asserted-by": "crossref", "first-page": "1908", "DOI": "10.1038/leu.2012.120", "volume": "26", "author": "JJ Dongen van", "year": "2012", "unstructured": "van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908\u201375.", "journal-title": "Leukemia"}, {"issue": "1", "key": "277_CR171", "doi-asserted-by": "crossref", "first-page": "e78644", "DOI": "10.1371/journal.pone.0078644", "volume": "9", "author": "S Zhao", "year": "2014", "unstructured": "Zhao S, Fung-Leung WP, Bittner A, Ngo K, Liu X. Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells. PLoS One. 2014;9(1):e78644.", "journal-title": "PLoS One"}, {"key": "277_CR172", "doi-asserted-by": "crossref", "first-page": "60", "DOI": "10.1186/1479-5876-6-60", "volume": "6", "author": "US Kammula", "year": "2008", "unstructured": "Kammula US, Serrano OK. Use of high throughput qPCR screening to rapidly clone low frequency tumour specific T-cells from peripheral blood for adoptive immunotherapy. J Transl Med. 2008;6:60.", "journal-title": "J Transl Med"}, {"issue": "9_suppl 2", "key": "277_CR173", "first-page": "S266", "volume": "10", "author": "SH Lin", "year": "2015", "unstructured": "Lin SH, He J, Edelman M, Xu T, Gao H, Reuben J, et al. MINI 02.04 sequential assessment of DNA damage response and PD-L1 expression in circulating cells of lung cancer patients during treatment with radiotherapy. J Thoracic Oncol. 2015;10(9_suppl 2):S266\u20137.", "journal-title": "J Thoracic Oncol"}, {"issue": "9", "key": "277_CR174", "doi-asserted-by": "crossref", "first-page": "3514", "DOI": "10.1073/pnas.1320198111", "volume": "111", "author": "DL Adams", "year": "2014", "unstructured": "Adams DL, Martin SS, Alpaugh RK, Charpentier M, Tsai S, Bergan RC, et al. Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A. 2014;111(9):3514\u20139.", "journal-title": "Proc Natl Acad Sci U S A"}], "container-title": ["Journal of Hematology & Oncology"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1186/s13045-016-0277-y", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 24]], "date-time": "2017-06-24T15:12:53Z", "timestamp": 1498317173000}, "score": 25.691463, "issued": {"date-parts": [[2016, 5, 27]]}, "references-count": 174, "journal-issue": {"published-print": {"date-parts": [[2016, 12]]}, "issue": "1"}, "alternative-id": ["277"], "URL": "http://dx.doi.org/10.1186/s13045-016-0277-y", "relation": {"cites": []}, "ISSN": ["1756-8722"], "issn-type": [{"value": "1756-8722", "type": "electronic"}], "article-number": "47"}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T21:40:53Z", "timestamp": 1575236453427}, "reference-count": 29, "publisher": "Springer Science and Business Media LLC", "issue": "2", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2018, 1, 30]], "date-time": "2018-01-30T00:00:00Z", "timestamp": 1517270400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Curr Radiol Rep"], "published-print": {"date-parts": [[2018, 2]]}, "DOI": "10.1007/s40134-018-0269-5", "type": "journal-article", "created": {"date-parts": [[2018, 1, 30]], "date-time": "2018-01-30T11:14:01Z", "timestamp": 1517310841000}, "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Thoracic Imaging of Solid Tumor Patients Treated with Immune Checkpoint Inhibitors"], "prefix": "10.1007", "volume": "6", "author": [{"given": "Mark M.", "family": "Hammer", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2018, 1, 30]]}, "reference": [{"key": "269_CR1", "doi-asserted-by": "publisher", "first-page": "177", "DOI": "10.1016/S0190-9622(99)70185-4", "volume": "40", "author": "P Jensen", "year": "1999", "unstructured": "Jensen P, Hansen S, M\u00f8ller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177\u201386.", "journal-title": "J Am Acad Dermatol"}, {"key": "269_CR2", "doi-asserted-by": "publisher", "first-page": "568", "DOI": "10.1038/nature13954", "volume": "515", "author": "PC Tumeh", "year": "2014", "unstructured": "Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568\u201371.", "journal-title": "Nature"}, {"key": "269_CR3", "doi-asserted-by": "publisher", "first-page": "539", "DOI": "10.1146/annurev-immunol-032414-112049", "volume": "34", "author": "SH Baumeister", "year": "2016", "unstructured": "Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 2016;34:539\u201373.", "journal-title": "Annu Rev Immunol"}, {"key": "269_CR4", "doi-asserted-by": "publisher", "first-page": "711", "DOI": "10.1056/NEJMoa1003466", "volume": "363", "author": "FS Hodi", "year": "2010", "unstructured": "Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.", "journal-title": "N Engl J Med"}, {"key": "269_CR5", "doi-asserted-by": "publisher", "first-page": "989", "DOI": "10.1016/j.immuni.2016.05.001", "volume": "44", "author": "AC Anderson", "year": "2016", "unstructured": "Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44:989\u20131004.", "journal-title": "Immunity"}, {"key": "269_CR6", "doi-asserted-by": "publisher", "first-page": "1388", "DOI": "10.1093/jnci/djq310", "volume": "102", "author": "A Hoos", "year": "2010", "unstructured": "Hoos A, Eggermont AMM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102:1388\u201397.", "journal-title": "J Natl Cancer Inst"}, {"key": "269_CR7", "doi-asserted-by": "publisher", "first-page": "1889", "DOI": "10.1200/JCO.2014.56.2736", "volume": "33", "author": "D Schadendorf", "year": "2015", "unstructured": "Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889\u201394.", "journal-title": "J Clin Oncol"}, {"key": "269_CR8", "doi-asserted-by": "publisher", "first-page": "1627", "DOI": "10.1056/NEJMoa1507643", "volume": "373", "author": "H Borghaei", "year": "2015", "unstructured": "Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339.", "journal-title": "N Engl J Med"}, {"key": "269_CR9", "doi-asserted-by": "publisher", "first-page": "123", "DOI": "10.1056/NEJMoa1504627", "volume": "373", "author": "J Brahmer", "year": "2015", "unstructured": "Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123\u201335.", "journal-title": "N Engl J Med"}, {"key": "269_CR10", "doi-asserted-by": "publisher", "first-page": "2018", "DOI": "10.1056/NEJMoa1501824", "volume": "372", "author": "EB Garon", "year": "2015", "unstructured": "Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018\u201328.", "journal-title": "N Engl J Med"}, {"key": "269_CR11", "doi-asserted-by": "publisher", "first-page": "12", "DOI": "10.1186/s40364-017-0093-8", "volume": "5", "author": "LP Diggs", "year": "2017", "unstructured": "Diggs LP, Hsueh EC. Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomark Res. 2017;5:12.", "journal-title": "Biomark Res"}, {"key": "269_CR12", "doi-asserted-by": "publisher", "first-page": "7412", "DOI": "10.1158/1078-0432.CCR-09-1624", "volume": "15", "author": "JD Wolchok", "year": "2009", "unstructured": "Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412\u201320.", "journal-title": "Clin Cancer Res"}, {"key": "269_CR13", "first-page": "2375", "volume": "26", "author": "J Naidoo", "year": "2015", "unstructured": "Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375\u201391.", "journal-title": "Ann Oncol"}, {"key": "269_CR14", "doi-asserted-by": "publisher", "first-page": "567", "DOI": "10.2214/AJR.16.17770", "volume": "209", "author": "GX Wang", "year": "2017", "unstructured": "Wang GX, Guo LQ, Gainor JF, Fintelmann FJ. Immune checkpoint inhibitors in lung cancer: imaging considerations. Am J Roentgenol. 2017;209:567\u201375.", "journal-title": "Am J Roentgenol"}, {"key": "269_CR15", "unstructured": "\u2022\u2022 Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. RadioGraphics. 2015;35:424\u201337. This article provides a nice imaging-based overview of how to evaluate patients being treated with immune checkpoint inhibitors. It shows examples of pseudoprogression, sarcoid-like reaction, and pneumonitis, as well as many extrathoracic immune-related adverse events.", "DOI": "10.1148/rg.352140121", "doi-asserted-by": "crossref"}, {"key": "269_CR16", "doi-asserted-by": "publisher", "first-page": "228", "DOI": "10.1016/j.ejca.2008.10.026", "volume": "45", "author": "EA Eisenhauer", "year": "2009", "unstructured": "Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.", "journal-title": "Eur J Cancer"}, {"key": "269_CR17", "doi-asserted-by": "publisher", "first-page": "17", "DOI": "10.1186/2051-1426-2-17", "volume": "2", "author": "M Nishino", "year": "2014", "unstructured": "Nishino M, Gargano M, Suda M, Ramaiya NH, Hodi FS. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer. 2014;2:17.", "journal-title": "J Immunother Cancer"}, {"key": "269_CR18", "unstructured": "\u2022 Hodi FS, Hwu W-J, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;JCO640391. This article shows the importance of using the immune-related response criteria instead of standard RECIST, as the latter would overestimate progression.", "DOI": "10.1200/JCO.2015.64.0391", "doi-asserted-by": "crossref"}, {"key": "269_CR19", "doi-asserted-by": "publisher", "first-page": "48", "DOI": "10.1007/s40134-016-0178-4", "volume": "4", "author": "J Henze", "year": "2016", "unstructured": "Henze J, Maintz D, Persigehl T. RECIST 1.1, irRECIST 1.1, and mRECIST: how to do. Curr Radiol Rep. 2016;4:48.", "journal-title": "Curr Radiol Rep"}, {"key": "269_CR20", "unstructured": "\u2022\u2022 Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K. Response Criteria in oncologic imaging: review of traditional and new criteria. RadioGraphics. 2013;33:1323\u201341. This article provides an excellent overview of a number of different tumor response criteria, including RECIST 1.1 and irRC.", "DOI": "10.1148/rg.335125214", "doi-asserted-by": "crossref"}, {"key": "269_CR21", "doi-asserted-by": "publisher", "first-page": "675", "DOI": "10.1016/j.crad.2009.03.005", "volume": "64", "author": "FU Chowdhury", "year": "2009", "unstructured": "Chowdhury FU, Sheerin F, Bradley KM, Gleeson FV. Sarcoid-like reaction to malignancy on whole-body integrated 18F-FDG PET/CT: prevalence and disease pattern. Clin Radiol. 2009;64:675\u201381.", "journal-title": "Clin Radiol"}, {"key": "269_CR22", "doi-asserted-by": "publisher", "first-page": "113", "DOI": "10.1186/2193-1801-2-113", "volume": "2", "author": "K Inoue", "year": "2013", "unstructured": "Inoue K, Goto R, Shimomura H, Fukuda H. FDG-PET/CT of sarcoidosis and sarcoid reactions following antineoplastic treatment. SpringerPlus. 2013;2:113.", "journal-title": "SpringerPlus"}, {"key": "269_CR23", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1016/j.critrevonc.2017.09.002", "volume": "119", "author": "BE Osta", "year": "2017", "unstructured": "Osta BE, Hu F, Sadek R, Chintalapally R, Tang S-C. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017;119:1\u201312.", "journal-title": "Crit Rev Oncol Hematol"}, {"key": "269_CR24", "doi-asserted-by": "publisher", "first-page": "4431", "DOI": "10.1210/jc.2016-2300", "volume": "101", "author": "J Filette de", "year": "2016", "unstructured": "de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, et al. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab. 2016;101:4431\u20139.", "journal-title": "J Clin Endocrinol Metab"}, {"key": "269_CR25", "doi-asserted-by": "publisher", "first-page": "2092", "DOI": "10.1200/JCO.2014.60.0379", "volume": "33", "author": "JS Weber", "year": "2015", "unstructured": "Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33:2092\u20139.", "journal-title": "J Clin Oncol"}, {"key": "269_CR26", "doi-asserted-by": "publisher", "first-page": "50", "DOI": "10.1186/s40425-016-0152-y", "volume": "4", "author": "L Heinzerling", "year": "2016", "unstructured": "Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50.", "journal-title": "J Immunother Cancer"}, {"key": "269_CR27", "doi-asserted-by": "publisher", "first-page": "1749", "DOI": "10.1056/NEJMoa1609214", "volume": "375", "author": "DB Johnson", "year": "2016", "unstructured": "Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749\u201355.", "journal-title": "N Engl J Med"}, {"key": "269_CR28", "doi-asserted-by": "publisher", "first-page": "231", "DOI": "10.1177/1078155216635853", "volume": "23", "author": "CA Dasanu", "year": "2017", "unstructured": "Dasanu CA, Jen T, Skulski R. Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma. J Oncol Pharm Pract. 2017;23:231\u20134.", "journal-title": "J Oncol Pharm Pract"}, {"key": "269_CR29", "unstructured": "Yun S, Vincelette ND, Mansour I, Hariri D, Motamed S. Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep Oncol Med. 2015. https://www.hindawi.com/journals/crionm/2015/794842/ . Accessed from 20 Sept 2017.", "DOI": "10.1155/2015/794842", "doi-asserted-by": "crossref"}], "container-title": ["Current Radiology Reports"], "language": "en", "link": [{"URL": "http://link.springer.com/article/10.1007/s40134-018-0269-5/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s40134-018-0269-5.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s40134-018-0269-5.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 10, 9]], "date-time": "2019-10-09T23:41:35Z", "timestamp": 1570664495000}, "score": 25.504438, "issued": {"date-parts": [[2018, 1, 30]]}, "references-count": 29, "journal-issue": {"published-print": {"date-parts": [[2018, 2]]}, "issue": "2"}, "alternative-id": ["269"], "URL": "http://dx.doi.org/10.1007/s40134-018-0269-5", "relation": {"cites": []}, "ISSN": ["2167-4825"], "issn-type": [{"value": "2167-4825", "type": "electronic"}], "assertion": [{"value": "30 January 2018", "order": 1, "name": "first_online", "label": "First Online", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"order": 1, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Compliance with Ethical Guidelines"}}, {"value": "Mark M. Hammer declares no potential conflicts of interest.", "order": 2, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Conflict of interest"}}, {"value": "This article does not contain any studies with human or animal subjects performed by any of the authors.", "order": 3, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Human and Animal Rights and Informed Consent"}}], "article-number": "8"}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T20:29:33Z", "timestamp": 1575232173206}, "reference-count": 0, "publisher": "AME Publishing Company", "content-domain": {"domain": ["amegroups.com"], "crossmark-restriction": false}, "short-container-title": ["Ann Lymphoma"], "DOI": "10.21037/aol.2017.10.03", "type": "journal-article", "created": {"date-parts": [[2018, 1, 23]], "date-time": "2018-01-23T02:49:06Z", "timestamp": 1516675746000}, "page": "1-1", "update-policy": "http://dx.doi.org/10.21037/ame_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Responses and response evaluation of immune checkpoint inhibitors in lymphoma"], "prefix": "10.21037", "volume": "1", "author": [{"given": "Theodora", "family": "Anagnostou", "sequence": "first", "affiliation": []}, {"given": "Stephen M.", "family": "Ansell", "sequence": "additional", "affiliation": []}], "member": "8611", "published-online": {"date-parts": [[2017]]}, "container-title": ["Annals of Lymphoma"], "link": [{"URL": "http://aol.amegroups.com/article/download/4211/5049", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 11, 12]], "date-time": "2018-11-12T01:46:13Z", "timestamp": 1541987173000}, "score": 25.306442, "issued": {"date-parts": [[2017]]}, "references-count": 0, "URL": "http://dx.doi.org/10.21037/aol.2017.10.03", "ISSN": ["2616-2695"], "issn-type": [{"value": "2616-2695", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T20:23:55Z", "timestamp": 1575491035559}, "reference-count": 145, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2019, 9, 1]], "date-time": "2019-09-01T00:00:00Z", "timestamp": 1567296000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Life Sciences"], "published-print": {"date-parts": [[2019, 9]]}, "DOI": "10.1016/j.lfs.2019.116713", "type": "journal-article", "created": {"date-parts": [[2019, 8, 3]], "date-time": "2019-08-03T14:03:30Z", "timestamp": 1564841010000}, "page": "116713", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view"], "prefix": "10.1016", "volume": "233", "author": [{"given": "Humera", "family": "Memon", "sequence": "first", "affiliation": []}, {"ORCID": "http://orcid.org/0000-0003-0594-5452", "authenticated-orcid": false, "given": "Bhoomika M.", "family": "Patel", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Life Sciences"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S002432051930640X?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S002432051930640X?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 8, 29]], "date-time": "2019-08-29T07:59:31Z", "timestamp": 1567065571000}, "score": 25.306442, "issued": {"date-parts": [[2019, 9]]}, "references-count": 145, "alternative-id": ["S002432051930640X"], "URL": "http://dx.doi.org/10.1016/j.lfs.2019.116713", "ISSN": ["0024-3205"], "issn-type": [{"value": "0024-3205", "type": "print"}], "subject": ["General Pharmacology, Toxicology and Pharmaceutics", "General Biochemistry, Genetics and Molecular Biology", "General Medicine"], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view", "name": "articletitle", "label": "Article Title"}, {"value": "Life Sciences", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.lfs.2019.116713", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "\u00a9 2019 Elsevier Inc. All rights reserved.", "name": "copyright", "label": "Copyright"}], "article-number": "116713"}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T14:36:46Z", "timestamp": 1575297406640}, "reference-count": 0, "publisher": "AME Publishing Company", "content-domain": {"domain": ["amegroups.com"], "crossmark-restriction": false}, "short-container-title": ["Shanghai Chest"], "DOI": "10.21037/shc.2018.04.06", "type": "journal-article", "created": {"date-parts": [[2018, 5, 12]], "date-time": "2018-05-12T11:57:31Z", "timestamp": 1526126251000}, "page": "35-35", "update-policy": "http://dx.doi.org/10.21037/ame_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["The role of immune checkpoint inhibitors in non-small cell lung cancer"], "prefix": "10.21037", "volume": "2", "author": [{"given": "Tiffany L.", "family": "George", "sequence": "first", "affiliation": []}, {"given": "Erin M.", "family": "Bertino", "sequence": "additional", "affiliation": []}], "member": "8611", "published-online": {"date-parts": [[2018]]}, "container-title": ["Shanghai Chest"], "link": [{"URL": "http://shc.amegroups.com/article/download/4263/5063", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 11, 12]], "date-time": "2018-11-12T02:47:26Z", "timestamp": 1541990846000}, "score": 25.052662, "issued": {"date-parts": [[2018]]}, "references-count": 0, "URL": "http://dx.doi.org/10.21037/shc.2018.04.06", "ISSN": ["2521-3768"], "issn-type": [{"value": "2521-3768", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T21:06:59Z", "timestamp": 1574802419454}, "reference-count": 0, "publisher": "American Medical Association (AMA)", "issue": "11", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JAMA Oncol"], "published-print": {"date-parts": [[2017, 11, 1]]}, "DOI": "10.1001/jamaoncol.2017.1819", "type": "journal-article", "created": {"date-parts": [[2017, 6, 29]], "date-time": "2017-06-29T16:32:37Z", "timestamp": 1498753957000}, "page": "1473", "source": "Crossref", "is-referenced-by-count": 8, "title": ["Treatment Beyond Progression With Immune Checkpoint Inhibitors\u2014Known Unknowns"], "prefix": "10.1001", "volume": "3", "author": [{"given": "Gideon M.", "family": "Blumenthal", "sequence": "first", "affiliation": [{"name": "Office of Hematology Oncology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}]}, {"given": "Marc R.", "family": "Theoret", "sequence": "additional", "affiliation": [{"name": "Office of Hematology Oncology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}]}, {"given": "Richard", "family": "Pazdur", "sequence": "additional", "affiliation": [{"name": "Office of Hematology Oncology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland2Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, Maryland"}]}], "member": "10", "container-title": ["JAMA Oncology"], "language": "en", "link": [{"URL": "http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.1819", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 11, 9]], "date-time": "2017-11-09T17:32:12Z", "timestamp": 1510248732000}, "score": 24.72934, "issued": {"date-parts": [[2017, 11, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2017, 11, 1]]}, "issue": "11"}, "URL": "http://dx.doi.org/10.1001/jamaoncol.2017.1819", "ISSN": ["2374-2437"], "issn-type": [{"value": "2374-2437", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T00:50:54Z", "timestamp": 1574729454643}, "reference-count": 0, "publisher": "Oxford University Press (OUP)", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Ann Oncol"], "DOI": "10.1093/annonc/mdw696", "type": "journal-article", "created": {"date-parts": [[2016, 12, 24]], "date-time": "2016-12-24T12:09:58Z", "timestamp": 1482581398000}, "page": "mdw696", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Immune checkpoint inhibitors-related orchitis"], "prefix": "10.1093", "author": [{"given": "F.", "family": "Brunet-Possenti", "sequence": "first", "affiliation": []}, {"given": "M. A.", "family": "Opsomer", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Gomez", "sequence": "additional", "affiliation": []}, {"given": "I.", "family": "Ouzaid", "sequence": "additional", "affiliation": []}, {"given": "V.", "family": "Descamps", "sequence": "additional", "affiliation": []}], "member": "286", "published-online": {"date-parts": [[2016, 12, 29]]}, "container-title": ["Annals of Oncology"], "language": "en", "deposited": {"date-parts": [[2017, 1, 13]], "date-time": "2017-01-13T17:18:51Z", "timestamp": 1484327931000}, "score": 24.327246, "issued": {"date-parts": [[2016, 12, 29]]}, "references-count": 0, "alternative-id": ["10.1093/annonc/mdw696"], "URL": "http://dx.doi.org/10.1093/annonc/mdw696", "ISSN": ["0923-7534", "1569-8041"], "issn-type": [{"value": "0923-7534", "type": "print"}, {"value": "1569-8041", "type": "electronic"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}